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Changes in lifestyle and contraceptive practices have favoured the spread of sexually
transmitted infections. The female reproductive tract is thus increasingly exposed to
potential pathogens. Mucosal epithelial surfaces provide a first line of defence against
the entry of these pathogens. The innate immune response is fundamental to the initial
recognition of pathogens and influences the subsequent cascade of effector mechanisms.
The natural antimicrobial peptides are a recently described innate immune defence
mechanism, which in common with other mucosal surfaces, have been identified within
the female reproductive tract.
The aims of this thesis are (1) To characterise the natural antimicrobials, human (3
defensin 1 and 2 (HBD1 and HBD2), secretory leukocyte protease inhibitor (SLPI) and
granulysin, within the human endometrium through the menstrual cycle and in early
pregnancy in vivo. (2) To assess the effect of exogenous sex steroids and chlamydial
infection on this expression. (3) To investigate the expression and regulation of the
natural antimicrobial peptides and pattern recognition receptors in vitro. (4) To examine
some of the early immune responses to Chlamydia trachomatis infection in vitro.
All the natural antimicrobials showed cyclical variation. HBD1 was maximal in the mid
secretory phase, granulysin in the late secretory phase, HBD2 in the menstrual phase and
SLPI in the late secretory and menstrual phases. SLPI, HBD1 and granulysisn were
present in first trimester decidua, while levels of HBD2 were undetectable. Exogenous
sex steroid, administered as the combined oral contraceptive pill and the levonorgestrel
releasing intrauterine system (LNG-IUS) significantly decreased mRNA expression of
HBD1 and 2 and granulysin. There was no significant effect of chlamydial infection on
natural antimicrobial mRNA expression in first trimester decidual samples. Natural
antimicrobials may play a role in the acquisition of infection and this is an important
consideration in future contraceptive development and in the outcome of pregnancy.
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Mimics of infection such as lipopolysaccharide (LPS - a mimic of Gram negative
infection) and polyinosinic-polycytidylic acid (a mimic of viral infection) altered the
mRNA expression of the natural antimicrobials in primary endometrial epithelial cells in
vitro. mRNA expression of HBD1 was increased while SLPI mRNA expression was
decreased. These mimics of infection are recognised by pathogen recognition receptors,
which include the Toll-like receptor (TLR) family. Variable modulation of TLR 4 and
the co-receptor CD 14 were observed following treatment with LPS. Infection of the
cervical epithelial cell line (HeLa) with Chlamydia trachomatis in vitro resulted in the
up-regulation of SLPI, TLR9 and inflammatory cytokines such as IL-8 and IL-1. These
data suggest that epithelial cells and the resulting cascade of innate immune responses
play a central role in the events following pathogen invasion of the female reproductive
tract.
This work furthers our understanding of the modulation of the natural antimicrobials,
which act as an initial innate immunological barrier to infection. As a result of this work,
further research might aim to manipulate these substances, or the effector mechanisms
that lead to their expression. It may thus be possible to prevent or treat sexually
transmitted infections and subsequently impact on the consequences of these infections
such as infertility and adverse pregnancy outcomes.
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1.1 The human endometrium and the menstrual cycle.
The human endometrium is a unique tissue in that it undergoes repetitive monthly
cyclical changes, with tissue proliferation, loss at menstruation and healing without
scarring. The regular and predictable nature of the menstrual cycle results from regulated
interactions between the hypothalamus, pituitary, ovaries and genital tract. The
regulation of the menstrual cycle and the endometrial changes that consequently occur
will be considered below.
1.1.1 Regulation of the human menstrual cycle
The menstrual cycle is regulated by hormones and peptides secreted from components of
the hypothalamic-pituitary-ovarian-uterine axis. It is believed that the ovarian steroids
are the main controlling factors (Chabbert Buffet et al. 1998), through a series of
positive and negative feedback loops. The menstrual cycle is divided into two phases, a
follicular or proliferative phase and a luteal or secretory phase. This can be further sub
divided based upon anatomical and functional changes within the endometrium into the
menstrual, proliferative, early secretory, mid secretory (with preparation for
implantation) and late secretory phases. The median length of the normal menstrual
cycle is 28 days, although this can vary from 25-35 days (Treleor et al. 1967). A 28 day
cycle is assumed within this thesis.
Within the ovary, follicular growth is initiated in the last few days of the luteal phase; it
terminates at the time of ovulation. As the corpus luteum regresses at the end of the
luteal phase, plasma oestrogen and progesterone concentrations fall. This is associated
with a decrease in the levels of inhibins A and B. Follicle stimulating hormone (FSH) is
no longer inhibited and begins to rise, initiating the development of follicles. As the
follicles develop there is a concomitant increase in oestrogen and inhibin resulting in a
negative feedback and suppression of FSH. This inhibits the development of further
follicles and a dominant follicle is recruited. A positive feedback occurs with increasing
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oestrogen secretion from the dominant follicle leading to increases in the number of
granulosa cells and FSH and luteinizing hormone (LH) receptors. Just before ovulation
the oestrogen secretion by the follicle rises dramatically initiating a LH surge from the
pituitary. LH initiates the luteinisation of the theca and granulosa cells and enhances
progesterone secretion which stimulates the mid cycle surge of FSH. Plasma levels of
oestrogen then fall and the LH levels increase dramatically. 10-12 hours after the peak of
the LH surge, ovulation occurs. Post ovulation, LH levels decrease dramatically, either
secondary to the low oestrogen levels or due to depletion of LH within the pituitary. The
corpus luteum then enlarges and secretes high levels of progesterone, which allow the
oestrogen primed endometrium to undergo changes in preparation for implantation. In
the absence of implantation, the corpus luteum regresses, oestrogen and progesterone
plasma levels decline and FSH levels begin to rise again, and the cycle repeats. Figure 1
summarises these changes.
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Figure 1: Concentrations of pituitary gonadotrophins luteinizing hormone (LH), follicle
stimulating hormone (FSH) (both U/L), oestradiol (pmol/L), progesterone (nmol/L),
inhibin A and inhibin B (both pg/mL) in the circulation through the menstrual cycle.
This is correlated to the ovarian cycle with selection of a follicle, maturation and
ovulation followed by formation of a corpus luteum, which then regresses.
Cyclical changes within the endometrium are also shown with the broad characterisation
into the proliferative, secretory and menstrual phases. (Adapted from Wilson et al. 1998)
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1.1.2 Endometrial histological changes
The endometrium can be divided morphologically into an upper two-thirds functionalis
layer, and a lower one-third basalis layer. The basalis layer is a regenerative layer that
does not undergo cyclical changes, while the functionalis layer undergoes cyclical
changes as it prepares for implantation of the blastocyst. These changes have been
described in classic publications by Noyes (Noyes et al. 1950)(Figure 2) and Markee
(Markee 1940) and reviewed by others (Critchley and Healy 1998; Dallenbach-Hellweg
1981; Speroff et al. 1999; Wilson et al. 1998). These changes will be briefly described in
the following sections 1.1.2.1 - 1.1.2.9.
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Figure 2: Dating the endometrium. Morphological features observed through the
menstrual cycle, which allow accurate dating of the endometrium. From Noyes et al
(Noyes et al. 1950).
DATING THE ENDOMETRIUM
APPROXIMATE RELATIONSHIP OF USEFUL MORPHOLOGICAL FACTORS
GLAND MITOSES
Gland mitoses Indicate proliferation. They
occur during menstruation because repair
and breakdown are progressing simultane¬
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phase but persists until active secretionbegins. It is not resumed until the
glands hove Involuted during menstruation.
BASAL VACUOLATION
This Is the earliest morphological evidence
of ovulation found In the endometrium.
It begins approximately 36 to 48 hours
following ovulation.
SECRETION
This curve represents visible secretion In
the gland lumen; active secretion falls off
more abruptly. In the later stages the
secretion becomes inspissated.
EARLY MIO LATE
MENSES PROLIF¬ PROLIF¬ PROLIF¬ SECRETION
ERATION ERATION ERATION
STROMAL EDEMA
This factor varies with the Individual,
particularly the rise during proliferation
which may be almost absent. The edema
which accompanies secretion is more con¬
stant.
PSEUDODECIDUAL REACTION
This is evident first around the arterioles
and progresses until Just before mens¬
truation a superficial compact layer Is
formed.
STROMAL MITOSES
These are most abundant during the pro¬
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of predeciduol formation.
LEUCOCYTIC INFILTRATION
Throughout the cycle there are always
- '— lymphocytes. Polymorphonuclear
ion begins about two days before
a few I]
Infiltroti
the onset of "flow.





1.1.2.1 Proliferative phase (Days 4-13)
Reconstruction and growth of the endometrium is seen. Glands are narrow and tubular,
mitoses and pseudostratification are present. The underlying stromal compartment,
consisting of pluripotent mesenchymal cells, is initially dense and cellular becoming
oedematous and then forming a loose syncytial-like structure. Spiral blood vessels are
initially unbranched and uncoiled.
1.1.2.2 Early secretory phase (Days 14-18)
After ovulation, epithelial proliferation ceases due to decreased levels of oestrogen and
increasing levels of progesterone. Glands continue to expand, becoming tortuous and
coiled. Within the glandular cells subnuclear intracytoplasmic glycogen vacuoles appear,
and active secretion of glycoproteins and peptides into the endometrial cavity follows.
1.1.2.3 Mid secretory or implantation phase (Days 19-23)
Initially secretory glands are prominent with little intervening stroma. The stroma then
becomes very oedematous. Spiral vessels undergo intense coiling. Leukocytes begin to
infiltrate the endometrium.
1.1.2.4.Late secretory phase (Days 24-28)
The functionalis layer can be divided into the superficial stratum compactum, with large
stromal decidua-like cells, and the middle portion, the stratum spongiosum. This middle
layer has loose oedematous stroma with numerous tightly coiled spiral vessels.
Leukocytes greatly increase within the endometrium around days 25-28.
1.1.2.5 Menstruation (Days 1-4)
In the absence of pregnancy, oestrogen and progesterone levels decline. The
endometrium becomes serrated in appearance and decreases in height as glandular
secretion becomes exhausted. Blood flow in the spiral vessels decreases. The arterioles
undergo constriction and vasodilatation leading to endometrial ischaemia and stasis.
Apoptosis occurs with menstruation and subsequent healing.
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1.1.2.6 Glands of the endocervix
The mucus secreting glands of the endocervix also undergo cyclical changes under the
influence of ovarian hormones. As oestrogen increases in the latter half of the follicular
phase the quantity of mucus increases up to 30 fold. At the time of ovulation the mucus
changes in quality becoming watery and elastic. Progesterone in the luteal phase then
reverses these changes.
1.1.2.7 Morphological changes in the endometrium following use of the combined
oral contraceptive pill (COCP)
In the first few months after a combined steroid contraceptive is used, cyclical
endometrial changes may occur, but after prolonged usage the regenerative capacity of
the endometrium becomes reduced as a result of progesterone predominance and the
endometrium becomes atrophic (Buckley and Fox 1989). Introduction of progesterone
on day 5 of the menstrual cycle shortens the proliferative phase, resulting in poorly
developed glands, sparse and lacking tortuosity, and stromal cells remaining spindled in
appearance. As oestrogenic priming is inadequate and the resultant progesterone
receptors are few in number, the secretory changes in the endometrium are weak and
poorly developed. Glands remain uncoiled and there is only a trace of secretions within
the lumina. Glands and stroma at different stages of maturity are observed and spiral
arterioles fail to develop. In the latter part of the cycle there is regression of the secretory
change and the endometrium becomes inactive. With prolonged pill taking, the
endometrium becomes inactive and atrophied with sparse, tiny glands. The stromal cells
decrease in number and collagenous fibres predominate.
1.1.2.8 Morphological changes in the endometrium following use of the
levonorgestrel intrauterine device (LNG-IUS)
The LNG-IUS releases a synthetic progestogen, levonorgestrel, directly into the uterine
cavity, which then acts in a paracrine manner. Cyclical activity of the endometrium is
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lost within one month following LNG-IUS insertion. With extended use morphological
changes are seen throughout the endometrium (Silverberg et al. 1986). Extensive
decidualization of the stroma is observed. The proliferative activity of the endometrium
is inhibited and the secretory activity of the epithelial glands cease, with time epithelial
glands atrophy. There is also an associated down-regulation of oestrogen and
progesterone receptors in all compartments of the endometrium after insertion of the
LNG-IUS, with a gradual return 6-12 months post insertion. An initial infiltrate of
CD56+ uterine natural killer cells and CD68+ macrophages has been described
(Critchley et al. 1998a; Jones and Critchley 2000) with a subsequent decrease in
macrophage numbers after 1 month of use. Vascular changes are also observed, with
thickening of the uterine arteries, suppression of spiral arterioles and the presence of
large distended vessels.
1.1.2.9 Decidualisation
Decidual cells are derived from the stromal cells of the endometrium, under the
stimulation of progesterone. They appear in the mid to late luteal phase (approximately
day 23) initially around the spiral arterioles, beneath the surface epithelium. The
decidual cell is characterised by the accumulation of glycogen and lipid droplets and the
expression of substances such as prolactin, insulin-like growth factors and insulin-like
growth factor binding proteins. The glands in the upper two-thirds of the decidua
become atrophied while those in the lower one-third remain secretory. If implantation
occurs decidual cells continue to differentiate and/or proliferate eventually lining the
entire endometrial cavity.
1.1.3 Regulation of local mediators in the endometrium
There are a number of potential regulatory mediators within the endometrium. Three of
these will be considered here. Progesterone and oestrogen are two fundamental
hormones involved in the cyclical changes observed within the endometrium, while
Nuclear Factor-kb (NFkB) is a transcription factor involved in inflammatory and
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immune responses (Baldwin 1996; Siebenlist et al. 1994), and may play a role in
regulation of events within the endometrium.
1.1.3.1 Oestrogen and progesterone receptor expression in the endometrium
Both oestrogen and progesterone receptors are present within the endometrium, and their
spatio-temporal distribution has been reviewed elsewhere (Critchley and Healy 1998;
Lessey et al. 1988; Snijders et al. 1996). As their role is crucial to the control of events
within the endometrium these changes will be summarised here. There are two
predominant forms of the human progesterone receptor (PR), PR-A and PR-B, there are
also two oestrogen receptors (ER), ERa and ER(3. The receptors are primarily located in
the cell nucleus. ER expression increases through the proliferative phase, peaking in the
early secretory phase and then declining. The glandular decline is delayed when
compared to the stroma. ERa expression is observed in glandular and stromal tissues,
while ERp is expressed by the glandular epithelium, stromal tissues and endometrial
endothelium (Critchley et al. 2001; Matsuzaki et al. 1999). ER(3 declines in glandular
cell nuclei, but not stroma, within the functionalis layer during the late secretory phase.
A parallel but delayed increase in PR in the stroma and glandular compartments occurs
in the proliferative phase. This is followed by decline in the glandular component in the
secretory phase. Some PR expression persists in the stroma in the secretory phase,
particularly in the cells adjacent to the blood vessels. While both PR-A and PR-B are
expressed in the proliferative phase, mainly PR-A is expressed in the stroma in the
secretory phase (Mote et al. 1999; Wang et al. 1998).
Data concerning ER and PR expression in the decidua of pregnancy are inconsistent.
Perrot-Applanat et al have reported that ER and PR are absent from the epithelium in
pregnancy (Perrot-Applanat et al. 1994). However others (Wang et al. 1992; Wu et al.
1993) report that during early pregnancy PR are expressed in stromal cells and in the
endothelium. ER expression in early pregnancy is minimal in decidualised cells of the
decidua parietalis, but stronger in the decidua capsularis. Staining of ER and PR has also
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been observed in the glandular cells and arteriolar cells of the decidua parietalis (Wu et
al. 1993).
In the absence of hormone the receptors are inactive, complexed to other proteins. On
binding hormone the receptor dissociates from the complex and can bind to specific
hormone responsive elements in DNA, altering gene expression (Carson-Jurica et al.
1990)
1.1.3.2 Transcription factor - Nuclear Factor-KB (NFkB)
NFkB is a transcription factor, one of the Rel transcription factor family. It is classically
a heterodimer consisting of a p50 and p65 protein. NFkB will usually act with other
transcription factors such as activator protein 1 (AP-1) to regulate gene transcription
(McKay and Cidlowski 1999). NFkB is held inactive in the cytoplasm by endogenous
inhibitors, IkB (which include IkBoc, IkB(3 and MBy) (Baeuerle and Baltimore 1988).
These inhibitors mask the NFkB nuclear localisation sequence. Upon stimulation of a
cell IkB becomes phosphorylated (Beg and Baldwin 1993; Beg et al. 1993), ubiquinated
(Scherer et al. 1995) and then dissociates from the NFkB. NFkB can then translocate to
the nucleus to regulate gene expression. A number of genes have NFkB binding sites in
their promoter regions, such as IL-1, IL-6, IL-8 (Mukaida et al. 1991) and COX-2
(Schmedtje et al. 1997). iKBa is also up regulated by NFkB resulting in a negative
feedback loop (Sun et al. 1993). NFkB activity can also be inhibited by progesterone,
which stimulates the synthesis of IkB or binds to the nuclear receptor competing for
NFkB binding sites on the target gene (Kalkhoven et al. 1996).
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1.2 Inflammatory mediators within the endometrium
The menstrual cycle and implantation have both been associated with inflammatory-like
events (Finn 1986; Kelly et al. 2001; Salamonsen et al. 1999). Mediators of these
responses include cytokines, chemokines and other factors such as the prostaglandins.
Representative mediators in each of these groups will be discussed in more detail below.
1.2.1 Cytokines
Cytokines are soluble polypeptides synthesised and secreted by activated immune cells,
as well as by the stromal, epithelial and endothelial cells within the human endometrium
(Table 1). They play an important part within the endometrium, in the pregnant and non¬
pregnant state (Kelly et al. 2001; Tabibzadeh 1991). In addition cytokines can interact
with pituitary and hypothalamic hormones and may thereby influence neuroendocrine
events. In vivo a cell is likely to be exposed to a number of cytokines, acting
synergistically or antagonistically therefore differentiating individual functions can be
difficult. Cytokines can be considered to be pro-inflammatory (e.g. interleukin (IL)-l,
interferon gamma (IFNy)) or anti- inflammatory (e.g. Interleukin (IL)-IO). Three pro¬
inflammatory cytokines will be considered further; IL-1, IFNy and tumour necrosis
factor alpha (TNFa).
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Table 1: Examples of Cytokines and Growth factors found within human endometrium,
and their cellular source
Stromal Epithelial Endothelial Macrophages T cells uNK cells
cells cells cells
IL-la IL-la IL-1 IL-1 IFNy TGFP
IL-lp IL-ip TNFa M-CSF TNFa
IL-6 EGF EGF G-CSF IFNy
EGF TGFa GM-CSF GM-CSF
TGFa TNFa TNFa G-CSF
TNFa IL-6 IFNa M-CSF
Adapted from (Bronson et al. 1996; Tabibzadeh and Sun 1992)
1.2.1.1.1 Interleukin-1
IL-1 is a multifunctional cytokine. Two forms of IL-1, IL-la and IL-ip and two IL-1
receptors (type 1 (IL-1RI) and 2 (IL-1RII)) have been described, as well as an IL-1
receptor antagonist (IL-lra), which binds to the type 1 receptor.
IL-la and IL-ip are 17kDa proteins consisting of 159 amino acids and 153 amino acids
respectively. At the protein level they show only 27% homology, but are nearly identical
in 3 dimensional structure (www.copewithcytokines.com). Their biological effects are
generally indistinguishable. They both bind to the IL-1 type 1 and 2 receptors. IL-1RI
transduces a signal while IL-1RII binds IL-1 but does not transduce a signal (see below).
IL-1 is produced by a number of cell types, including monocytes, endothelial cells,
fibroblasts, smooth muscle cells and epithelial cells (Dinarello 1991).
Within the endometrium IL-1 has been detected in the endothelium, stroma and
epithelium, with an increase in expression in the secretory phase of the cycle (Simon et
al. 1993a; Tabibzadeh and Sun 1992), while IL-lra expression is decreased in the
secretory phase (Simon et al. 1995). The IL-1 type 1 receptor is expressed by
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endometrial epithelial cells and expression is maximal in the secretory phase (Simon et
al. 1993a; Simon et al. 1993b).
IL-1 secretion can be induced by many factors including TNFa, IFN-y and endotoxins.
Inhibitors of secretion include PGE2, glucocorticoids, IL-lra and IL-6. IL-1 can act
directly or indirectly via the induction of PGE2 (Tabibzadeh et al. 1990), IL-6 (Laird et
al. 1994) and IL-8. It has numerous biological effects, activating T helper cells and NK
cells, stimulation of immunoglobulin production, proliferation of fibroblasts, up-
regulation of adhesion molecules and some chemotactic activity for neutrophils to list
but a few functions. IL-1 also synergises with other cytokines such as TNFa. Within the
endometrium it has been suggested that IL-1 may pay a role in the defence against
infection as well as in menstruation and implantation.
1.2.1.1.2 IL-1 receptor
The extracellular domains of the IL-1RI and IL-1RII proteins are members of the
immunoglobulin superfamily, and are each comprised of three immunoglobulin G-like
domains. IL-1 Type 1 receptor is the primary signal transducer (Sims et al. 1993). An
IL-1 accessory protein has been described and once IL-1 has bound with low affinity to
the type 1 receptor, the accessory protein docks and high affinity binding occurs. The
type 1 receptor has a single transmembrane segment and a cytoplasmic domain. The
type 2 receptor lacks a signal transducing cytoplasmic domain. The cytoplasmic domain
has 45% amino acid homology with the cytosolic domain of the Drosophila Toll gene
(Gay and Keith 1991) (see section 1.4.1).
Following binding to the receptor, several biochemical events occur. There are multiple
and sequential phosphorylations or dephosphorylations of kinases, resulting in nuclear
translocation of transcription factors and activation of proteins involved in translation of
RNA. This includes the activation of the adapter protein MyD88, the IL-1 Receptor
Associated Kinases (IRAK) and TNF Receptor-Associated Factor-6 (TRAF-6). Most of
the effects of IL-1 occur following nuclear translocation of nuclear NFkB (see section
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1.1.3.2) and activating protein-1 (AP-1) (Daun and Fenton 2000). NFkB and, or, AP-1
binding sites are present in the promoter regions of many IL-1 inducible genes, such as
PGE2, IL-6 and IL-8. This amplification system allows for very few receptors to be
expressed on primary cells, resulting in an efficient signalling mechanism.
1.2.1.2 Tumour Necrosis Factor a
TNFa is a 17kDa protein consisting of 157 amino acids. It is secreted by a number of
different cells including macrophages, monocytes, neutrophils, T lymphocytes, NK cells
and fibroblasts, smooth muscle cells and granulosa cells (Zhang and Tracey 1998). The
TNF promoter region has NFkB (Goldfeld et al. 1993), AP-1 and cAMP response
element (CRE) (Leitman et al. 1992) as well as other regulatory sites. The receptors
(type 1 and 2) are part of the TNF receptor superfamily and are found on all somatic
cells except erythrocytes.
TNFa expression has been demonstrated within the human endometrium, predominantly
in the glandular epithelium (Hunt et al. 1992). Different groups have examined the
cyclical nature of expression, but results have been inconsistent. TNFa mRNA appears
to be low in the proliferative phase and increases in secretory tissue (Hunt et al. 1992;
Philippeaux and Piguet 1993). In the late secretory phase, expression in glandular
epithelium declines, but stromal cells of the functionalis region show strong expression
of TNFa mRNA (Hunt et al. 1992).
TNFa secretion is induced by a variety of factors, including IFN-y, bacterial and viral
products and tumour cells. There are a wide range of TNFa inhibitors, including PGE2
IL-4, IL-10, glucocorticoids and spermine. The biological actions of TNFa are
extensive, both pro-inflammatory (Old 1985) and cytotoxic. Effects also include
cytolysis, cytostasis, monocyte and neutrophil chemotaxis (Ming et al. 1987),
angiogenic effects (Frater-Schroder et al. 1987) and endocrine effects (Zhang and
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Tracey 1998). Its role within the endometrium is not well defined and may like IL-1
include roles in immune defence, menstruation and implantation.
1.2.1.3 Interferon y
IFNy is a dimeric protein of 146 amino acids. Receptors are found on all human cells
except mature erythrocytes. A soluble receptor has also been described. IFNy is secreted
predominantly by T cells (Celis et al. 1986) and NK cells, which have been activated by
antigens, mitogens or alloantigens. Biological activities include antiviral and anti¬
parasitic effects as well as the inhibition of proliferation of normal and transformed
cells. IFNy has immunomodulatory effects such as augmenting MHC expression
(Tabibzadeh and Satyaswaroop 1988) and affecting T cell growth and functional
differentiation (Pestka et al. 1987).
Within the endometrium T cells, uNK cells and neutrophils are the source of IFNy
(Tabibzadeh 1994; Yeaman et al. 1998), particularly from the lymphoid follicles in the
basalis region of the endometrium. Its prominent role is in the modulation of the
immune response. Yeamen et al (Yeaman et al. 1998) found no correlation between
stage of the menstrual cycle and IFNy expression.
1.2.2 Chemokines
Chemokines are chemoattractant cytokines that promote the recruitment of leukocytes
into tissues via specific receptors on the attracted cells. They have four conserved
cysteine residues and two disulphide bridges. The chemokine superfamily has been
divided into four subgroups depending on the amino acid configuration with regards to
the first two cysteine residues; CC, C, CXC and CXXXC, with the CC and CXC groups
being the best studied (Zlotnik and Yoshie 2000) (see table 2). CXC chemokines, such
as IL-8 and IFNy-inducible protein (IP)-10, tend to be chemoattractant for neutrophils.
CC chemokines, such as RANTES and monocyte chemotactic protein (MCP) 1-4, tend
to be chemoattractant for monocytes, lymphocytes basophils, eosinophils, but not for
28
neutrophils. Lymphotactin is the only C chemokine, and fractalkine is a CXXXC
chemokine. Chemokines act via 7-transmembrane spanning G-protein coupled receptors
(Murphy 1996).
Table 2: Examples of Chemokines in human endometrium
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Adapted from (Salamonsen and Lathbury 2000)
1.2.2.1 IL-8
IL-8 is produced by a number of cell types including monocytes (Yoshimura et al.
1987), NK cells, neutrophils (Fujishima et al. 1993), fibroblasts, endothelial cells
(Gimbrone et al. 1989), epithelial cells and some tumour cells. Other CXC chemokines
have a far more limited cellular source. IL-8 can be induced by cytokines (e.g. IL-1 and
TNFa (Fujishima et al. 1993)), bacterial and viral products (Wuyts et al. 1998). There
are four CXC receptors. The effects of IL-8 are predominantly through the CXCR1
receptor, which binds IL-8 with high affinity (Samanta et al. 1989).
IL-8 has neutrophil (Schroder et al. 1987) and T cell chemotactic (Larsen et al. 1989)
properties. Within the endometrium it has angiogenic and proliferative properties,
inducing the proliferation of endometrial stromal cells (Arici et al. 1998). Other actions
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include augmenting the bacteriocidal activity of neutrophils (Baggiolini et al. 1989) and
chemotaxis of endothelial cells (Koch et al. 1992) and smooth muscle cells (Yue et al.
1994).
Within the endometrium IL-8 has been localised to the perivascular cells and surface
epithelium and glands (Critchley et al. 1994; Jones et al. 1997), increasing in the late
secretory phase. In vivo levels are seen to increase 48 hours after progesterone
withdrawal (Critchley et al. 1999) while in vitro IL-1 and TNFa increase stromal cell
production.
1.2.2.2 Monocyte chemotactic protein -1
MCP-1 is released by a wide range of cell types including monocytes (Yoshimura et al.
1989), fibroblasts (Yoshimura and Leonard 1990) and endothelial cells (Sica et al.
1990). It is induced by factors including IL-1, TNFa (Sica et al. 1990) and LPS and is
inhibited by progesterone (Kelly et al. 1997) A number of CC receptors have been
described, and the effects of MCP-1 are mediated primarily through CCR2 (Bacon et al.
1998).
MCP-1 recruits and activates monocytes (Rollins 1991), and also T cells (Carr et al.
1994), basophils (Bischoff et al. 1992) and NK cells (Allavena et al. 1994) in sites of
inflammation. It has also been described as an angiogenic agent, a mitogen for smooth
muscle (Bacon et al. 1998) and a regulator of cytokine expression (Jiang et al. 1992).
MCP-1 has been identified in the endometrium (Arici et al. 1995; Jones et al. 1997),
predominantly in the perivascular cells. Expression increases on progesterone
withdrawal (Jones et al. 1997) and MCP-1 may therefore be involved in leukocyte
recruitment at this time.
1.2.3 Prostaglandins
Prostaglandins (PG) are a group of inflammatory mediators (PG A to J) first described in
1936 (Von Euler 1936). They are produced by de novo synthesis from arachidonic acid
released from membrane bound phospholipids. Via the action of the cyclooxygenase
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enzymes, COX-1 and COX-2, PGH2is derived. COX-1 is considered to be synthesised
constitutively, while COX-2 expression is regulated (O'Banion et al. 1992). The COX-2
gene has a NFkB binding site, and can be up-regulated by factors such as LPS, IL-1
(Huang et al. 1998) and TNFa and inhibited by others such as progesterone (Abel and
Baird 1980). Modification of PGH2by the enzymes PGE synthase (PGES) and PGF
synthase (PGFS) results in the two PGs considered in this thesis, PGE2and PGF2a
respectively. Prostaglandin 15-dehydrogenase (PGDH) is then responsible for the
catabolism of the PGs. PGDH has been shown to be progesterone dependent in
reproductive tissues (Greenland et al. 2000).
There have been a number of PGE receptors identified, including EP1, 2, 3a, 3b, 3c, 3d
and EP4. The EP1 receptor is calcium dependent, EP2 and EP4 receptors are both cyclic
adenosine monophosphate (cAMP) dependent (Fedyk and Phipps 1996) and the EP3
receptor can act via calcium and cAMP.
Prostaglandins have a wide range of actions. These include immunomodulatory effects
(Harris et al. 2002) such as the regulation of other cytokines, stimulation of IL-8 and IL-
10 (Denison et al. 1999b) and inhibition of IL-12 from activated monocytes (Kraan et al.
1995) and antibody class switching of B cells (Phipps et al. 1991). Prostaglandins also
have vasoactive properties and play a role in menstruation (Baird et al. 1996).
Prostaglandins are found in high levels in semen and this may result in
immunomodulatory effects that are advantageous to the spermatozoa, but may be
detrimental in terms of acquisition of sexually transmitted infections (Kelly 1995; Kelly
and Critchley 1997).
Concentrations of all prostaglandins are greater within the endometrium than in the
myometrium. PGF2a, which is found in the greatest concentrations, is highest in the
mid-secretory phase in both endometrium and myometrium. Within the myometrium the
concentration of PGE2 does not vary through the menstrual cycle (Lumsden et al. 1986).
However, the ability to produce and release PGE2 appears to be maximal in the
menstrual phase of the cycle (Rees et al. 1984).
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1.3 Endometrial Immunity
1.3.1 Leukocytes within the endometrium
As a mucosal surface exposed to pathogens as well as foreign antigens in seminal
plasma and trophoblast, the endometrium (which is normally sterile) has to be able to
mount a regulated immune response. A wide range of immune cells has been identified
in the endometrium within the stratum basalis, stratum functionalis and in an
intraepithelial position. Their numbers vary over the menstrual cycle (Loke and King
1995) (Table 3 and figure 3). The cells identified include granulocytes (neutrophils and
eosinophils), T and B-lymphocytes, macrophages and uterine natural killer (NK) cells.
Table 3: Proportion of leukocytes in human endometrium











From (Bulmer et al. 1991b)
32
Figure 3: Leucocyte populations (number of leukocytes/10 high power fields) in human
endometrium and first trimester decidua. Adapted from (Loke and King 1997).
(prolif = proliferative phase endometrium; secretory = secretory phase endometrium)
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1.3.1.1 Neutrophils
Neutrophils are the most abundant leukocyte in the human immune system, but within
the endometrium they are barely detectable through most of the cycle. Perimenstrually
the numbers rise to make up 6-15% of the total cell number in the tissue at this time
(Salamonsen and Woolley 1999). They are found scattered through the stratum
functionalis.
1.3.1.2 Eosinophils
Like neutrophils, eosinophils are absent from the endometrium through most of the
menstrual cycle until just prior to menstruation. Their numbers then increase and form 3-
5% of the total cell number in the tissue at this time, mostly found as aggregates
(Salamonsen and Lathbury 2000).
1.3.1.3 B-lymphocytes
B-lymphocytes are only detected in very low numbers throughout the menstrual cycle.
They are found in aggregates in the stratum basalis, and do not vary in number through
the menstrual cycle (Bulmer et al. 1991a). At other mucosal sites (gastrointestinal tract
and respiratory tract), local production of secretory IgA antibodies provide a local
immune defence system. A sub set of B-lymphocytes, IgA synthesising plasma cells,
have been demonstrated in the vagina, ectocervix and endocervix, but not within the
human endometrium. Plasma cells are not considered to be a normal component of
endometrial stroma and their presence is used as evidence of endometritis (Buckley and
Fox 1989). IgG, IgM and IgA have been localised in the stroma of secretory
endometrium, but it is proposed that these derive from the plasma in association with
stromal oedema (Bulmer et al. 1986).
1.3.1.4 T-Iymphocytes
T-lymphocytes are found in the aggregates in the stratum basalis where their numbers do
not vary (Bulmer et al. 1991a). They are also found scattered within the stratum
functionalis and in intraepithelial sites (Loke and King 1995). Their numbers increase
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slightly perimenstrually, but are only 1-2% of the total cell number in the tissue at this
time. The majority of the T cells present are a(3 T Cell Receptor -i-ve (TCR+) (85%), but
a small population of yb TCR+ cells are found within the endometrium (Chen et al.
1995). The role of the yb TCR+ cells is unclear and include possible immunosupressive
(Suzuki et al. 1995) and/or cytolytic activity (Mincheva-Nilsson et al. 2000). It has been
noted that there is an increase in the ratio of CD8+ cells to CD4+cells in the
endometrium, when compared to peripheral blood T cells.
The CD8+ cells are cytolytically active in the proliferative phase of the menstrual cycle,
but inactive during the subsequent secretory phase (White et al. 1997). In pregnancy
decidual T cells appear to have an activated phenotype (Mincheva-Nilsson et al. 1994).
The likely role of these cells is as part of the immune defence armoury, and as a source
of cytokine production. There has been some speculation about the existence of
suppressor T-lymphocytes, but evidence is inconclusive at this stage (Kuhnert et al.
1998; Mahmoud et al. 2001).
1.3.1.5 Macrophages
Macrophages are present in the stratum basalis aggregates through the menstrual cycle,
and are also present scattered throughout the stratum functionalis. There is a small
increase in numbers in the functionalis from the proliferative through to the secretory
phase (Bonatz et al. 1992), reaching a maximum of 6-15% of the total cell number in the
tissue prior to menstruation.
Most of the endometrial macrophages express MHC class II and this expression does not
seem to vary through the menstrual cycle (Bulmer et al. 1988a). This suggests that these
cells are acting as antigen-presenting cells. As prostaglandin secretors, macrophages
may play a role in intrauterine immunosupresssion. They also secrete and can respond to
a number of cytokines. Finally macrophages are well described as phagocytic cells and
their role may be the removal of tissue debris perimenstrually.
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1.3.1.6 Natural Killer cells
CD56 is the classic NK cell antigen, and is an isoform of the neural cell adhesion
molecule - NCAM, while CD16 is the low affinity Fc-y receptor. "Classical" CD 56+16+
NK cells are rare throughout the menstrual cycle. In contrast "uterine" CD 56+16" NK
(uNK) cells are found occasionally in intraepithelial sites and in the stratum functionalis
where they form a major cellular component of the endometrial stroma. Although few
uNK cells are present in the proliferative phase, they increase dramatically in the
secretory phase, being 15-25% of the total number of cells in the stroma (Bulmer et al.
1991b; King et al. 1989; Salamonsen and Woolley 1999) at their maximum. The
increase of cells is both as a result of migration into the endometrium followed by
differentiation, as well as proliferation of cells already within the endometrium.
Scattered single cells and aggregates adjacent to endometrial glands and around spiral
arterioles are observed. In the absence of pregnancy, numbers of uNK cells decline. It is
controversial as to whether or not this unique cell type undergoes apoptosis (Jones et al.
1998a; Jones et al. 1998b; King 2000; Loke and King 1995).
These cells were recognised in non-pregnant endometrium by Weill in 1921 (Weill
1921) and have been described morphologically as large lymphocytes with prominent
cytoplasmic granules (King 2000; King et al. 1991). These cells have been referred to in
the literature as large granular lymphocytes (LGL), endometrial stromal or granulated
lymphocytes, Kornchenzellen or K cells, decidual granulated lymphocytes, or uterine
NK (uNK) cells. They shall be referred to as uNK cells through this thesis.
The role of uNK cells has been widely speculated. As they express the NK cell marker
CD56, and have a number of cytoplasmic granules, the uNK cells may be functioning as
traditional cytotoxic, non MHC restricted NK cells. Cytotoxic activity has been
demonstrated in vitro (Ferry et al. 1990). uNK cells have receptors for HLA class I
molecules and as an extension to this it has been suggested that uNK cells may play a
role in controlling the invasion of fetal trophoblast cells into the maternal uterine tissue
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(Loke and King 2000). uNK cells also secrete a wide range of cytokines and may play a
role in decidualisation as well as implantation and early placental development (King
2000).
1.3.2 Leukocytes in Pregnancy
Leukocytes are a major component of decidua throughout pregnancy (Bulmer and
Sunderland 1983). There are 3 major populations, T-lymphocytes, macrophages and
uNK cells. Macrophage numbers stay relatively constant through pregnancy, accounting
for approximately 10 - 20% of cells and are found throughout the decidua (Bulmer et al.
1988b). T-lymphocytes account for less than 20% of the leukocytes in first trimester
decidua and are predominantly CD8+. Later in pregnancy T-lymphocytes account for a
larger proportion of the leukocytes as uNK cells decrease in number (Bulmer and
Sunderland 1984). uNK cells are predominant in the first trimester, scattered throughout
the decidua as well as aggregating around the glands and arterioles (Bulmer et al.
1991a). These cells comprise more than 75% of the leukocytes in first trimester decidua
(Bulmer et al. 1991b), they then decline in the second trimester and are uncommon at
term.
1.3.3 Regulation of Leukocyte distribution
The mediators regulating leukocyte numbers and distribution have not been fully
elucidated. Cells may increase in number due to local proliferation (Klentzeris et al.
1992), or due to influx from peripheral blood circulation in the tissue (Marzusch et al.
1993). Changes occurring through the menstrual cycle are likely to be hormonally
mediated either directly or indirectly via other factors such as chemokines or cytokines.
Immunohistochemical analysis of T lymphocytes, macrophages and uNK cells have
failed to show either progesterone or classic oestrogen receptors (ERa) on these cells
(King et al. 1996; Stewart et al. 1998). In contrast, expression of cytokine receptors on
these cells has been demonstrated. Stromal cells express the progesterone receptor (Mote
et al. 1999; Wang et al. 1998) and it has therefore been proposed that progesterone acts
directly on endometrial stromal cells inducing production of secretory products which
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then influence endometrial leukocytes. uNK cells require progesterone for their
recruitment, as evidenced by the fact that they are not seen in ovariectomised women,
unless they had been exposed to both oestrogen and progesterone (Loke and King 1995).
Adhesion molecules are necessary for attachment to endothelium, extravasation and
trafficking through tissues. These molecules include NCAM, ICAM-1, VCAM-1 and E-
selectin, and have been detected in the endometrium (Tabibzadeh et al. 1994).
Expression of adhesion molecules is modulated by a wide range of cytokines and these
may play a role in recruitment of leukocytes.
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1.4 Innate Immunity
The immune system in divided into two, the acquired immune system and the non-
acquired innate immune system. Within the human endometrium the cellular
components of these systems have been described above in sections 1.3.1 and 1.3.2. The
innate system encompasses a range of first line responses to invading pathogens. It
consists of mechanical barriers such as skin and mucosal membranes, secretions, such as
complement, lysozyme and natural antimicrobials and has a cellular component such as
phagocytic cells and natural killer cells. It does not require previous exposure to
pathogens, or immunological memory. The innate immune response is relatively non¬
specific and rapidly kills invading microbes. This is in contrast to the adaptive immune
response, which is specific in its response and maintains memory. As such, the adaptive
immune response can take time (days) to develop and can produce inflammatory side
effects. The innate immune response can activate the adaptive immune response. Two
components of the innate immune response and their role in the endometrium will be
considered further:
i) Toll-like receptors, which recognise pathogens
ii) Natural antimicrobials, a component of the secretory innate immune response
1.4.1 Pathogen recognition: Toll-like receptors
The early recognition of infection by the host is a fundamental component of the
immune response, providing an early line of defence against pathogens (Janeway
1992a). It is now recognised that there is more specificity in the activation of the innate
immune system than was initially believed. This has been attributed to germline-
encoded pattern recognition receptors (PRRs) expressed on host cells. These PRR
recognise highly conserved motifs, defined as pathogen-associated molecular patterns
(PAMPs) that are shared by large groups of microorganisms (Medzhitov and Janeway
1997). Examples of PAMPs include lipopolysaccharide (LPS) of Gram negative
bacteria, lipoteichoic acid (LTA) of Gram positive bacteria, double-stranded RNA of
several RNA viruses and unmethylated CpG DNA motifs (Medzhitov and Janeway
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1997). Ligation of particular PRRs results in intracellular signalling events that activate
cells in defined ways.
The receptors involved in direct activation of signalling pathways after PAMP
recognition have remained, until recently, elusive. It is now understood that the Toll-like
receptor (TLR) family mediate the recognition of a number of PAMPs. Mammalian TLR
proteins derive their name from the Drosophila Toll protein. This was originally shown
to be critical for dorsal-ventral patterning in fly embryos (Stein et al. 1991). In addition
it was observed that mutations in the Toll receptor resulted in increased susceptibility to
fungal infection and that Toll controlled the expression of the antifungal peptide gene
drosomycin (Lemaitre et al. 1996; Lemaitre et al. 1997). In 1997 Medzhitov et al
(Medzhitov et al. 1997) reported the discovery of the human equivalent "hToll", now
known as TLR4. Subsequently a total of ten human TLRs have been identified (TLR1-
10). Ligands have been characterized for 5 of the TLR (Table 4). Cells may use a
number of different TLR to detect several features of a microbe simultaneously. In
addition some of the receptors can dimerise (e.g. TLR2/1, TLR6/1, TLR2/6) allowing
additional specificity (Ozinsky et al. 2000). This allows the nature of the microbe to be
elucidated and an effective immune response, both innate and adaptive, to be activated.
TLR proteins are characterised by an extracellular leucine-rich repeat (LRR) domain,
small extracellular cysteine-rich domains, and a cytoplasmic domain that is responsible
for signal transduction. The number and arrangement of the cysteine-rich domains varies
between different members of the Toll family. The mechanisms of microbial recognition
are not well defined. It may be a direct recognition of the PAMP by the receptor, or
recognition of a molecule that initially recognises the PAMP (Wright 1999). In flies Toll
is activated by a secreted ligand, Spatzle. A mammalian homologue of Spatzle has not
been identified. The cytoplasmic domain is homologous to the cytoplasmic domain of
the IL-1 receptor (IL-1R) family. This area is therefore referred to as the Toll/IL-IR
homology (TIR) domain. This TIR domain is responsible for signal transduction. The
extracellular domain of the TLR bears no homology to the IL-1R. Downstream
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signalling events after ligand binding to the TLR follow those seen after activation of the
IL-1R (see section 1.2.1.1.2). The protein MyD88 is an adapter of signal transduction
with a TIR domain, which is recruited following TLR ligation. Myd88-adaptor-like
(MAL) is another such protein (Fitzgerald et al. 2001). Myd88 appears to be a signal
adaptor used by several TLRs (including TLR4), while MAL is used predominately by
TLR4 (O'Neill 2002). Recruitment of MyD88 or MAL result in a cascade of events
culminating in the nuclear translocation of NF-kB (Cario et al. 2000; Kopp and
Medzhitov 1999; Muzio et al. 1998) and activation of the AP-1 transcription factor
family. This results in the activation of a number of genes, including pro-inflammatory
cytokines and antimicrobial peptides (Becker et al. 2000) (Figure 4). Although a
common inflammatory "danger signal" is activated following ligation of TLR, the exact
genes and resultant proteins expressed differ according to the TLRs activated
(Hirschfeld et al. 2001; Jones et al. 2001a) and the cell type involved (Thoma-Uszynski
et al. 2000). It has been suggested that the signal transducers recruited such as MyD88
and MAL may tailor the response generated (O'Neill 2002).
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LPS - Leptospira interrogans
Porphyromonas gingivalis
M. tuberculosis - lipoarabinomannan
phosphatidylinositol diamannoside




HSP60 (human and chlamydial)
Taxol
Fibronectin extra domain A (EDA)
F protein - respiratory syncytial
virus
Escherichia coli P fimbriae
Flagellin
unmethylated CpG DNA motifs
(Aderem and Ulevitch 2000;
Lien et al. 1999)
(Aderem and Ulevitch 2000)
(Aderem and Ulevitch 2000)
(Werts et al. 2001)
(Hirschfeld et al. 2001)
(Means et al. 1999a; Means et
al. 1999b; Thoma-Uszynski
et al. 2001)
(Underhill et al. 1999)
(Alexopoulou et al. 2001)
(Aderem and Ulevitch 2000)
(Ohashi et al. 2000)
(Kawasaki et al. 2000)
(Okamura et al. 2001)
(Kurt-Jones et al. 2000)
(Frendeus et al. 2001;
Hedlund et al. 2001)
(Hayashi et al. 2001)
(Bauer et al. 2001; Hemmi et
al. 2000; Takeshita et al.
2001)
Adapted from Underhill and Ozinsky 2002
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The cellular distribution of TLRs is wide (Medzhitov et al. 1997; Muzio et al. 2000) and
different TLR are differentially expressed and regulated (Hornung et al. 2002; Zarember
and Godowski 2002). In general, cells expressing TLRs include effectors of the immune
system such as antigen presenting cells (APC) - e.g. macrophages (Akashi et al. 2000;
Yang et al. 1999b), dendritic cells (Thoma-Uszynski et al. 2000) - and B cells (Roshak
et al. 1999). Expression has also been detected in epithelial cells (Cario et al. 2000;
Fichorova et al. 2002; Schilling et al. 2001), endothelial cells (Faure et al. 2001) and
adipocytes (Lin et al. 2000). Using immortalised human vaginal, ectocervical and
endocervical cell lines, TLR1,2,3,5 and 6 mRNA expression has been identified
(Fichorova et al. 2002). However these cell lines failed to express TLR4. Recent reports
suggest that within the human endometrium, TLR1-6 and CD 14 mRNA is identifiable.
The endometrial epithelial cell line RL expresses TLR1,2,3,5,6, CD14 and possibly
TLR4 (Young et al. 2002). TLR4 expression has been examined through the menstrual
cycle, and is present in the proliferative and secretory phases, but not in the menstrual
phase. TLR3 is present in all phases with the exception of the late secretory phase
(Young et al. 2002).
Bacterial products such as LPS and cytokines including IL-ip, TNFa and IFNy increase
TLR4 expression in human monocytes and neutrophils (Muzio et al. 2000). Endothelial
cell expression of TLR2 is induced by LPS, TNFa, and IFNy while LPS and IFNy also
up-regulated TLR4 in endothelial cells (Faure et al. 2001) and intestinal epithelial cells
(Abreu et al. 2002). IL-4 (Staege et al. 2000) and IL-10 (Muzio et al. 2000) have been
demonstrated to down regulate TLR4 expression, suggesting that a Th2-type immune
response may inhibit TLR activation. An LPS-tolerization phenomenon has been
observed and two groups have described a transient decrease in TLR4 mRNA levels on
LPS stimulation in mice (Medvedev et al. 2000; Nomura et al. 2000) that may explain
this phenomenon. Decreased expression of TLR has been suggested as a protective
mechanism in areas like the intestinal mucosa, vagina and cervix where cells are
continually being exposed to bacterial LPS (Abreu et al. 2001; Fichorova et al. 2002).
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1.4.1.1 TLR4
TLR4 has now been recognised as the predominant receptor for lipopolysaccharide
(LPS) of gram negative bacteria. This was originally identified in mice, where a genetic
defect resulting in hypo/non-responsiveness to LPS was linked to TLR4 (Poltorak et al.
1998). This has subsequently been confirmed in other systems (Chow et al. 1999;
Hoshino et al. 1999; Lien et al. 2000; Rhee and Hwang 2000; Tapping et al. 2000). A
constitutively active TLR4 construct drives NF-kB activation, AP-1 activation and
cytokine production (Medzhitov et al. 1997). There are a number of other proteins
involved in this interaction: LPS binding protein (LBP) was identified in plasma with
high affinity binding to the lipid A moity of LPS (Schumann et al. 1990). Further to this
CD 14, a differentiation antigen of monocytes, was found to bind complexes of LPS and
LBP, and blockade of CD 14 with monoclonal antibodies prevented synthesis of TNF-a
by whole blood incubated with LPS. (Wright et al. 1990). TLR4 acts with the
CD14/LBP/LPS complex to generate a transmembrane signal and cell activation. An
additional protein, MD-2, has been identified as being important for signalling via TLR4
(Shimazu et al. 1999; Yang et al. 2000b). MD-2 is a secreted protein that binds to the
extracellular portion of TLR4 where it facilitates LPS responsiveness. Work has shown
that direct physical contact occurs between LPS, CD 14, TLR4 and MD-2 (da Silva
Correia et al. 2001; Poltorak et al. 2000), suggesting that for TLR4 a direct recognition
of LPS occurs in conjunction with these molecules.
In vitro human (3 defensin 2 has been up-regulated following stimulation with LPS and
bacterial lipoprotein. This has been dependent on CD 14 and TLR2 expression
respectively (Becker et al. 2000; Birchler et al. 2001; Diamond et al. 1996). Scott et al
(Scott et al. 2000) suggest that cationic antimicrobials, including HBD2, may block the
binding of LPS to LBP, thus limiting the magnitude of an inflammatory response.
1.4.1.2 CD14
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The CD 14 molecule, like TLR, has multiple leucine rich repeats extracellularly, but
CD14 does not have an intracellular signalling domain. CD14 exists both as a soluble
form (Bazil et al. 1989) and as a glycosylphosphatidylinositol (GPI)-linked outer
membrane protein (Bazil et al. 1989; Haziot et al. 1988). The soluble form appears to
mediate LPS stimulation of cells that do not express membrane bound CD 14 (Frey et al.
1992; Pugin et al. 1993). CD14 is predominantly expressed on monocytes, macrophages
and neutrophils while expression on endothelial and epithelial cells has not been clearly
defined. If present on these latter cells it is at a far lower level of expression (Jersmann
et al. 2001). Some work has been carried out looking at the regulation of CD 14: LPS
(Imai et al. 2000) and PGE2 (Iwahashi et al. 2000) stimulate CD 14 expression, while
TGF(3 down regulates CD 14 expression in mouse macrophages. TNFa and IFNy
increased CD 14 expression in human neutrophils (Takeshita et al. 1998). Expression of
CD14 in human umbilical vein endothelial cells is up-regulated by LPS,
lysophosphatidic acid and fetal calf serum. TNFa, and IFNy had no effect on CD 14
expression in this system, while PMA reduced the expression (Jersmann et al. 2001).
Heinemann et al 1996 (Heinemann et al. 1996) have shown that monocytes infected with
C. pneumonia up-regulated CD 14 surface expression 8 hours post infection. CD 14 has
been shown to be an essential receptor for HSP60 and chlamydial HSP60 activation of
mononuclear cells (Kol et al. 2000).
1.4.1.3 TLR9
Bacterial DNA has been shown to be capable of activating cells in a TLR-dependent
manner. Bacterial DNA contains unmethylated CpG ("C followed by a G")
dinucleotides that have inflammatory and adjuvant properties (McCluskie et al. 2001;
Zimmermann et al. 1998). In contrast vertebrate DNA CpG dinucleotides occur
infrequently and are highly methylated (Krieg 1999). Hemmi et al (Hemmi et al. 2000)
demonstrated that TLR9 deficient mice failed to elicit an inflammatory response to CpG
DNA in vitro. This has been subsequently confirmed in human cells (Bauer et al. 2001;
Flornung et al. 2002; Takeshita et al. 2001). Unmethylated CpG DNA motifs are
recognised by macrophages, dendritic cells and B cells, but it is unclear how important
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this is in the response to bacteria, considering that the cells will also see a variety of
bacterial cell wall products. There may however be a role for the detection of
intracellular pathogens. Limited investigation has addressed the regulation of TLR9
expression. Interestingly, LPS stimulated TLR9 gene expression in a mouse macrophage
cell line (An et al. 2002).
1.4.2 Natural antimicrobials
Gene encoded natural antimicrobials are secreted proteins of the innate immune
response that play a major part in both innate and adaptive immunity. They are widely
distributed in nature and represent an ancient mechanism of host defence. Natural
antimicrobials have been described in plants (thionins), insects (eg. cecropins,
drosomycin and insect defensins), and vertebrates (eg. magainins, protegrins,
cathelicidin and defensins) (Hancock and Lehrer 1998; Schroder 1999). Within a single
species, there will be a number of different natural antimicrobials. This allows for a wide
spectrum of antimicrobial activity and for synergy to occur. Some natural antimicrobials
will have additional non-antimicrobial functions (Hancock and Diamond 2000).
The natural antimicrobials are typically cationic (containing excess basic lysine, arginine
and histidine residues) hydrophobic molecules composed of 12-45 amino acid residues.
They have a variety of 3-D structures and can be divided into four structural classes
(Hancock and Diamond 2000); (3-sheets, a-helices, extended peptides and loop peptides.
Some of these are constitutively expressed while others are inducible.
The predominant mechanism of killing micro-organisms appears to be by
permeabilisation of the cell membranes (Risso 2000). The positively charged
antimicrobials interact with negatively charged components of bacterial membranes such
as LPS, LTA and phospholipids. Their selective toxicity is thought to be due to the high
anionic phospholipid content of microbial membranes, in contrast to the zwitterionic
phospholipids (which have both a cationic and an anionic region) and the high content of
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cholesterol in mammalian cells. Antimicrobial peptides are thought to aggregate,
forming multimeric pores in the cytoplasmic membrane. Depolarisation of the cell
membrane may also occur. Wu et al (Wu et al. 1999) propose that other mechanisms of
action could include stimulation of autolytic enzymes and interference with bacterial
DNA and /or protein synthesis.
In humans endogenous antimicrobials under investigation in this thesis include the
defensins, secretory leukocyte protease inhibitor (SLPI), and granulysin.
1.4.2.1 Defensins
Mammalian defensins are peptides containing 28 - 42 amino acids, with 6 invariant
cysteines, which form triple stranded (3 sheets. They were first recognised 30 years ago
in rabbit macrophages and subsequently in rabbit and guinea pig neutrophils (Zeya and
Spitznagel 1966; Zeya and Spitznagel 1968). The defensins have been further
characterised and divided into 2 classes a and (3, distinguished by structural features at
gene and peptide levels. The early peptides identified were of the a defensin sub class.
A third, 0 defensin, isolated from macaque leukocytes has been described and it has a
unique circular structure (Tang et al. 1999). The a defensins consist of 29-35 amino
acids and are shorter than the (3 defensins, which consist of 38-42 residues. The tertiary
structures of the a and (3 defensins are nearly superimposable (Zimmermann et al. 1995),
but the position of the cysteine residues in the amino acid sequence and their disulphide
motifs differs between the classes as shown below (adapted from (Huttner and Bevins
1999; Raj and Dentino 2002)):
• Position of the cysteine residue in the amino acid sequence;
Human neutrophil a defensins (HNP1-4 and HD-5 and HD-6)
X-C1 -X, -C2-X4-C3-X9-C4-X9-C5-C6
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Human (3 defensins (HBD-1-4)
X-C1-X6-C2-X4-C3-X9-C4-X6-C5-C6
• Disulphide motif:
a defensins C, C6; C2.„__C4;C3 C5
(3 defensins C! C5; C2 C4; C3 C6
0 defensin C1...._C6; C2 C5;C3 C4
The a defensins have been localised to human (HNP 1-4) and rabbit neutrophils, rabbit
lung macrophages, mouse, rabbit and human (HD5 and 6) small intestine Paneth cells
(Diamond and Bevins 1998; Lehrer et al. 1993) and more recently to the human female
reproductive tract. HD5 has been described in the vagina, ectocervix, endocervix,
endometrium, fallopian tubes and chorion (Quayle et al. 1998; Svinarich et al. 1997b).
Expression of HD5 in the endometrium was found to be highest in the early secretory
phase of the menstrual cycle and similarly in cervico-vaginal lavages highest
concentrations were found in the secretory phase (Quayle et al. 1998). The a defensins
are produced and stored as pre-propeptides and undergo post translational and enzymatic
processing either within the cytoplasmic granules of the neutrophil or in the lumen of the
small intestine. In mouse small intestine, matrilysin co-localises with a defensins in
paneth cell granules, and in vitro it cleaves the pro segment from a defensin precursors
(Wilson et al. 1999). However, this does not appear to be the case in humans. A
corresponding enzyme involved in the processing of human defensins has not been
clearly identified. Ghosh et al (Ghosh et al. 2002) demonstatrate a specific pattern of
trypsin isozymes expressed in Paneth cells co-localize with HD5 and that this protease
can efficiently cleave HD5 propeptide to forms identical to those isolated in vivo.
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P defensins were initially described in the bovine tracheal mucosa where levels where
found to increase in vitro in response to stimulation with heat killed bacteria and LPS
(Diamond et al. 1991). Four human P defensins (HBD1-4) have since been described in
a variety of epithelial tissues, some monocytes and alveolar macrophages. HBD1 and 2
were initially identified in skin, plasma, saliva and lung (Bals et al. 1998; Bensch et al.
1995; Harder et al. 1997; Zhao et al. 1996). In the human female reproductive tract
HBD1 and 2 have been isolated from the mucosa of the vagina, ectocervix and
endocervix, uterus and fallopian tubes, urine and cervical mucus (Jameson 1999; Valore
et al. 1998). Cyclical variation has not been investigated. HBD3 has been identified in
adult heart, skeletal muscle, placenta, uterus skin, testis, oesophagus, gingival
keratinocytes, trachea and fetal thymus (Garcia et al. 2001; Peng Jia et al. 2001). HBD4
expression has been detected during infection in the testis, uterus, thyroid gland, lung
and kidney (Garcia et al. 2001). In addition to the above described P defensins a further
28 new human P defensin genes have been identified using a genomics based approach
(Schutte et al. 2002), providing new opportunities to examine the functions of these
proteins.
All the genes for the human P defensins can be localised to gene clusters on 3
chromosomes; 6, 8, and 20 (Schutte et al. 2002). The 5'-flanking region of HBD1
contains nuclear factor (NF)-interleukin (IL)-6 and IFNy consensus sites (Raj and
Dentino 2002), HBD2 has NF-kB, NF-IL-6, STAT and AP-1 family sites (Tsutsumi-
Ishii and Nagaoka 2002), while HBD3 has NF-IL-6, STAT and AP-1 family sites (Jia et
al. 2001). These consensus sites suggest that inflammatory mediators regulate the
expression of these proteins. Unlike the a defensins in the azurophil granules of
neutrophils, the epithelial P defensins are not stored in cytoplasmic granules, and
therefore concentrations are governed by synthesis and secretion rates. The P defensins
are constitutively expressed and can in some cases, particularly HBD2, be up-regulated
upon infection or inflammation (Krisanaprakornkit et al. 2000; Krisanaprakornkit et al.
1998; Liu et al. 1998; Zhao et al. 1996). This can be mimicked in vitro with LPS and
inflammatory cytokines, such as IL-1 and TNFa, in systems such as the lung, gut and
gingiva (Diamond et al. 1996; Harder et al. 2000a; Krisanaprakornkit et al. 2000; O'Neil
et al. 1999). The inflammatory mediators INFy, IL-1 (3 and IL-1 (3 in combination with
TNFa have been shown to increase HBD2 mRNA in human endometrium (King et al.
2002).
The defensins have been shown to have antimicrobial activity to a wide range of
bacteria, fungi and viruses (Ganz et al. 1985; Risso 2000). The in vitro minimal
inhibitory concentrations against a panel of microorganisms ranged between 0.5-10pM
for most defensin peptides (Risso 2000). Different defensins can have significantly
different specificities and microbicidal potencies. For example HNP 1 is a potent
antifungal agent against Candida albicans, whereas HNP 3 has minimal activity (Raj
and Dentino 2002).
In vivo studies show that the defensins are elevated in patients with bacterial infections.
For example, in psoriasis where there are constant skin lesions, infection is only a minor
problem and this may be due to the fact that there are higher levels of HBD2 than the
levels seen in normal skin (Schroder and Harder 1999). A role for defensins in cystic
fibrosis has been postulated, where increases in ion concentration inactivate (3 defensins
and Pseudomonas aeruginosa colonises the respiratory epithelium with potentially
devastating consequences (Goldman et al. 1997). There is the possibility of a similar role
in the female reproductive tract where cyclical changes in the chemical composition
(e.g. pH, cytokines) occur through the menstrual cycle.
The defensins have been found to have a number of functions in addition to their
antimicrobial activity (Hancock and Diamond 2000; Yang et al. 2001b). Other innate
immune functions include the induction of histamine secretion (van Wetering et al.
1999) and the classical complement pathway (van den Berg et al. 1998), and modulation
of cytokine production and adhesion molecule expression (Chaly et al. 2000; Perregaux
et al. 2002). Evidence is accumulating that the defensins may play a role in the
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recruitment of cells of the adaptive immune response, a defensins are chemotactic for
monocytes, dendritic cells and T-cells (Chertov et al. 1996; Yang et al. 2000a), while (3
defensins are chemotactic for dendritic and memory T-cells (Yang et al. 1999a; Yang et
al. 2001a; Yang et al. 2001b). a defensins inhibit fibrinolysis and may therefore play a
role in thrombosis (Higazi et al. 1996). They can also induce a proteoglycan-dependent
catabolism of low-density lipoproteins, possibly contributing to atherosclerosis (Higazi
et al. 2000). In vitro neutrophil defensins can interact with ACTH receptors to inhibit
ACTH-induced steroidogenesis (Lehrer et al. 1993), potentially decreasing Cortisol
release during stress from infection. Defensins increase proliferation of epithelial cells
and may thus play a role in wound healing (Murphy et al. 1993; van Wetering et al.
1999).
The defensins can be seen to play an important part in the innate immune response, but
can also integrate this into the evolving adaptive immune response. In addition other
regulatory functions of these molecules are being realised.
1.4.2.2 Secretory Leukocyte Protease Inhibitor (SLPI)
SLPI, also known as antileukoprotease, is an 11.7kDa proteinase inhibitor comprising
107 amino acids with 16 cysteine residues (Seemuller et al. 1986) forming eight
intramolecular disulfide bonds. It was first described in bronchial secretions in 1972 and
subsequently in human cervical secretions and seminal plasma (Franken et al. 1989).
SLPI is produced by neutrophils (Bohm et al. 1992), (Jin et al. 1997) and epithelial cells
(Abe et al. 1991).
The presence of SLPI in a variety of human reproductive tissues including the cervical
crypts, cervical mucous (Franken et al. 1989), uterine fluid (Casslen et al. 1981), term
decidua (Denison et al. 1999c) and amniotic membranes and fluid (Zhang et al. 2001)
has been described. Franken et al (Franken et al. 1989) did not find it in the
endometrium, ovaries or fallopian tubes or urine. King et al (King et al. 2000) have
subsequently described the presence of SLPI in the endometrium, first trimester decidua,
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trophoblast and term decidua. SLPI protein levels have been found to increase in the
ovulatory phase in human cervical mucosa (Moriyama et al. 1999), and increased
endometrial expression occurs within the late secretory phase of the menstrual cycle
(King et al. 2000).
SLPI has been characterised as a neutrophil elastase inhibitor in the lung, and has
inhibitory effects on other neutrophil proteases, cathepsin G and pancreatic enzymes -
trypsin and chymotrypsin (Thompson and Ohlsson 1986). SLPI activity limits the
damage that these proteases may have on normal tissue, particularly in chronic
inflammatory diseases such as emphysema and cystic fibrosis. SLPI inhibits histamine
release from mast cells in vitro (Dietze et al. 1990). It suppresses the production of
matrix metalloproteinases from monocytes by inhibiting enzymes involved in PGE2
synthesis (Zhang et al. 1997). It may also play a role in wound healing as SLPI null mice
show impaired cutaneous wound healing and increased inflammation and elastase
activity (Ashcroft et al. 2000). SLPI has been found prevent NK-kB activation (Lentsch
et al. 1999), a possible mechanism by which it exerts anti-inflammatory effects.
SLPI has another protective role as a protein of the innate immune defence armoury.
SLPI has been demonstrated to have bactericidal activity against Escherichia coli and
Staphylococcus aureus in vitro (Hiemstra et al. 1996), skin associated bacteria (P.
aeruginosa and S. epidermidis (Wiedow et al. 1998)) and intestinal pathogens such as
Salmonella typhimurium (Si-Tahar et al. 2000). This suggests that SLPI has activity
against both gram negative and gram positive bacteria. Anti-viral effects of SLPI in
saliva against HIV has been demonstrated (McNeely et al. 1995). In vivo women with
lower vaginal fluid concentrations of SLPI had higher concentrations of vaginal HIV-1
and higher transmission rates to their babies (Pillay et al. 2001). Levels of vaginal SLPI
are also decreased in women with other STIs such as gonorrhoea, chlamydia and
Trichomonas vaginalis (Draper et al. 2000). Anti-fungal effects against Aspergillus
fumigatus and Candida albicans have been reported (Tomee et al. 1997; Wiedow et al.
1998). The antimicrobial effects of SLPI are augmented in the presence of other
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antimicrobials. Singh et al (Singh et al. 2000) have demonstrated synergistic and
additive effects of combinations of antimicrobials.
The gene for SLPI is found on chromosome 20ql2 (Kikuchi et al. 1998). The promoter
region has not been extensively studied, but early investigations demonstrated AP-1 and
AP-2 transcription factors (Abe et al. 1991). Another serine protease inhibitor, elafin has
been demonstrated to have a NF-kB promoter site (Bingle et al. 2001), which has not
been identified for SLPI. The SLPI protein is composed of two homologous domains,
about equal in size. The C terminal domain of the protein is responsible for the protease
inhibitory effects (Eisenberg et al. 1990; Kramps et al. 1990), while the N terminal has
been shown to effect bacteriocidal functions (Hiemstra et al. 1996).
The mechanism of the antimicrobial action of SLPI is unclear. Like the defensins SLPI
is also a cationic protein, and it may be that cationic/anionic interactions with bacterial
cell membranes results in permeabilisation as described above. High salt concentrations
are known to inhibit the bacteriocidal effects of SLPI (Hiemstra et al. 1996). Another
mechanism has been proposed by Miller et al (Miller et al. 1989) who show that SLPI
binds to mRNA and DNA interfering with the interaction of RNA-metabolizing
enzymes, such as RNase.
Release of SLPI is stimulated by corticosteroids (Abbinante-Nissen et al. 1995),
progesterone (Denison et al. 1999a), cytokines including IL-1, TNFa in amniotic cells
(Zhang et al. 2001) airway epithelial cells (Sallenave et al. 1994) and intestinal epithelial
cells (Si-Tahar et al. 2000), and IL-10 and IL-6 in mouse macrophages (Jin et al. 1998).
Jin et al also demonstrated SLPI induction with LPS, LTA in vitro and Pseudomonas
aeruginosa in vivo. Neutrophil elastase and defensins results in an increase of cell
associated SLPI (van Wetering et al. 2000a; van Wetering et al. 2000b) in primary
bronchial epithelial cells. IFNy (Jin et al. 1997), TGF-(3 (Jaumann et al. 2000) and PGE2
(Denison et al. 1999a) have been shown to inhibit SLPI release.
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1.4.2.3 Granulysin
Granulysin, also known as 519 and NKG5, is a protein present in cytotoxic T
lymphocytes (CTL) (Jongstra et al. 1987) and NK cells (Pena et al. 1997; Yabe et al.
1990). It has been localised to the cytotoxic granules of CTL and NK cells that are
released upon antigenic stimulation by exocytosis (Smyth et al. 2001) with the capacity
to directly kill intracellular microbial pathogens. It is a gene product which is expressed
by T lymphocytes 3-5 days after activation (Jongstra et al. 1987) and in this context is
therefore a weapon of the adaptive immune response.
Granulysin is a member of the saposin-like protein (SAPLIP) family. SAPLIP molecules
contain six conserved cysteines and hydrophobic residues (Munford et al. 1995). The
cysteine residues show a disulfide bonding pattern C, C6, C2....C5 and C3___. C4, a similar
pattern to that seen for the 0 defensins. Granulysin contains a tyrosine instead of a
cysteine at the first position. The most closely related member of the SAPLIP family to
granulysin is porcine NK-lysin which was originally isolated on its antibacterial activity,
but in addition kills nucleated target cells (Andersson et al. 1995a). Granulysin shows
43% identity and 66% similarity to NK-lysin in the SAPLIP domain (Krensky 2000).
The 5'-flanking region of granulysin contains NF-kB, AP-1 and cAMP-response
element promoter sites that may be involved in transcriptional regulation (Manning et al.
1992). Granulysin is initially made as a 15kDa pro-protein which is then processed to a
9kDa protein. It has been proposed that the structural differences between the 15kDa and
9kDa proteins regulate the lytic potential of the molecule, limiting the potential damage
it could cause intracellularly post synthesis (Hanson et al. 1999). As seen with the
defensins, granulysin is pH sensitive - an acidic environment reducing the lytic potential
of the molecule.
Granulysin from cytolytic T lymphocytes has been shown to kill extracellular
Mycobacterium tuberculosis and decrease the viability of intracellular M. tuberculosis
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(Stenger et al. 1998). Synergy between granulysin and perforin, a pore-forming protein
contained within the same cytolytic granules, was demonstrated. In vitro bactericidal
activity of recombinant granulysin has been shown against Escherichia coli,
Staphlococcus aureus, Listeria monocytogenes, Salmonella typhimurium, Cryptococcus
neoformans, Candida albicans, and Leishmania major (Stenger et al. 1998). Mackewicz
et al (Mackewicz et al. 2000) have shown in vitro that granulysin is unable to affect the
infectivity of HIV virions or HIV replication. Therefore granulysin has appreciable
activity against gram negative and positive bacteria, fungi and parasites, but activity
against viruses has yet to be demonstrated. In addition to antimicrobial activities
granulysin induces apoptosis of tumour cell lines (Gamen et al. 1998) and stimulates
mitogenicity of endothelial cells (Langer et al. 1999).
The mechanisms of antimicrobial activity are not fully elucidated. SAPLIP proteins are
known to interact with lipids, activating lipid degrading enzymes, and it has therefore
been proposed that granulysin interacts directly with lipids in the bacterial cell wall.
Granulysin does not appear to form pores, but it does allow leakage of intracellular dye
from liposomes (Krensky 2000). Gamen et al (Gamen et al. 1998) show that apoptosis is
induced in Jurkat cells, with ceramide release (which initiates the caspase cascade and
induces apoptosis) and mitochondrial pertubations, and these mechanisms may also be
involved in the antimicrobial activity of granulysin.
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1.5 Sexually transmitted infections (STI)
There are over 25 STIs, few of which are fatal and most of which can be treated.
However, if left untreated STIs may cause serious and permanent damage such as
infertility in adults, as well as pathology in the fetus and neonate. The damage can be
both physical and psychological. The most common of the STIs and their incidence in
the UK is shown in Table 5.
Table 5: New episodes of the common STIs in the UK
STI 1998 1999 comments
Chlamydia* 48 956 56 855 including asymptomatic cases
Gonorrhoea* 13 190 16 470 uncomplicated cases only.
HIV 2 761 2 942 number of HIV infected individuals
Genital herpes 17 098 17 456 first attack
simplex*
Genital warts* 70 460 72 233 first attack
Hepatitis B 861 749 For England Wales and Northern Island
295 386 For Scotland
Hepatitis C 4 521 5 768 For England Wales and Northern Island
2 017 1 954 For Scotland
*New episodes seen in genitourinary medicine clinics, episodes seen can involve the
same individual more than once. (Adapted from Morgan 2002)
A review of the effect of the menstrual cycle and contraceptive use on STI acquisition
follows. Chlamydia trachomatis infection is then considered in further detail.
1.5.1 Sexually transmitted infections and the menstrual cycle
Under the influence of endogenous hormones components of the immune system vary as
discussed previously (section 1.3.1). When considering STIs it could be envisaged that
these cyclical changes allow certain phases of the menstrual cycle to be more prone to
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acquisition of STIs. An increase in chlamydial salpingitis is seen early in the
proliferative phase with significantly more cases occurring within seven days of the
onset of menstruation (Korn et al. 1998; Sweet et al. 1986), while increased detection of
asymptomatic infection occurs in the late secretory phase (Crowley et al. 1997). Anti-
chlamydial activity of cervical secretions varies through the menstrual cycle, being
greatest in the first three weeks of a five week cycle. This anti-chlamydial effect was
more pronounced in women not using hormonal contraceptives when compared to users
of hormonal contraceptives (Mahmoud et al. 1994). Acquisition of gonorrhoea has been
shown to increase at the time of menstruation (Eschenbach et al. 1977; Sweet et al.
1986). A variation in the detection of HIV RNA levels in HIV positive women
according to the phase of the menstrual cycle has been demonstrated; levels falling from
the proliferative to the secretory phase (Greenblatt et al. 2000).
1.5.2 Role of contraception in the acquisition of sexually transmitted infections
A number of studies have investigated the role of hormones and contraception in STI
acquisition and transmission with conflicting results. The one clear message is that
hormones do play a role and the consequences of this need to be considered (Brabin
2001). The review presented here concentrates on the evidence relating to chlamydial
infection with some examples of other STIs.
Barrier methods of contraception afford good protection against STIs although this is not
absolute due to incorrect or inconsistent usage and rupture. The male condom protects
against infections such as Trichomonas vaginalis, C. trachomatis, N. gonorrhoea, and
Herpes simplex virus.
The data on hormonal methods of contraception is inconsistent. Animal models
(reviewed in (Washington et al. 1985)) show that progesterone suppresses the growth of
gonorrhoea but enhances the growth and survival of chlamydia in rats (Kaushic et al.
1998). Oestrogen similarly enhances growth and survival of chlamydia in guinea pigs
(Rank et al. 1982) but infection with gonorrhoea is unaffected or slightly increased. In
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monkeys, OCP had no effect on the course of chlamydial acute salpingitis (Patton et al.
1994b). In vitro Kleinman et al (Kleinman et al. 1987) present data showing that ethinyl
oestradiol, mestranol (a synthetic oestrogen metabolised to ethinyl oestradiol in the
body) and medroxyprogesterone acetate (6a methyl 17a hydroxyprogesterone acetate)
do not affect chlamydial replication in cultured human endometrium. In contrast, others
have shown chlamydial inclusions in epithelial cultures are decreased in the presence of
progesterone or progesterone in combination with an oestrogen (Moorman et al. 1986;
Wyrick et al. 1989) while oestrogen alone increases attachment of C. trachomatis to
epithelial cells (Maslow et al. 1988).
In vivo the OCP has been shown to cause a 70% increase in gonorrhoea and a 3 fold
increase if injectable contraceptives are used although other studies have shown no
significant association with OCP use (Carlin and Boag 1995). Studies on chlamydia are
more consistent, with women on the COCP having higher rates of chlamydial infection
of the lower genital tract (Bontis et al. 1994; Cottingham and Hunter 1992; Kinghorn
and Waugh 1981). However, the COCP may be protective for upper genital tract
infection (Rubin et al. 1982; Washington et al. 1985; Wolner-Hanssen et al. 1990). It has
been suggested that thicker cervical mucus and decreased menstrual flow may account
for the decrease in pelvic inflammatory disease (PID).
The LNG-IUS has thus far been shown to be protective for PID (Toivonen et al. 1991),
in contrast to copper and inert intra uterine devices which have been associated with an
increased incidence of infection in the first 20 days following insertion (Farley et al.
1992), and average levels of infection thereafter.
1.5.3 Chlamydia trachomatis
Chlamydia trachomatis is one of the most common causes of sexually transmitted
infections (Gerbase et al. 1998; Groseclose et al. 1999; Morgan 2002). Infection can be
both acute and chronic with long term morbidity. The following review will examine
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the clinical epidemiology, the developmental cycle of the organism and the immune
responses to infection. How this relates to the resultant pathology will be discussed.
1.5.3.1 Clinical infection and sequelae
The most important implications of genital chlamydia are the reproductive health
sequelae of upper genital tract infection in women. In addition chlamydia causes genital
tract complications in men. Much chlamydial infection goes undiagnosed because it is
asymptomatic. If symptoms do appear they usually do so 1-3 weeks after the time of
infection. In men the symptoms include dysuria, penile discharge, itchiness and
occasionally testicular tenderness, with epididymitis, and proctitis. In men and women, a
reactive arthritis can occur. In women the infection is more often asymptomatic but
cervicitis, abnormal vaginal bleeding and intermenstrual bleeding, and pelvic pain may
occur. Untreated infection can ascend into the fallopian tubes causing a salpingitis and
PID (Cates and Wasserheit 1991; McCormack 1994).
Continued infection, inflammation and scarring can lead to chronic pelvic pain, tubal
pregnancy, infertility (Buchan et al. 1993; Cates and Wasserheit 1991) and possible
adverse events in pregnancy, such as chorioamnionitis, premature rupture of membranes
and preterm delivery (Gravett et al. 1986; Martin et al. 1982; Sweet et al. 1987).
Evidence suggests that 20% of women with chlamydial lower genital tract infection will
develop PID, 4% chronic pelvic pain, 3% infertility and 2% adverse pregnancy
outcomes (Paavonen and Eggert-Kruse 1999). After a single episode of PID, the relative
risk for tubal factor infertility is approximately 10%, but with repeated episodes this risk
doubles rising to almost 40% after 3 or more episodes (Westrom 1994). Women with a
history of PID have a 7 - 10 fold increased risk of tubal pregnancy when compared to
women with no history of PID (Westrom et al. 1981). More recently, cervical
chlamydial infection has been suggested as an independent risk factor in the
development of cervical neoplasia (Anttila et al. 2001; Koskela et al. 2000).
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Perinatal transmission of infection to neonates during a vaginal birth occurs in 50%-60%
of infants born to infected mothers (Gencay et al. 2001; Schachter et al. 1986).
Conjunctivitis and/or chlamydial pneumonia (Beem and Saxon 1977; Gencay et al.
1995; McGregor and French 1991) may develop in 10%-30% of these cases.
Diagnosis of C. trachomatis is a routine procedure, with either an ELISA or the more
expensive but more sensitive nucleic acid amplification tests (polymerase chain reaction
or ligase chain reaction). These more sensitive tests can be carried out on endocervical
swabs, as well as first void urine specimens or vaginal or vulval swabs. Tetracyclines or
the macroglides - particularly azithromycin - are effective in treating the infection. As
C. trachomatis is an infection which can be asymptomatic, is detectable and can be
treated before expensive complications arise the possibility of population screening is
under consideration. At present screening is only carried out in known at risk
populations such as those undergoing a termination of pregnancy. Further analysis and
review of this topic is ongoing (Pimenta et al. 2000; Pimenta and Fenton 2001).
1.5.3.2 Taxonomy
Chlamydia taxonomic classification was updated in 1999 (Everett et al. 1999), and will
be briefly reviewed here and in figure 5. The classification is supported by analysis of
phenotype, antigenicity, associated disease, host range, biological data and genetic data.
Members of the order Chlamydiales are obligate intracellular bacteria that have
chlamydia-like developmental cycle of replication and have >80% rDNA sequence
identity with chlamydial 16S or 23S rRNA genes. The order includes four families; i)
Chlamydiaceae, with gram negative elementary bodies (EBs), ii) Simkaniaceae also
with gram negative EBs but with rRNA sequence differences and antigenic differences,
iii) Parachlamydiaceae, which have variable gram staining EBs iv) an unnamed group
containing the strain WSU 86-1044. The family Chlamydiaceae contains the two genera;
Chlamydia and Chlamydophila. The genus Chlamydia includes the species Chlamydia
trachomatis, Chlamydia muridarum and Chlamydia suis, while the genus
Chlamydophila includes the species Chlamydophila psittaci, Chlamydophila
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pneumoniae, Chlamydophila pecorum, Chlamydophila abortus, Chlamydophila caviae
and Chlamydophila felis. Chlamydia trachomatis can be further divided into 18 serovars,
clustered into 2 biovars: trachoma and lymphogranuloma venereum (LGV), each serovar
being recognised by specific monoclonal antibodies. Trachoma serovars are designated
by the letters A-K and Ba, Da and la; A-C being primarily associated with endemic
trachoma and D-K with sexually transmitted infection. LGV biovar includes the serovars
















1.5.3.3 Structure and developmental cycle
Chlamydiales are obligate intracellular parasites, but in contrast to viruses they do have
an inner cytoplasmic and outer membrane like gram negative bacteria. However, they
lack the peptidoglycan layer seen in bacterial cell walls. The outer membrane of the
elementary body is instead cross-linked by disulphide bonds between cysteine residues.
The predominant components of the outer membrane are the major outer membrane
proteins (MOMP), which are 370-375 amino acid proteins. MOMPs make up two thirds
of the cell wall weight and are species specific (Caldwell et al. 1981). LPS is also
present and is genus specific. Intracellularly RNA and DNA and prokaryotic ribosomes
are present. The chlamydiales can synthesis their own proteins, nucleic acids and lipids,
but cannot synthesis high energy phosphate compounds such as adenosine triphosphate
(ATP) and are therefore reliant on the host cell for energy, hence are known as "energy
parasites" (Moulder 1974).
The developmental cycle of chlamydiales sets them apart from other bacteria. It can be
divided into several steps: attachment and entry of an elementary body (EB) to the host
cell, morphological change from an EB to a reticulate body (RB) with intracellular
growth and replication, morphological change from a RB to an EB and release of
infectious particles (Figure 6).
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Figure 6: The chlamydial developmental cycle. (Adapted from Davis and Wyrick 1997)
1. Infectious elementary body (EB) attaches to the host epithelial cell
2. EB invades cell within a vesicle
3. Vesicles fuse. EBs convert to metabolically active reticulate bodies (RB)
4. RBs grow and divide by binary fission in a membrane bound chlamydial inclusion
5. Non infectious RBs differentiate into infectious EBs and exocytosis or host cell lysis
results in release of infectious EBs.
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The EB is an infectious spherical particle about 300-400nm in diameter. The initial
attachment to the susceptible host cell may involve a specific receptor-ligand interaction,
but the exact natures of the structures involved have not been elucidated. There is some
evidence suggesting a heparin sulphate like molecule on the surface of C. trachomatis
may play a role. Attachment may also be charge dependent, as treatment with DEAE-
dextran in vitro can enhance attachment and infectivity (Kuo et al. 1973). C. trachomatis
is only able to infect a limited range of cells and these include non-ciliated columnar,
cuboidal and transitional epithelium for example the mucous membranes of the urethra,
endocervix, endometrium, fallopian tubes, respiratory tract and conjunctivae. Once
attached to the cell the EB is rapidly internalised, the mechanisms are controversial but
are thought to involve receptor-mediated endocytosis, the receptor involved being
unknown. The EB enters the cell in a phagosome and remains in a phagosome through
its entire life cycle. Fusion with a lysosome is inhibited by an unknown mechanism
(Friis 1972; van Ooij et al. 1997). Vesicles containing C. trachomatis EBs fuse and
within 6-8 hours the EBs reorganise into RBs. These are larger particles, 800-1000nm in
diameter. Their outer cell walls lack the cross-linking of protein and are therefore more
osmotically fragile, but this permeability allows uptake of ATP and other nutrients. The
RBs are metabolically active and divide by binary fission over the next 18-24 hours
within the vesicle, now as an inclusion, which can expand to accommodate 200-1000
organisms. Outer membrane antigens and LPS are shed into the inclusion and can be
excreted by the cell (Schachter 1988). Cellular nutrients are required for effective
growth, if a cell is starved or depleted of nutrients the chlamydiae can become slow
growing and non-productive (Jones et al. 2001b). Cycloheximide can inhibit metabolism
of the host cell, but the RB continue to grow, their growth being independent of the host
cells metabolism if nutrients are not in short supply. Finally RBs condense and
differentiate to infectious EBs, which are released from the host cell either by exocytosis
or cell rupture 48-72 hours after initial infection of the cell.
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1.5.3.4 Immune Response to C. trachomatis in the female reproductive tract
The female reproductive tract with the exception of the vagina is a sterile environment.
As detailed previously (section 1.3.1), components of the immune system are present to
mount a response if required. In the case of C. trachomatis both a non-specific innate
immune response and an adaptive immune response are observed.
The histopathological response to C. trachomatis (Kiviat et al. 1990) shows epithelial
cell degeneration, with intraepithelial lymphocytes present. Beneath the epithelium is a
dense infiltration of mononuclear cells and neutrophil exudation occurs through the
epithelium into the lumen. Through the stroma further T lymphocytes and plasma cells
are identifiable.
Experimental infections in animals are usually self-limiting; indicating that the immune
response generated is sufficient to eliminate chlamydiae from the genital tract. It is
believed that the pathology following chlamydial infection is as a result of a persistent
immune response. The response has not been clearly elucidated in humans, and much of
the work has been carried out in animal or in vitro models. The following review
concentrates on data relating to human infection.
The three components of the innate immune response play a role in early chlamydial
infection. The epithelium and mucus secretions provide a physical barrier to infection.
C. trachomatis overcomes this barrier by inducing the epithelial cells to phagocytose the
EB once it is attached to the cell (Moulder 1985). This is unusual, as epithelial cells are
not normally phagocytic. The mechanisms involved are unknown. Within the mucus
lining the reproductive tract are a number of chemical substances that may play a role in
limiting infection. Lactoferrin, lysozyme and zinc are often detailed as having
antimicrobial actions. The natural antimicrobials, such as the defensins detailed
previously, may also play a role in the initial immune response (Yasin et al. 1996).
Spermine and zinc, present in seminal fluid have been reported as having activity against
chlamydia (Mardh et al. 1980). Neutrophils can ingest and degrade EBs; they collect in
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large numbers in the inflammatory exudate and may play an important part in the early
localisation of infection. Epithelial cells themselves will also play a role in the initiation
of the immune response through the secretion of proinflammatory cytokines such as IL-
1 and IL-8 (Kagnoff and Eckmann 1997; Rasmussen et al. 1997).
Both an antibody mediated and a cell mediated specific immune response occur
following chlamydial infection. Antigen specific slgA and IgG are found in the serum
following infection (Cerrone et al. 1991; Watts et al. 1989). MOMP are the principal
target for neutralising antibodies, but chlamydial heat shock proteins may also play a
part (see below). In vitro these antibodies neutralise infectivity, but do not inhibit
adhesion or internalisation of the chlamydia (Caldwell and Perry 1982; Peeling et al.
1984). An inverse correlation between the titre of slgA in genital secretions and the
quantity of chlamydiae isolated from the cervix has been demonstrated (Brunham et al.
1983). Chlamydial heat shock proteins (Chsp), particularly Chsp-60, bears close
homology with the human equivalent (48% homology) and may be a major target for
immunopathological responses. Heat shock proteins (HSP) were first identified in cells
after exposure to elevated temperature. Subsequently HSP have been identified as a
critical component of a highly conserved cellular defense mechanism to preserve cell
survival under adverse environmental conditions. HSP interact with intracellular
polypeptides and prevent their denaturation or incorrect assembly. Chsp-60 immune
recognition may result in an autoimmune response through molecular mimicary
(Domeika et al. 1998; Lin et al. 1991). In human microvascular endothelial cells and
mouse macrophages, recombinant Chsp-60 rapidly activates NF-kB and induces human
IL-8 promoter activity (Bulut et al. 2002). These effects were shown to be TLR4/MD2
dependent. Expression of Chsp is up-regulated in IFNy induced persistent infection
(Ward 1995). Antibody to Chsp60 is strongly associated with occluded fallopian tubes,
but not with acute C. trachomatis infection (Eckert et al. 1997) and is also associated
with ectopic pregnancy (Sziller et al. 1998). The immune response to Chsp in mice has
been demonstrated to be genetically determined and it has been speculated that the same
may be true of human infection (Cohen and Brunham 1999; Zhong and Brunham 1992).
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This could explain why some women are more susceptible to pathology following
chlamydial infection.
Another means of eliminating C. trachomatis is the cell-mediated immune response.
Chlamydia specific T cell clones are generated following infection (Qvigstad et al.
1985). Studies in non-human primates have demonstrated the induction of mRNA for
IFNy, IL-2, IL-6 and IL-10, but not for IL-4 following single or repeated chlamydial
infection of salpingeal tissue (Van Voorhis et al. 1997). CD8+ T lymphocytes are
prominent, although CD4+ T lymphocytes are also present. Fibrosis is also observed in
some subjects. These findings suggest that Thl cytokines (e.g. IFNy) may play a role in
intracellular killing of C. trachomatis. Through the production of cytokines, particularly
IFNy, infection can be limited (Loomis and Starnbach 2002). In vitro IFNy can inhibit
the infection of cell cultures with chlamydia. IFNy induces an enzyme of tryptophan
catabolism, indoleamine 2,3- dioxygenase (IDO), which is responsible for conversion of
tryptophan and other indole derivatives to kynurenine (Taylor and Feng 1991).
Tryptophan is required for chlamydial growth and without it abnormal growth occurs
(Beatty et al. 1993). IL-1 can potentiate this effect of IFNy (Carlin and Weller 1995).
While playing a role in the limitation of infection, the cell-mediated response may also
contribute to the delayed, continued immune response thought to be responsible for long
term sequelae such as infertility. Studies in macaques have shown that while a single
episode of chlamydial salpingitis is usually self limiting, repeated infections will result
in tubal scarring (Patton et al. 1987). Delayed hypersensitivity responses to chlamydiae,
characterized by a submucosal cellular infiltrate of lymphocytes and macrophages,
caused by repeated or persistent infection are thought to be important in the development
of the severe scarring sequelae characteristic of chronic salpingitis (Patton et al. 1994a).
Beatty et al (Beatty et al. 1994) suggest the following model for persistent chlamydial
development and resultant pathology: Chlamydial infection results in the induction of
IFNy from the stimulated immune system. This leads to IDO induction, tryptophan
depletion and aberrant chlamydial growth. The RBs are non-infectious, but viable and
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continue to produce Chsp60, but decrease production of MOMP and LPS (Beatty et al.
1993; Shaw et al. 1999). This maintains the antibody response and ensuing tissue
damage.
The immune mechanisms following chlamydial infection are not yet fully understood.
They are complex, involving the interaction of a number of different systems. The exact
role of local or secretory antibody and cell-mediated immune responses in mediating
recovery from infection and immunity to reinfection remains unclear. By continuing to
unravel these responses, the possibilities for the prevention of chlamydial pathology may
become apparent.
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1.6 Aims of the Thesis
The human endometrium is continually exposed to a wide selection of pathogens and
non-self antigenic stimuli. Wide ranges of immune mechanisms are needed to control
the response to these factors. The natural antimicrobials are a recently described innate
immune defence mechanism. They have been identified within the human female
reproductive tract and in some cases have been found to be cyclically expressed. This
suggests that hormonal regulation plays a role in their expression. If this is the case,
hormonal methods of contraception, with administration of exogenous sex steroids, may
affect their expression.
With components of the immune mechanism within the endometrium altering during the
menstrual cycle, the endometrium may be more susceptible to infection at certain stages
of the menstrual cycle. Changes in early pregnancy may also result in altered acquisition
of infection.
The importance of pattern recognition receptors, in particular Toll-like receptors, in
initiation of the immune response is being realised, although the mediators of expression
of these receptors and the natural antimicrobials within the human endometrium have
not been fully investigated. To elucidate further the innate immune response to
Chlamydia trachomatis, one of the commonest sexually transmitted infections, these
components of the early immune response need to be defined.
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Thus the aims of this thesis are:
1. To characterise the natural antimicrobials (HBD1, HBD2, SLPI and granulysin)
within the human endometrium through the menstrual cycle. To assess the effect of
exogenous sex steroid hormones, in the form of the COCP and LNG-IUS, on this
expression.
2. To investigate the expression of the natural antimicrobials (HBD1, HBD2, SLPI and
granulysin) in early pregnancy. To assess the effect of chlamydial infection on this
expression.
3. To investigate the expression and regulation of components of the innate immune
response (natural antimicrobials and Toll like receptors) in vitro.






All materials used in the work described in this thesis are detailed in Appendix 1.
2.1 Sample collection
Endometrium was collected from women undergoing gynaecological procedures for
benign conditions either while under investigation in the out patient setting, during a day
case procedure or during hysterectomy. All women reported regular menstrual cycles
(25-35 days) and had not received any form of hormonal treatment in the three months
preceding biopsy (unless otherwise stated). Biopsies were performed with a Pipelle
suction curette or, if following hysterectomy, a full thickness endometrial biopsy (lumen
to endometrial/myometrial junction) was excised and the endometrium separated from
the underlying myometrium. Biopsies were dated from the patient's last menstrual
period (LMP); histological dating, according to published criteria (Noyes et al. 1950)
was consistent with the date of LMP. Furthermore, circulating sex steroid concentrations
were consistent with the histological dating of the biopsy. Serum was separated from
venous blood samples at the time of biopsy and frozen at -20°C for subsequent
radioimmunoassay of oestradiol and progesterone. The inter-assay coefficients of
variation (CV) for these assays were 8.5% and 5.3% respectively: intra-assay CV were
8.6% and 3.5% respectively. Table 6 details the number of endometrial biopsies
included in this study.
First trimester decidua (8-11 weeks gestation, as determined by last menstrual period
and/or ultrasound scan) was obtained from patients undergoing surgical termination of
pregnancy. Prior to the surgical termination, biopsies were collected by curettage of the
uterine wall away from the site of implantation. On some occasions trophoblastic villi
were also collected during the procedure. Decidua parietalis (without trophoblast) was
confirmed by examination of hematoxylin and eosin (H and E) stained sections and
75
cytokeratin immunolocalization confirmed the absence of infiltrating trophoblast cells.
Table 6 details the number of decidual biopsies included in this study.
Saliva and vaginal secretions were collected from patients undergoing surgical
termination of pregnancy (8-11 weeks gestation, as determined by last menstrual period
and/or ultrasound scan). Prior to surgical termination women were asked to collect saliva
using a citric acid salivette as per manufacturers instructions (Sarsted). Immediately
prior to surgical termination procedure, the vagina was lavaged with 5 ml of phosphate
buffered saline (PBS) using a 50ml syringe. Table 6 details the number of saliva and
vaginal fluid samples included in this study.
Written informed consent was obtained from all patients prior to biopsy collection and
ethical approval was received from Lothian Research Ethics Committee
(LREC/2000/6/56, LREC/1994/6/17 and LREC/1993/6/73).
Tissue samples were collected in Roswell Park Memorial Institute (RPMI) 1640
medium. Part of the sample was fixed overnight in 10% neutral buffered formalin (NBF)
at 4°C, rinsed and stored in 70% ethanol and thereafter routinely wax embedded.
Sections 5pm thick were cut for routine histopathology (H and E). Tissue was also
immersed in Tri reagent (a RNA/DNA/protein isolation reagent), homogenised and
stored at -70°C for subsequent RNA extraction. Finally tissue portions were used for
culture if required, as described in section 2.2.1 and 2.2.2. The saliva and vaginal
secretions were centrifuged (450g, 3 minutes) to remove debris. Samples were then
stored at -70°C for subsequent enzyme linked immunosorbant assay (ELISA) (see
section 2.6).
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Table 6: Overview of patient samples analysed in this research project*
Cycle Stage Day of Cycle Number of
Biopsies
Endometrium Proliferative 5-13 7
Early secretory 14-18 3
Mid secretory 19-23 5








median length of time






















Primary Proliferative 1-13 28
endometrial
epithelial cell
cultures Secretory 14-28 14
*Further details of samples in each particular study are given in the relevant data
chapter.
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2.2 In vitro tissue culture
2.2.1 Explant culture
Explants (approximately 4mm3) of proliferative phase endometrial samples or secretory
phase endometrial samples were cultured for 24 hours on sterilised polypropylene
capillary matting in RPMI 1640 supplemented with 10% fetal calf serum (FCS),
penicillin (lOOiu/ml), streptomycin (lOOpg/ml), gentamycin (20jxg/ml) and L-glutamine
(2mM) (complete (c) RPMI). They were cultured in the presence of oestradiol (10 8
mol/l) either alone or with treatments as described in the data chapters. The treatments
were removed at 24 hours and the culture medium stored at -20°C for subsequent
analysis by ELISAs (see section 2.6). Explants were immersed in Tri reagent,
homogenised and stored at -70°C for subsequent RNA extraction as detailed in section
2.4. Table 6 details endometrial samples used for explant studies.
2.2.2 Separation of endometrial biopsies into glandular and stromal compartments
This method of separation of glandular and stromal compartments of endometrium was
adapted from that of Osteen et al 1989 (Osteen et al. 1989). Several modifications were
made and details of the methods used in this study are described. Endometrial biopsies
are washed twice in PBS, sliced into small fragments, and immersed in
collagenase/DNAase (lmg/ml and O.lmg/ml) and incubated for 80 minutes at 37°C.
After incubation, RPMI 1640 medium was added and tissue disagreggated using a
syringe. This yielded single cells and larger glandular fragments. The suspension was
centrifuged (450g, 3 minutes) and the resulting cell pellet was resuspended in fresh
medium and allowed to separate by density sedimentation. After 5 minutes the
supernatant (stromal compartment) was removed leaving 2ml of medium. Fresh medium
was added and the density separation step repeated. The remaining 2ml of medium,
containing the glandular fraction, was then centrifuged as above. The resulting cell pellet
was resuspended in collagenase/DNAase, as above, for 2 hours at 37°C. After incubation
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the cell suspension was centrifuged (as above), medium removed and the epithelial cell
pellet resuspended in 50% matrigel. A drop of matrigel was added to each well of a 12
well plate, allowed to solidify and medium added as below.
2.2.3 Cell Culture
2.2.3.1 Primary endometrial epithelial cells
Cells were cultured in cRPMI supplemented with epidermal growth factor (25ng/ml),
vascular endothelial growth factor (lng/ml), basic fibroblast growth factor (5ng/ml) and
oestradiol (108 mol/1) (epithelial growth medium). Growth factors were included in the
culture medium as there is evidence that endometrial epithelial cells express their
receptors and hence they are likely to be involved in modulation of cell growth (Li et al.
1994; Meduri et al. 2000; Sangha et al. 1997; Zhang et al. 1995). When subconfluent (7-
10 days) the epithelial growth medium was removed and cells were rested for 24 hours
in cRPMI supplemented with oestradiol (10~8 mol/1) with either 10% FCS or 5% human
serum as detailed in the data chapters. Treatments were then added as detailed in the
data chapters. Immunohistochemical staining (using mouse anti-human cytokeratin
antibody, clone MNF116) of representative primary cultures for the epithelial marker
cytokeratin (see section 2.5.2), confirmed that at the time of treatment the purity of the
epithelial cells was >90% (Figure 7). The majority of the contaminating cells were likely
to be of stromal origin and morphologically resembled fibroblasts. Table 6 details the
number of endometrial epithelial cell samples included in this study.
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Figure 7: Primary endometrial epithelial cells. Cells were grown in matrigel in 12-well
plates prior to immunostaining. (a and c) Immunolocalization of cytokeratin in primary
endometrial epithelial cells at two different magnifications. Cytokeratin was present in
within the cytoplasm of most cells. Arrow denotes area of unstained cells, which
morphologically resemble fibroblasts, (b and d) Negative controls. The primary
antibody was replaced with equimolar concentrations of an isotype control.




(i) MFE, HES and HeLa Cell Culture
MFE-296 (Hackenberg et al. 1994) and HES (Desai et al. 1994) endometrial epithelial
cell lines and HeLa a cervical epithelial cell line, were cultured in 25cm2 culture flasks.
After passaging cells were seeded at lxlO6 cells/flask, and then incubated for 24 hours to
allow adherence to the flask. Cells were grown or maintained in cRPMI except that
either 10% fetal calf serum or 5% human serum was added as detailed in chapters 3 to 6.
Treatments were added and incubated for an appropriate time, as detailed in chapters 3
to 6. Culture supernatants were then removed and stored at -20°C for subsequent
analysis by ELISAs (see section 2.6). Cells were collected for RNA extraction by adding
Tri reagent directly to the culture flask and then storing the harvest at -70°C for
subsequent RNA extraction as detailed in section 2.4.
(ii) HeLa Cell culture for Chlamydia Experiments
The human cervical cell line HeLa was grown or maintained in Iscove's modified
Dulbecco's medium (IMDM) supplemented with the appropriate concentration of fetal
bovine serum (FBS). No antibiotics or other supplements were used unless stated
otherwise. The cells were routinely grown in 225cm2 vented plastic flasks in IMDM
supplemented with 5% FBS.
2.3 Chlamydiae culture
C. trachomatis serovar E was used throughout, propagated in HeLa cell monolayers.
2.3.1 Chlamydial stock cultures
Subconfluent monolayers of HeLa cells in 225cm2 flasks were prepared. Medium was
discarded. 5ml of Hanks' Balanced Salt Solution (HBSS) containing 30mg/L DEAE-
dextran was added and the cells were left at room temperature for 20 minutes. DEAE-
dextran was removed and Chlamydia stock (elementary bodies (EBs)) added. This was
allowed to absorb for lhour at 37°C and the monolayer was then rinsed with HBSS. The
82
chlamydia infected cells were incubated at 37°C for 72 hours in IMDM supplemented
with 5% FBS, gentamycin (25pg/ml) and cyclohexamide (lpg/ml).
2.3.2 Purification of C. Trachomatis
All media was decanted from the infected flask. Sterile glass beads (approximately 50,
4mm beads) suspended in 10ml IMDM, and 5% FBS were added to the flask. Cells were
disrupted mechanically. The suspension was centrifuged at 2000g for 5 minutes at 5°C.
The cell pellet obtained was homogenised and added to the supernatant obtained from
the initial centrifugation. A further 5 minute centrifugation at 2000g, 5°C was
undertaken. The cell debris was discarded and the supernatant ultracentrifuged at
13000g for 15 minutes. The resulting EB pellet was resuspended in chlamydia transport
medium and stored at -70°C.
Multiplicity of infection (MOI) (the number of inclusion forming units (ifu) relative to
the number of cells) was determined by titration on HeLa cell monolayers and staining
with a FITC labelled monoclonal antibody against chlamydial lipopolysaccharide (LPS)
(see section 2.5.4). The number of chlamydial inclusions relative to the number of cells
at 72 hours is determined. Knowing the volume of infecting media initially used ifu/ml
can be deduced and used to calculate the required volume for the MOI finally required.
2.3.3 Infection protocol
FleLa cell monolayers were seeded into 24-well plates at a density of 5xl04 cells/well,
and cultured for 24 hours. Medium was then removed and cells infected with C.
trachomatis MOI 0.1 or 0.01 diluted in IMDM (200pl/well). Plates were incubated for 1
hour. The inoculum was then aspirated and 1ml of IMDM added. Other treatments
included heat-treated organisms (incubated at 65 °C in a water bath for 1 hour) and cell
lysate. Cell lysate was obtained by the procedure described for the purification of C.
trachomatis (section 2.3.2), however a mock infected flask of HeLa cells was purified so
that the resultant pellet contained no C. trachomatis. Further treatments and incubation
times are as detailed in Chapter 6. At each time point supernatant was collected and
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stored at -70°C for subsequent ELISAs (see section 2.6); cells were lysed in Tri reagent
and stored at -70°C for subsequent mRNA extraction (see section 2.4).
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2.4 RNA extraction and quantitative reverse transcription-polymerase chain
reaction (Q-RT-PCR)
2.4.1 RNA extraction
Tissue samples were immersed in 1ml Tri reagent, homogenised and RNA extracted as
follows. Samples were transferred into eppendorfs containing phase lock gel
(Eppendorf AG) and incubated for 5 minutes at 4°C. 200pl of chloroform was then
added and the sample mixed by inversion. After a further 5 minute incubation at 4°C,
samples were centrifuged at 12000g for 20 minutes at 4°C, allowing separation into
three phases. Upon centrifugation the phase lock gel migrates to form a tight seal
between phases of an aqueous/organic extraction. The upper aqueous phase above the
phase lock gel contained RNA with the remaining phases containing DNA and protein.
The aqueous layer was pipetted to a fresh eppendorf tube and 500pl of 100%
isopropanol was added. Samples were mixed thoroughly and then incubated at 4°C for at
least 60 minutes. Samples were then centrifuged at 12000g for 15 minutes. The resulting
supernatant was removed leaving a pellet of RNA. This was washed in 1ml of 70%
ethanol by vortexing briefly and then centrifugation at 12000g for 5 minutes at 4°C.
Ethanol was removed and the pellet resuspended in RNA storage solution.
The optical densities of the RNA samples were measured at 260nm and 280nm to
determine the purity and the concentration of RNA present. A 260:280 value of
approximately 1.8 indicates a pure RNA sample. An optical density value of 1 at 260nm
is equivalent to 40pg/ml of mRNA.
Concentrations of RNA were determined using the following formula:
260nm value x dilution of RNA x 40 = RNA concentration (ng/pl)
For use in RT-PCR all RNA samples were diluted with TE buffer to 100ng/pl.
Samples were then stored at -70°C for subsequent use.
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2.4.2 Reverse transcription
RNA samples were reverse transcribed using random primers with MgCl2 (5.5 mmol/1),
dNTPs (lmmol/1), random hexamers (2.5 pmol/1), RNAase inhibitor (0.4 IU/pl) and
Multiscribe reverse transcriptase (1.25 IU/pl). The mix was divided into aliquots in
individual tubes (16pl/tube) and template RNA was added (4pl/tube of 100ng/pl RNA).
Mineral oil was added and samples were incubated for 20 minutes at 25°C, 60 minutes
at 42°C and then at 95°C for 5 minutes. cDNA was diluted 2.5x with TE buffer.
The possiblity of contamination of RNA samples with genomic DNA was excluded by
detection of (3-actin signal in RNA samples (without reverse transcriptase). All samples
included for analysis in this thesis had a p-actin signal that was above a previously
defined, arbitrary level of 27 cycles, which was 3 standard deviations from a mean of
samples (King et al. 2000) indicating that there was no major genomic DNA
contamination (see figure 8).
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Figure 8: [3-actin levels in mRNA samples that were subsequently used for RT-PCR.
All endometrial and decidual samples were checked. The control samples for all explant,
primary epithelial cell experiments and cell line experiments were checked. The cycle
number is the value at which fluorescence release reached a threshold value. Any sample
with a (3-actin measurement below 27 (dashed line) was excluded from this thesis.
One sample was excluded on this basis.
Excluded
♦ Endometrial samples ■ Decidual samples A Trophoblast samples
X Endometrial explants x Epithelial primary cells • Cell lines
10 20 30 40 50 60 70
sample number
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2.4.3 Real time quantitative polymerase chain reaction (Taqman; Q-RT-PCR)
This PCR method allows the measurement of PCR product via the detection of released
fluorescent reporter dye (see Bustin et al (Bustin 2000) for a comparative review of
conventional RT-PCR and Q-RT-PCR). Forward and reverse primers are used which
recognise the sequence of target DNA. Concurrently a probe is used which recognises a
sequence present between the annealing sequences of the two primers. The probe is
labelled with two fluorescent dyes: a 5 prime reporter dye (all amplicons except 18S use
FAM; 6-carboxyfluorescein) and a 3 prime quencher dye (TAMRA; 6-
carboxytetramethylrhodamine). The reporter dye on 18S is VIC (chemical name is
unavailable). When annealed to the target sequence the quencher dye suppresses the
fluorescence of the reporter dye as they are in close proximity. But as the target
sequence is amplified during a PCR reaction the probe is cleaved by the endonuclease
activity of taq polymerase. This results in separation of the two dyes so the quencher is
no longer suppressed and fluorescence is therefore increased and can be measured (see
figure 9). This increase in fluorescence is detected only if the target sequence for the
probe is amplified during the reaction, thus preventing the detection of non-specific
amplification. The amount of specific amplicon is related to ribosomal 18S (constant to
the relative amount of cDNA present) and subsequently to an internal control. Two
controls were used; either the control for the particular experiment being undertaken or
when whole tissue samples were being compared a mixture of leukocyte mRNA.
Concurrent measurement of ribosomal 18S and specific amplicons in the PCR well is
possible as the reporter dyes of each emit different wavelengths.
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Figure 9: Quantitative polymerase chain reaction (Taqman).
Stage 1 shows initiation of polymerisation. The probe has annealed to the desired
sequence and the reporter (FAM) and quencher (TAMRA) dye are in close proximity,
decreasing the amount of fluorescence detected.
Stage 2 shows the forward primer extending along the template displacing the reporter
dye of the probe.
Acting as an endonuclease, Taq polymerase then cleaves the probe, stage 3, breaking the
link between the reporter and quencher dyes resulting in increased 'free' reporter dye -
FAM. The reporter dye is no longer in close proximity to the quencher dye and therefore
fluorescence increases.
Finally, stage 4,polymerisation is completed. The amount of fluorescence generated will
be proportional to the amount of PCR product generated, which in turn will reflect the
initial quantities of the desired sequence.
Adapted from the Taqman PCR Reagent Kit Protocol.
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A reaction mix was made from a Stratagene kit containing Taqman buffer, MgCl2 (3.6
mmol/1), dNTPs (0.8 mmol/1), "sure start" taq polymerase (0.025U/pl), reference dye
(0.03%), to which was added ribosomal 18S forward and reverse primers and probe (all
at 50nmol/l), and the primers and probe of the RNA message under investigation
(300nmol/l). The mixture was divided into aliquots in separate tubes for each cDNA
sample. 2.5p,l/replicate of cDNA was added to each tube. After mixing 24p,l of sample
was added to the wells on a PCR plate. Each sample was added in at least duplicate. A
no template control (containing water) and a positive control (containing mixed
leukocyte mRNA) were run on each PCR plate. Wells were sealed with optical caps and
the PCR run on ABI Prism 7700 using standard conditions.
PCR data was analysed using the formula 2_AACt (Ct is the cycle number at which the PCR
fluorescent signal crosses a threshold; ACt is the difference between Ct values for the
specific amplicon and 18S; AACt relates the ACt value of each sample to the internal
control). This normalises the amount of target mRNA to the amount of 18S RNA and
then relates this to the internal control, finally giving a value showing the fold difference
in amount of amplicon in relation to the control.
Primers and probes for quantitative PCR were designed using the PRIMER express
program (PE Biosystems). The sequences for the primers and probes used are shown in
Table 7. BLAST (Basic Local Alignment Tool) searches (www.ncbi.nlm.nih.gov) were
used to determine the presence of sequences in the scientific databases that are similar to
those amplified by each set of primers. The results of these searches showed that, in all
cases, the primer and probe sets used were unlikely to amplify an inappropriate template.
The results of BLAST searches gives an expected (E) value which shows the number of
hits expected by chance when searching the data base (Table 7). The lower the E value
the less likely another sequence matches the sequence of interest by chance.
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*SequencesfortheVIClab lled18Sprobearnavailable.Withinssayp e ionf c nn tb vid di t possibletc rrecthisdatarelativetamountfcDNAprese t.
Linearity of the response was validated using a serial dilution of a standard pool of
RNA. The log of total RNA in ng was plotted against ACt value and a regression line
obtained. Slope of the regression line was <0.1. Representative validation plots are
shown in Figure 10. Within assay variation of the PCR measurement of specific
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Figure 10: Validation of (a) Toll-like receptor 9 (TLR9) and (b) Granulysin PCR
primers and probe. Validation was performed for each set of primers and probe used in
this thesis. This figure shows two representative graphs. ACt is the difference between
the cycle number at which fluorescence reaches a threshold value for the probe of
interest and 18S. To validate the gradient of the line of best fit is <0.1.
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2.5 Immunohistochemistry
Immunohistochemistry was used to detect SLPI and cytokeratin proteins in formalin
fixed paraffin embedded tissue biopsies (5p,m). The protocols were optimised to
determine appropriate conditions for maximum immunostaining. Immunohistochemistry
for HBD2 was undertaken on both paraffin fixed tissue biopsies (5pm) and frozen tissue
biopsies (5pm) using two different commercially available antibodies. Staining obtained
was not satisfactory and therefore HBD2 protein analysis was not carried out. No
antibodies are available commercially for granulysin, so once again protein analysis was
not carried out. Immunostaining was used to determine the presence of C. trachomatis
LPS in HeLa cells.
2.5.1 SLPI
SLPI immunohistochmistry was performed on cultured primary epithelial cells as well
as on fixed tissue sections. This method has been previously described (King et al.
2002). Matrigel was removed from primary epithelial cells and they were fixed in NBF
for 10 minutes at room temperature and subsequently permeabilised with Triton XI00
(0.05%). Tissue sections were dewaxed in histoclear and rehydrated in descending
grades of ethanol to distilled water. The sections were then washed twice in 0.01M PBS
for 5 minutes. Non-specific endogenous peroxidase activity was blocked in the sections
and cells by treatment with 3% hydrogen peroxide in distilled water for 10 minutes at
room temperature. Sections/cells were again washed. A non-immune block of diluted
horse serum for 20 minutes in a humidified chamber at room temperature was used to
reduce non-specific binding. This was then carefully removed and the primary antibody,
SLPI IgGl (diluted 1:200 in horse serum), was applied. Slides/cells were incubated
overnight at 4°C. After the primary antibody incubation, sections/cells were washed for
10 minutes between each stage with PBS + Tween 20. Antibody binding was detected
by the sequential application of biotinylated horse anti-mouse IgG and an avidin-biotin-
peroxidase complex (Elite ABC), both for 60 minutes at room temperature. The
peroxidase substrate diaminobenzidine (DAB), which forms a brown precipitate on
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contact with the antigen-antibody complex, was used to identify positive staining.
Finally sections were counter stained with Harris' hematoxylin, dehydrated in ascending
grades of ethanol and mounted in Pertex. Cells were counter stained with Harris'
hematoxylin and then stored in ethanol.
Negative controls were included for the SLPI immunohistochemistry, where the primary
antibody was substituted with equimolar concentrations of mouse immunoglobulin
(IgGl) to exclude the possibility of non-specific binding. Human first trimester decidua
acted as a positive control.
2.5.2 Cytokeratin
Cytokeratin immunolocalisation was performed to assess the purity of epithelial cell
cultures and was also used to confirm the absence of infiltrating trophoblast cells in first
trimester decidual biopsies. Cytokeratin is present in endometrial epithelial cells, but in
decidua any additional immunoreactivity indicates the presence of trophoblast cells. Any
decidual biopsies with trophoblast cells were excluded from analysis.
To assess epithelial cell purity primary epithelial cells were cultured as described above.
Matrigel was then removed and the cells fixed in acetone for 10 minutes at room
temperature. Following a wash in PBS, cells were permeabilised with TritonXlOO
(0.05%) in PBS for 20 minutes at 37°C. The protocol then followed that of SLPI
(section 2.5.1). The primary antibody was anti-cytokeratin IgGl (diluted 1:60 in horse
serum) and the incubation with this primary antibody was for 1 hour at 37°C.
The protocol for paraffin sections of decidua was identical to that of SLPI (section
2.5.1), with the exception that the primary antibody was anti-cytokeratin IgGl (diluted




HBD2 immunohistochemistry was performed on both paraffin and frozen endometrial
tissue sections and paraffin placental tissue sections. Two different commercially
available antibodies were used. Despite the variation in protocol detailed in appendix III,
we continued to get high background and non-specific staining. Therefore HBD2 protein
analysis was not carried out.
2.5.4 C.trachomatis LPS
HeLa cells were grown on slides and infected with C. trachomatis or other treatments as
detailed elsewhere. After 72 hours medium was removed and slides fixed in acetone for
10 minutes. After washing in PBS, primary anti-chlamydial LPS antibody (monoclonal
antibody 13/4 (Graham et al. 1995), diluted 1:200 in PBS) was applied. Negative
controls were incubated with isotype matched IgG. Slides were incubated for 30 minutes
at room temperature. There after the slides were washed 3 x 5minutes in PBS. Antibody
binding was detected with a 30 minute incubation with FITC conjugated rabbit anti-
mouse antibody (diluted 1:50 under sterile conditions in PBS). Cell nuclei were labelled
for 30 seconds with propidium iodide (diluted 1:2000 in PBS). Slides were finally
washed with PBS and fixed with glycerol/PBS. Use of a fluorescent microscope allowed
determination of staining. Slides were kept at 4°C, with light excluded, following
staining.
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2.5.5 Scoring of immunohistochemistry
Location and intensity of immunostaining was measured using a semi-quantitative
scoring system. Sections were scored blind by two observers (blind to the stage of the
menstrual cycle and to the others results). This scoring system is a standard method used
in previous studies. (Critchley et al. 1998b; Jones et al. 1997; Wang et al. 1998). A high
correlation has been demonstrated between objectively measured immunoreactivity
(measured by computerised image analysis) and subjective semi-quantitative scoring of
immunostaining patterns (Wang et al. 1998).
0 = no immunoreactivity
1 = faint immunoreactivity
2 = moderate immunoreactivity
3 = strong immunoreactivity
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2.6 Enzyme Linked immunosorbant assays (ELISA)
SLPI, PGE2 and IL-8 protein concentrations in culture supernatants were determined by
ELISA. This technique allows the determination of the concentration of a given
substance in solution by comparing it to a standard curve created from solutions of
known concentration.
SLPI and IL-8 ELISAs are two site (double antibody) sandwich ELISAs, the PGE2
ELISA is a polyclonal competition displacement assay (see Figure 11 and 12).
2.6.1 SLPI ELISA
This is a two site sandwich ELISA assay. Throughout the ELISA all dilutions were
made in SLPI ELISA buffer. 96 well assay plates were coated overnight at 4°C with
200pl/well of goat anti-SLPI (2pg/ml) and then blocked for 30 minutes with 200jil/well
of blocking/protecting solution. Plates were washed with wash buffer and subsequently,
200pl of standard/sample were added to each well and incubated for 2 hours at room
temperature on a plate shaker. Two non-specific binding wells (200pl buffer only) were
included on each plate. Standards were added in duplicate and their concentration range
was from 0.024-25ng/ml (recombinant SLPI). Plates were washed and then incubated
for 1 hour with 200pl/well of biotinylated mouse anti-human SLPI (1:10000) as above.
After further washing, 200(il/well of streptavidin peroxidase (1:4000) was added and
incubation was for 20 minutes as above. Plates were washed again and then 200pl/well
of ELISA substrate were added. After 10 minutes wells were quenched with 50pl/well
of 2N sulphuric acid. Plates were read in a plate reader at 450nm. Intra- and interassay
coefficients of variation were 12.80% and 14.76% respectively.
2.6.2 PGE2 ELISA
This ELISA has been detailed previously (Denison et al. 1999a; Greystoke et al. 2000)
and will be described only briefly here. On collection samples were treated 1:1 with
methyloximating solution. It is a polyclonal competition displacement assay. The
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standard concentration range was from lOpg/ml - 5120pg/ml. Plates were coated with
purified donkey anti-rabbit serum and blocked with bovine serum albumin. Samples and
standards were incubated overnight at 4°C in the presence of antisera and a biotin
labelled link. After washing followed a 20 minute incubation with streptavidin
peroxidase (lOOpl/well) at room temperature. Finally ELISA plates were washed and
ELISA substrate (200p,l/well) was added for 10 minutes. Subsequently, plates were
quenched with 2N sulphuric acid at 50pl/well and absorption was read at 450nm.
The ELISA measures a stable oximated derivative. The specificities and cross
reactivities of these antibodies have been detailed previously (Kelly and Critchley 1997;
Kelly and Smith 1987). Inter-assay coefficients of variation were 15.0% and the intra-
assay coefficients of variation were 7.8% for the PGE2 ELISA.
2.6.3 IL-8 ELISA
The protocol for this ELISA has been previously described (Denison et al. 1997). This is
a two site sandwich ELISA assay. Briefly, plates were coated overnight at 4°C with 100
pl/well of capture antibody (2jig/ml). After incubation, plates were washed in water and
100(al/well of blocking solution was added. After 30 min at room temperature the
solution was flicked out, plates were air-dried and stored at 4°C. Standards were diluted
in ELISA buffer plus tween - standard concentration range lOOOpg/ml - 3.9pg/ml.
100pl/well of standard or sample was added. Plates were sealed and incubated overnight
at 4°C. Plates were washed 4 times in wash buffer and then detection antibody (50ng/ml)
was added at 100pl/well. A 90 minute incubation on a plate shaker, at room temperature
then followed. Plates were washed a further 4 times. lOOpdAvell of streptavidin
peroxidase (1:1000 dilution) was added and plates were incubated for 20 minutes on a
plate shaker at room temperature. 4 further washes were followed by addition of
200pl/well of ELISA substrate. Plates were left for 20 minutes, quenched with 50|jl/well
of 2N sulphuric acid and then read on a plate reader at 450nm. Intra- and inter-assay
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2.7 Flow cytometric analysis
Flow cytometry is a method for quantitating components or structural features of cells
primarily by optical means. It makes measurements on one cell at a time, but can process
thousands of cells in a few seconds. A single cell suspension of cells is passed through a
laser beam. Each cell scatters some of the laser light and also emits fluorescent light
excited by the laser. A flow cytometer then measures several parameters simultaneously
for each cell:
• low angle forward scatter intensity, approximately proportional to the cell
diameter
• 90 degree scatter intensity, approximately proportional to the granularity of the
cell
• fluorescence intensities at several wavelengths - fluorescent probes can be used
to report the quantities of specific components of the cells such as surface
receptors
2.7.1 CD14 expression, analysed by flow cytometry
Cells infected with C. trachomatis were harvested with acutase. Activated U937 cells, a
monocyte cell line, were used as a positive control. Cells were incubated with 25pl of a
non-specific isotype control antibody (VPM 20) for 15 minutes at room temperature.
Cells were washed and then labelled with a PC5-conjugated anti-CD14 antibody for 30
minutes on ice. After further washing cells were resuspended and fixed in 1%




Significant differences of PCR and ELISA results were determined by Student's t test or
analysis of variance (ANOVA; Statview 3.0). Fisher's protected least significant
difference (PLSD) was used to assign individual differences (see chapters 3-6 for
details).
The immunohistochemistry data, which are discrete and non-continuous, were analysed
by non-parametric Kruskal-Wallis analysis, using Dunns Multiple Comparisons Test to
assign significance (Instat 2.03).
Statistical differences are indicated on graphs by the use of letters above the relevant
bars. P values relating to the letters used are detailed in the figure legends. P<0.05 was
taken as being significant.
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Chapter 3
Natural Antimicrobial gene transcription
through the Menstrual cycle and the
effect of Hormonal Contraception
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3.1 Intoduction
The female reproductive tract is potentially exposed to a wide range of pathogens,
providing a need for an effective immune response. The innate response is crucial in
initial limitation of infection and is comprised of mechanical barriers, secretions and
phagocytic or natural killer cells. The natural antimicrobials, which are a part of the
innate immune defence system, are small cationic peptides produced by leukocytes as
well as by epithelial cells at mucosal surfaces (Hancock and Diamond 2000; Huttner and
Bevins 1999; Ryley 2001). This study investigates four of these molecules: Secretory
leukocyte protease inhibitor (SLPI), human P defensins 1 and 2 (HBD1 and HBD2) and
granulysin.
SLPI is a neutrophil elastase inhibitor, which has also been shown to have antimicrobial
activity (Hiemstra et al. 1996; McNeely et al. 1995; Tomee et al. 1997). It has been
detected in human endometrium and is maximal in the secretory phase (King et al.
2000). The defensins and granulysin have been shown to have anti-bacterial, anti-viral
and anti-fungal activity in vitro (Krensky 2000; Lehrer et al. 1993; Stenger et al. 1998).
HBD1 and HBD2 are secreted from epithelial cells at mucosal surfaces. They have been
identified in endometrium, but their cyclical variations have not been described (Bals et
al. 1998; Valore et al. 1998; Zhao et al. 1996). Granulysin is a protein secreted from
cytolytic T lymphocytes and natural killer (NK) cells (Andersson et al. 1995b; Krensky
2000). Uterine NK cells (CD56+) are the predominant leukocyte found in the human
endometrium, being phenotypically distinct from peripheral NK cells. They increase in
number in the secretory phase of the menstrual cycle (King et al. 1989; Starkey et al.
1991).
Sexually transmitted infections (STI) in the female reproductive tract can have acute and
chronic sequelae and include Chlamydia trachomatis, gonorrhoea, herpes simplex virus,
human papilloma virus and human immunodeficiency virus (HIV). C. trachomatis is the
most commonly diagnosed bacterial sexually transmitted infection in the developed
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world and a leading cause of pelvic inflammatory disease (PID) (Groseclose et al. 1999;
Morgan 2002). Studies suggest a link between the occurrence of chlamydial infection
and the menstrual cycle. An increase in chlamydial salpingitis is seen early in the
proliferative phase and significantly more cases occur within seven days of the onset of
menstruation (Sweet et al. 1986), while increased detection of asymptomatic infection
occurs in the late secretory phase. There are a number of possible reasons for the
changes in susceptibility to infection through the menstrual cycle, such as changes in
composition and consistency of cervical mucus and cervical ectopy.
Anti-chlamydial activity of cervical secretions varies cyclically, and this is modulated by
hormonal contraceptives (Mahmoud et al. 1994). Women on the COCP have higher
rates of chlamydial infection of the lower genital tract (Avonts et al. 1990; Bontis et al.
1994; Kinghorn and Waugh 1981), but the COCP may be protective for upper genital
tract infection (Rubin et al. 1982; Washington et al. 1985; Wolner-Hanssen et al. 1990).
The LNG-IUS has thus far been shown to be protective for PID (Toivonen et al. 1991),
which contrasts with copper and inert intra uterine devices which have been associated
with an increased incidence of infection in the first 20 days following insertion (Farley
et al. 1992).
The aim of this study is to investigate natural antimicrobial expression in the human
endometrium through the menstrual cycle. How this might be related to the acquisition
of infection can be speculated upon. In addition the effects of two methods of hormonal
contraception, the COCP and the LNG-IUS, with systemic and local hormone delivery




Endometrium was collected from three groups of women undergoing gynaecological
procedures for benign conditions either while under investigation in the out patient
setting, during a day case procedure or during hysterectomy. Group 1 had not used any
method of contraception other than barrier methods in the 3 months preceding biopsy
(n=25). Group 2 had been on the COCP for at least 3 months prior to biopsy (n=20) and
could be at any day of the menstrual cycle including a day in the pill free week (day 1
taken as first day of menses). Group 3 had a LNG-IUS in situ for at least 3 months prior
to biopsy (n=17). All women reported regular menstrual cycles (25-35 days) unless they
had a LNG-IUS in situ in which case cycles were variable. Biopsies from patients in
group 1 were dated as described in section 2.1. A hematoxylin and eosin section of each
sample was examined for signs of infection such as acute or chronic inflammatory
changes, in particular the presence of a plasma cell infiltrate. One sample from group 1,
no samples from group 2 and 4 samples from group 3 were excluded on these grounds.
Final numbers of samples in each group were therefore; group 1 n=24, group 2 n=20 and
group 3 n=13. Five subgroups of group 1 were further defined as: (i) proliferative phase
samples (day 5-13), n=7; (ii) early secretory (day 14-18), n=3; (iii) mid secretory (day
19-23), n=5; (iv) late secretory (day 24-28) n=3; (vi) menstrual phase samples (day 1-4),
n=6. Figure 13a shows significant differences between serum oestradiol levels in the
proliferative and menstrual phases of the menstrual cycle in women who provided
endometrial samples. Progesterone levels (figure 13b) were significantly higher in the
early and mid secretory phases compared to the other phases of the menstrual cycle.
Written informed consent was obtained from all patients prior to biopsy collection and
ethical approval was received from Lothian Research Ethics Committee
(LERC/2000/6/56, LREC/1994/6/17 and LREC/1993/6/73). See Table 8 for details of
endometrial samples analysed in this chapter.
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Table 8: Endometrial samples analysed in this chapter

































































Not available Not available
EXPLANTS












Details the endometrial samples used when analysing the natural antimicrobials through
the menstrual cycle and the effect of hormonal contraception.
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3.2.2 Tissue culture
Endometrial explants of approximately 4mm3 were obtained. Proliferative endometrial
samples (n=8) and secretory endometrial samples (n=4) were cultured for 24 hours on
sterilised polypropylene capillary matting as described in section 2.2.1. They were
cultured in the presence of oestradiol (10~8 mol/l) either alone or with progesterone (10 6
mol/1), with the anti-progestin Ru486/mifepristone (10"6mol/l), or with progesterone (10~6
mol/l) and Ru486/mifepristone (10~6 mol/1) in combination. The treatments were
removed at 24 hours and the explants immersed in Tri reagent, homogenised and stored
at -70°C for subsequent RNA extraction. See Table 8 for details of endometrial explant
tissue samples used in this chapter and figure 14 showing significantly higher serum














Figure 13: (a) Oestradiol (pmol/1) and (b) progesterone (nmol/1) serum measurements
from women who provided endometrial samples analysed in this chapter. Data
represents mean + s.e.m. Paired letters indicate significance. Note the significant fall in
progesterone serum levels in the late secretory and menstrual phases.
(a) a and b: P=0.02
(b) a: P=0.0002, b: P=0.004, c: P=0.0001, d: P<0.0001, e, g and h: P<0.0001,
f: P=0.0008
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Figure 14: (a) Oestradiol (pmol/1) and (b) progesterone (nmol/1) serum measurements
from women who provided endometrial explant samples analysed in this chapter. Data
represents mean ± s.e.m. Paired letters indicate significance, a: P=0.0003
proliferative secretory
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3.2.3 RNA extraction and Q-RT-PCR
Tissue samples or explants (following treatment) were immersed in Tri reagent and
cDNA prepared. Amounts of HBD1, HBD2, SLPI and granulysin mRNA were
determined using quantitative real time PCR. (See section 2.4 for details of method)
3.2.4 Immunohistochemistry
To localise the expression of SLPI protein in the primary endometrial samples,
immunohistochemistry was performed as described in section 2.5. Three components
were assessed subjectively: cellular staining intensity, luminal secretions staining
intensity and the volume of luminal secretions.
3.2.5 Statistical analysis
Significant difference of PCR results obtained for whole endometrium was determined
by analysis of variance (ANOVA; Statview 3.0). Fisher's protected least significant
difference (PLSD) was used to assign individual differences. The data on explant
samples were analysed using unpaired student t test (Statview 3.0).
There were no significant differences between levels of antimicrobial mRNA
investigated in samples from women on the COCP collected during the proliferative,
secretory or menstrual phases as determined by day of cycle. They were therefore
treated as one group for statistical analysis. Similarly length of time since insertion of
LNG-IUS showed no significant differences between levels of antimicrobial mRNA
investigated and they were treated as one group for statistical analysis.
The immunohistochemistry data, which are discrete and non-continuous, were analysed
by non-parametric Kruskal-Wallis analysis, using Dunns Multiple Comparisons Test to




SLPI mRNA expression increased at least 11 fold in the late secretory and menstrual
phase when compared to both the proliferative and early secretory phases of the
menstrual cycle. (Figure 15a). The COCP and the LNG-IUS induced at least a 7 fold
increase of SLPI mRNA, over the proliferative and early secretory phases. (Table 9)
HBD1 mRNA expression was maximal in the mid secretory phase, 21 fold higher than
the levels observed in the proliferative phase (PcO.OOOl) and at least twice the levels in
the early secretory (P=0.0004) and menstrual phases (P=0.008) (Figure 15b). Mid
secretory levels of HBD-1 mRNA were at least 6 fold higher than those in women on the
COCP (PcO.OOOl) and with the LNG-IUS in situ (PcO.OOOl). Levels of HBD1 mRNA in
woman using hormonal methods of contraception under investigation were not
significantly different to the other phases of the menstrual cycle (Figure 15b). (Table 9)
At least a 40 fold increase of HBD2 mRNA was observed in the menstrual phase when
compared to all other phases (PcO.OOl) of the menstrual cycle and compared to women
using the COCP (PcO.OOOl) or with a LNG-IUS in situ (P=0.001) (Figure 15c).(Table 9)
Granulysin mRNA expression was maximal in the late secretory phase being 76, 1910
and 31 fold increased above the proliferative and early and mid secretory phases
respectively. Granulysin mRNA expression in the late secretory phase was 5 and 8 fold
higher than those levels seen in women on the COCP or with a LNG-IUS in situ
respectively. Women on the COCP or with a LNG-IUS in situ had increased expression
of granulysin mRNA compared to women in the proliferative phase of the menstrual
cycle (not significant) (Figure 15d). (Table 9)
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Figure 15: Natural antimicrobial mRNA expression within the endometrium through the
menstrual cycle, and level of expression in women on the COCP or with a LNG-IUS in
situ, 'n' numbers are shown below the x-axis. Data are presented as the fold changes in
mRNA expression relative to a control (mixed leukocyte mRNA), given a nominal value
of 1, mean + s.e.m. Paired letters indicate statistical significance. Note the difference in
y axis scale for figure 15d.
(a). SLPI expression, (b). HBD1 expression. a,b,c,d,e: P<0.008. (c). HBD2 expression.
a,b,c,d,e,f: P<0.001. (d). Granulysin expression a,b,c,d,e,f: P<0.001.
Abbreviations: Prolif, proliferative phase, ES, early secretory, MS, mid secretory phase,
LS, late secretory phase, Menst, menstrual phase, COCP, combined oral contraceptive
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Table 9: mRNA fold changes through the menstrual cycle and under the
influence of the combined oral contraceptive pill or levonorgestrel intrauterine
device
Prolif¬ Early Mid Late Mens- COCP LNG-
erative Secretory secretory secretory trual IUS
SLPI 1.0 0.05 4.7 12.6 11.0 8.1 7.0
HBD1 0.3 0.02 6.9 3.3 2.8 1.1 0.4
HBD2 0.4 0.005 0.2 0.02 15.32 0.1 0.1
Granu- 2.0 0.08 5.3 153.1 14.4 31.9 18.4
lysin
Values are presented as the mean fold change of the mRNA related to an internal control
with a value of 1. Values in bold represent the phase of the menstrual cycle during which
each antimicrobial is maximally expressed.
COCP, combined oral contraceptive pill; LNG-IUS, levonorgestrel intrauterine device
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3.3.2 Immunhistochemistry SLPI
Expression of SLPI was limited to the glandular epithelium and secretions. No staining
was observed in the stromal compartment (Figure 17a). There was significantly more
staining of luminal secretions in the secretory phase when compared to the proliferative
phase or from women on the COCP (P<0.05) (Figure 16b). No significant differences
were observed in the glandular epithelial staining in the proliferative and secretory
phases of the menstrual cycle and from women on the COCP, although the trends were
the same as those observed in the staining of luminal secretions (Figure 16a). Samples
from women on the COCP or from the proliferative phase of the cycle had significantly
less secretions within the glands when compared to those in the secretory phase (P<0.05)
(Figure 16c, Figure 17).
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Figure 16: Box and whisker plots showing relative amounts of (a) SLPI
immunostaining in the glandular epithelial compartment, (b) SLPI immunostaining in
the glandular, luminal secretions or (c) secretions within the glands of the endometrium,
of women in the proliferative or secretory phase of the menstrual cycle, or women on the
COCP, as determined by scoring of immunohistochemistry slides. n=5 in each group.
Paired letters indicate statistical significance. The box extends from the 25th percentile
(bottom line) to the 75th percentile (top line). The horizontal line represents the median,
which sometimes falls at the 25th or 75th percentile. Whiskers are drawn to the 10th or
90th centiles.
(a) Significantly more SLPI was observed in the luminal secretions of women in the
secretory phase of the menstrual cycle. a,b: P<0.05. (c) Significantly more secretions












Figure 17: Photomicrographs of Secretory Leukocyte Protease Inhibitor (SLPI)
immunostaining in human endometrium, (a) and (b) Mid secretory endometrium.
Immunoreactivity is present in the epithelial cells and secretions of the glands, (c) and
(d) Negative control (primary antibody replaced with mouse immunoglobulin at
equimolar concentrations), (e) Endometrium of a woman on the COCP, with secretions
within the glands, and strong immunoreactivity for SLPI. (f) Inactive endometrium of a
woman on the COCP, with few secretions within the glands, and little immunoreactivity
for SLPI.




Progesterone treatment (10"6mol/l) of proliferative endometrial explants for 24 hours
significantly increased the expression of SLPI mRNA (P=0.04) while significantly
decreasing the expression of HBD1 and 2 mRNA (P<0.01). No significant differences
were seen in the expression of granulysin mRNA. (Figure 4). Anti-progestin treatment
(RU 486/mifepristone) of secretory endometrial explants for 24 hours decreased
granulysin mRNA expression (P=0.03) while having no significant effects on the
expression of SLPI, HBD1 or HBD2 when compared to samples treated with
























Figure 18: Regulation of antimicrobial mRNA expression by progesterone and
progesterone withdrawal in endometrial explants. Data are presented as the fold changes
in mRNA expression relative to the control, mean + s.e.m. Paired letters indicate
statistical significance.
Proliferative endometrial explants (n=8) were treated with progesterone (10"6mol/l) and
compared to untreated controls. a,b,c: P<0.04. Secretory explants (n=4) were treated
with progesterone (10"6mol/l) and the anti-progestin RU486/mifepristone (10~6mol/l) in
combination and compared to progesterone (10"6mol/l) treated control, d: P=0.03.
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3.4 Discussion
The presence of natural antimicrobial mRNA in the human endometrium has been
demonstrated. This study also shows variation through the menstrual cycle of HBD1,
HBD2 and granulysin, which has not been previously demonstrated. All the
antimicrobials investigated showed an increase in mRNA expression in the mid
secretory, late secretory or menstrual phase when compared to the proliferative or early
secretory phase. Furthermore, as well as being regulated by endogenous hormones they
are also modulated by exogenous delivery of sex steroid hormones.
The patterns of mRNA expression through the menstrual cycle are similar, all being
maximal in the latter half of the cycle. It has been shown that the antimicrobials can
have additive and synergistic effects (Singh et al. 2000) when present in combination as
is observed here. The menstrual and early proliferative phases of the menstrual cycle
have been linked to an increased susceptibility to sexually transmitted infections (STIs)
(Crowley et al. 1997; Sweet et al. 1986). Menstruation is a time when the endometrial
surface is exposed due to the disruption of the epithelial barrier hence, there is a
potential enhanced risk of infection. Similar observations have been made in the eye
where HBD2 is up-regulated during re-epithelialization of the cornea after injury, in
keeping with the defensins acting as antimicrobial peptides (McDermott et al. 2001). It
may be that the increase in antimicrobials during menstruation is an attempt to limit
infection, and without this observed increase, infection rates would be even higher.
Additionally, the secretory phase of the menstrual cycle is a time when the maternal
immune system undergoes changes and implantation of an allogeneic fetus occurs.
Previous work on the defensins has described HBD1 as being constitutively expressed
(Krisanaprakornkit et al. 1998; O'Neil et al. 2000). In the endometrium HBD1 is
maximal at a time of high circulating progesterone concentrations. In vitro studies did
not support a direct effect of progesterone, where progesterone in fact decreased levels
of HBD1 mRNA. It may be that by affecting endometrial morphology and secretions,
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progesterone induces the changes in gene expression indirectly (O'Neil et al. 1999; Zhao
et al. 1996). HBD2 has been shown to be inducible by inflammatory mediators such as
IL-1 and TNFa and mimics of infection such as lipopolysaccharide (Diamond et al.
2000; King et al. 2002; Krisanaprakornkit et al. 2000; Russell et al. 1996). We show that
HBD2 is maximal in the menstrual phase and it is likely that the inflammatory
mediators, which are present at this time such as IL-1 and TNFa, will be influencing
HBD2 expression (Hunt et al. 1992; Simon et al. 1993a; Tabibzadeh and Sun 1992).
This is probably an indirect effect of progesterone, with progesterone withdrawal
resulting in up-regulation of the inflammatory mediators (Critchley et al. 1999).
Granulysin is a protein produced by NK cells, which proliferate within the endometrium
or infiltrate the endometrium and differentiate there during the mid/late secretory phase
of the menstrual cycle (King et al. 1989) presumably under the influence of progesterone
(albeit probably indirectly). Increased numbers and differentiation of NK cells may
result in the rise in granulysin mRNA levels, enhancing the innate immune capacity of
the endometrium.
In vitro, progesterone inhibits HBD2 mRNA expression and increases SLPI mRNA
expression as is seen in the menstrual cycle. However, progesterone down-regulated
HBD1 expression in vitro. This may be due to time of exposure to progesterone not
mimicking the in vivo cyclical nature of exposure. Furthermore, as suggested previously,
in vivo progesterone may be acting indirectly to increase HBD1 levels. Treatment of
proliferative phase explants of endometrium with progesterone did not mimic the in vivo
increase in granulysin, because of a lack of NK cells within the endometrium during the
proliferative phase. In secretory phase explants granulysin expression was decreased by
anti-progestin (RU486/mifepristone) whereas the opposite is observed with progesterone
withdrawal in the late secretory phase in vivo (see Figure 15d). Once again this may be
due to time of exposure to progesterone not mimicking the in vivo cyclical nature of
exposure or due to the absence or presence of other undefined factors in vivo. Addition
of an anti-progestin (RU486/mifepristone) negated the effects of progesterone alone on
HBD1 and HBD2 mRNA expression in secretory phase explants.
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The endometrium of women on the COCP shows a histological pattern with poorly
developed glands and stroma, which with prolonged COCP use becomes inactive
(Dallenbach-Hellweg 1981; Deligdisch 2000). The effect of the COCP on HBD1, HBD2
and granulysin mRNA expression is to suppress the increase in mRNA levels seen in
mid secretory, late secretory and menstrual phases. The lower levels of gene
transcription of the defensins and granulysin may be secondary to the reduced amounts
of cervical mucus observed in the endometrium of women on the COCP. Studies have
shown that women on the COCP have higher rates of chlamydial and HIV infection
(Carlin and Boag 1995; Kinghorn and Waugh 1981) and it may be that the loss of the
increased levels of antimicrobials pre and perimenstrually contribute to this
susceptibility to infection. The incidence of PID has been shown to be lower in women
on the COCP (Rubin et al. 1982; Washington et al. 1985; Wolner-Hanssen et al. 1990)
and mechanical factors such as thicker secretions and decreased menstrual flow in these
women may result in decreased ascension of infection into the upper genital tract. The
data regarding whether the effects of contraceptive steroids on infection acquisition are
direct or indirect is conflicting. With regards to Chlamydia, Kleinman et al (Kleinman
et al. 1987) present data showing that ethinyl oestradiol, mestranol and
medroxyprogesterone acetate (6a methyl 17a hydroxyprogesterone acetate) do not
affect chlamydial replication in cultured human endometrium, thus implying that the
effects of the contraceptive steroids in chlamydial infections are indirect. In contrast,
others have shown chlamydial inclusions in epithelial cultures are decreased in the
presence of progesterone or progesterone in combination with an oestrogen (Moorman et
al. 1986; Wyrick et al. 1989) while oestrogen alone increases attachment of C.
trachomatis to epithelial cells in vitro (Maslow et al. 1988). Work on other STIs has
similarly been inconclusive thus far.
Immunohistochemistry results concur with the cyclical data showing increased levels of
SLPI in the secretions of the secretory phase of the cycle. However, these levels were
not maintained in the COCP samples, and this may be due to the fact that these samples
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have significantly fewer secretions, probably due to their inactive glandular morphology.
In one sample where glands containing secretions and an arrested histological growth
was seen, the secretions stained strongly for SLPI (Figure 17). Commercially available
HBD2 polyclonal antibodies lacked sensitivity in a western blot of human endometrium
and immunohistochemistry was also unsuccessful (see appendix III). Using a genomics
approach 28 additional new (3 defensin genes have been identified with close homology
(Schutte et al. 2002). Preliminary analysis suggests that 26 of these are transcribed,
potentially making sensitive/specific antibody production difficult. Lack of
commercially available antibodies to granulysin meant that protein data were not
obtained.
The effects of locally delivered high dose progestogen (LNG-IUS) are similar to that of
the COCP. mRNA levels of the antimicrobials, with the exception of SLPI, are
suppressed by the LNG-IUS. A local high dose of levonorgestrel will cause extensive
endometrial gland atrophy, similar to the effects observed after long term COCP use.
Other mechanisms, such as the uterine NK cells or thicker cervical secretions would
explain reported protective effects of the LNG-IUS.
Thus, it has been shown here that natural antimicrobial gene transcription varies through
the menstrual cycle and can be suppressed by hormonal contraceptives. Currently, a
priority in the development of new contraceptives is that they should have an anti-
infective component and in this context the expression of natural antimicrobials needs to
be assessed. New strategies should be sought to up-regulate the innate defence
mechanisms of the female reproductive tract.
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Chapter 4
Natural antimicrobials in early




Secretory leukocyte protease inhibitor (SLPI), the defensins and granulysin all have
natural antimicrobial activity in vitro (Hiemstra et al. 1996; Krensky 2000; Lehrer et al.
1993; McNeely et al. 1995; Stenger et al. 1998; Tomee et al. 1997). It has therefore been
suggested that these molecules play a role in the defence against infection within the
human body, and particularly at mucosal surfaces (Franken et al. 1989). SLPI, HBD1
and HBD2 have been identified in the human endometrium (Bals et al. 1998; King et al.
2000; Valore et al. 1998; Zhao et al. 1996). The cyclical activity through the menstrual
cycle has been described for SLPI (King et al. 2000) and within this thesis for HBD1,
HBD2 and granulysin (Chapter 3). SLPI expression during pregnancy has been well
characterised, levels of SLPI mRNA and protein are higher in decidual tissue than in
secretory phase endometrium (King et al. 2000). SLPI levels increase through pregnancy
and at term SLPI is found in large decidualised stromal cells, amnion and amniotic fluid
(Denison et al. 1999c; Zhang et al. 2001). mRNA for a (neutrophil) defensins has been
demonstrated in the placenta, amnion and chorion at term (Svinarich et al. 1997a). The (3
defensins have not been characterised in pregnancy. Granulysin has been identified in
the yS cytotoxic T cells in decidual samples at 8-14 weeks gestation (Mincheva-Nilsson
et al. 2000).
The role of infection in pregnancy is controversial. There is a large body of evidence
suggesting that preterm rupture of fetal membranes and preterm delivery (<37 weeks
gestation) are associated with clinical or subclinical infection (Cram et al. 2002; Gibbs
2001; Yost and Cox 2000). It is hypothesised that infection leads to release of
inflammatory cytokines such as IL-1 and IFNy and collagenases such as the matrix
metalloproteinases (MMPs). The micro-organisms may degrade fetal membranes
directly, via the MMPs or by induction of leukocyte invasion. Cytokines in combination
with the initial infection result in increased levels of prostaglandins, which can then
initiate labour (Gibb 1998). Bacterial vaginosis, Ureaplasma urealyticum, Chlamydia
trachomatis and Neisseria gonorrhoeae have been more clearly associated with preterm
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labour (Cram et al. 2002; Gravett et al. 1986: McGregor, 1991 #521; Purwar et al.
2001), while the roles of other infections such as group B streptococci, Escherichia coli,
and Mycoplasma hominis are less certain. The use of antibiotic treatment has therefore
been suggested to prevent these adverse outcomes. Randomised controlled trials,
ORACLE I and II, have been carried out (Kenyon et al. 2001b; Kenyon et al. 2001c) and
show that following preterm, prelabour rupture of fetal membranes erythromycin
administration is associated with a range of health benefits for the neonate. A Cochrane
review also suggests a significant reduction in maternal morbidity if antibiotics are
administered following preterm, prelabour rupture of fetal membranes (Kenyon et al.
2001a). No significant improvement in neonatal outcome was found when antibiotics
were given to women in spontaneous preterm labour in the absence of clinical infection.
The role of infection in adverse pregnancy outcome thus remains uncertain, perhaps
playing a greater role in preterm, prelabour rupture of fetal membranes than in
spontaneous preterm labour.
It is proposed that a relative deficiency in gene-encoded natural antimicrobial expression
might be a predisposing factor in premature rupture of fetal membranes or premature
labour. This could combine with other factors such as a shortened cervix or the
prominence of a particular pathogenic organism in the vagina. The aim of this study was
to look at the expression of natural antimicrobials in early pregnancy and to assess the
effect of asymptomatic infection with C. trachomatis on the mRNA expression of these
molecules. The oral cavity provides a mucosal surface that might mimic the immune
character of other mucosal surfaces such as the mucosa within the female reproductive
tract. Preliminary work was undertaken to investigate the possibility of using salivary
measurements of natural antimicrobials as non-invasive surrogate markers of natural




Endometrium was collected from women undergoing gynaecological procedures for
benign conditions either during a day case procedure or during hysterectomy, n=24 (as
described in sections 2.1 and 3.2.1).
First trimester decidua (8-11 weeks gestation, as determined by last menstrual period
and/or ultrasound scan) was obtained from patients undergoing surgical termination of
pregnancy, n=19 (as described in section 2.1). On some occasions trophoblastic villi
were also collected during the procedure, n=5. Prior to the termination chlamydia status
of the patient had been routinely assessed and 11 patients were found to be chlamydia
uninfected and 8 patients chlamydia infected. All the trophoblast samples were from
chlamydia uninfected patients. Patients who were chlamydia positive were treated with
antibiotics after the decidual sample had been taken and the termination procedure
completed. All samples were examined histologically to exclude or confirm the presence
of trophoblast. No samples had clear evidence of an inflammatory response with a
plasma cell infiltrate.
Saliva and vaginal secretions were collected from patients undergoing first trimester
surgical termination of pregnancy (8-11 weeks gestation), n=10 (as described in section
2.1). None of these patients were infected with C. trachomatis. Prior to the termination
women were asked to collect saliva using a citric acid salivette. Immediately prior to the
termination procedure, the vagina was lavaged with 5ml of phosphate buffered saline
(PBS) using a 50ml syringe.
Written informed consent was obtained from all patients prior to biopsy collection and
ethical approval was received from Lothian Research Ethics Committee
(LREC/2000/6/56 and LREC/1993/6/73). See Tables 10 and 11 for details of
endometrial, decidual, trophoblast, saliva and vaginal samples analysed in this chapter.
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Table 10: Endometrial samples analysed in this chapter (as chapter 3)
Cycle Stage Day of
Cycle







































Menstrual 1-4 6 39.5 103 2
(33-43) (57-189) (1.6-4.4)
Table 11: Early pregnancy samples analysed in this chapter
Tissue Chlamydia Misoprostol Number Gestation* Age Parous Nulli-




Decidua Infected Yes 8 10+1.5 19 0 8
(7-11+6) (16-29)
Decidua Uninfected Yes 5 9+3 21 0 5
(9-11) (17-24)
Decidua Uninfected No 6 8+4.5 34 6 0
(7+2-9+4) (31-39)
Tropho- Uninfected For the 5 8(8-11) 27 2 3
blast nulliparous (25-36)
women
Saliva, Uninfected No 10 9+.5.5 28 10 0
vaginal (7-11+6) (26-45)
secretions
* Gestation determined by last menstrual period and/or ultrasound
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4.2.2 RNA extraction and Q-RT-PCR
Tissue samples were immersed in Tri reagent and cDNA prepared. Amounts of HBD1,
HBD2, SLPI and granulysin mRNA were determined using quantitative real time PCR.
(See section 2.4 for details of method)
4.2.3 SLPI ELISA
SLPI protein concentrations in saliva and vaginal samples were determined by ELISA,
using a commercially available kit (R&D systems).
3.2.5 Statistical analysis
Significant difference of PCR results obtained for whole endometrium was determined
by analysis of variance (ANOVA; Statview 3.0). Fisher's protected least significant
difference (PLSD) was used to assign individual differences.
The data on samples from chlamydia uninfected and chlamydia infected patients was
analysed using unpaired student t-test (Statview 3.0). Use of misoprostol in the
chlamydia uninfected group did not statistically alter the expression of the natural
antimicrobials, so the women not infected with chlamydia were analysed as one group.
SLPI protein levels in saliva and vaginal samples were analysed for a correlation
between the two (Statview 3.0).
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4.3 Results
4.3.1 Natural antimicrobial mRNA levels in early pregnancy as compared to levels
through the normal menstrual cycle.
SLPI levels are highest in the late secretory and menstrual phases of the menstrual cycle
as determined previously (section 3.3.1). mRNA levels of SLPI in decidual tissue are
approximately half the levels seen in the late secretory and menstrual phases (p=0.047
and p=0.05 respectively). See Figurel9a.
Decidual levels of HBD1 mRNA were approximately 4.6 fold lower than mRNA levels
in the mid secretory phase (when levels of mRNA HBD1 are at their highest), p=0.002.
See Figure 19b.
Granulysin mRNA levels were 21 fold higher in the late secretory phase when compared
to mRNA levels detected in the decidual tissue (p=<0.0001). See Figure 19d.
HBD2 mRNA was undetectable in decidua. See Figure 19c
mRNA levels of all the antimicrobials investigated, SLPI, HBD1, HBD2 and granulysin,
were undetectable in trophoblast tissue. See Figure 19.
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Figure 19: Natural antimicrobial mRNA expression in decidual and trophoblast tissue
compared to mRNA levels within the endometrium through the menstrual cycle. Data
represents mean + s.e.m for decidual and trophoblast samples. Data through the
menstrual cycle is as that presented in chapter 3 and only the mean of the data is
presented in these graphs. All values are compared to an internal control (mixed
leukocyte mRNA) given a nominal value of one. Paired letters indicate statistical
significance. Note differences in y axis scales.
(a). SLPI mRNA expression a,b,c: p<0.05.
(b). HBD1 expression. a,b: p<0.002.
(c). HBD2 expression. a,b: P<0.003.
(d). Granulysin expression a,b: P<0.0001.
Decidua n=ll, trophoblast n=5, with the exception of SLPI where n=4, proliferative
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4.3.2 Natural antimocrobial levels in decidual samples from women with known
chlamydial infection.
The effect of chlamydial infection on natural antimicrobial mRNA expression in first
trimester pregnancy was determined. No significant changes were observed between




















Chlamydia uninfected Chlamydia infected
Figure 20: Natural antimicrobial mRNA expression in decidual tissue from women
infected with Chlamydia trachomatis (n=8) and woman without C. trachomatis infection
(n=l 1). Data represents mean + s.e.m.
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4.3.3 Correlation between SLPI protein levels in saliva samples when compared to
paired vaginal fluid samples.
Samples from woman with acute infections of the genital tract are difficult to obtain due
to pain and the risk of ascending infection. A pilot study was therefore undertaken to
determine whether levels of the antimicrobial SLPI in saliva could be correlated to levels
in vaginal fluid. A correlation would allow saliva samples to be collected instead of
vaginal samples.
The median value of SLPI in saliva was 801.5ng/ml (range 377 - 2515ng/ml). Median
value of SLPI in vaginal fluids was 211.2ng/ml (range 5.4 - 5266.1ng/ml).
No significant correlation was found between levels of SLPI in the saliva or in the
vaginal fluids (correlation coefficient 0.76). See Figure 21.
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This study confirms the presence of the natural antimicrobials SLPI, HBD1 and
granulysin in first trimester decidua, where they may play an anti-infective role. Preterm
labour represents only approximately 10% of all labours, but results in more than 70% of
neonatal morbidity and mortality (Yost and Cox 2000). There is evidence that infection
plays a part in the aetiology of these events although the exact role that it plays is
debated.
In this study levels of mRNA for SLPI in decidua are approximately half the levels seen
in the late secretory and menstrual phases. In contrast, levels of SLPI have been reported
as being higher in decidual tissue than those levels observed in secretory phase
endometrium (King et al. 2000). However, the secretory phase had been examined as a
whole and the different stages of the secretory phase were not examined as has been
done in the present study. A role for progesterone in the control of SLPI expression
either directly or indirectly via changes in endometrial morphology and cytokine
expression, has been suggested by King et al (King et al. 2000). At a time of high
circulating progesterone concentrations the levels of SLPI expression are lower than
those seen as progesterone concentrations decrease in the late secretory and menstrual
phases. SLPI expression is decreased in three further circumstances, supporting a role
for progesterone in the control of SLPI expression:
a) when there are high circulating levels of progesterone in early pregnancy
b) under the influence of high progesterone levels locally (levonorgestrel
intrauterine device (LNG-IUS) in situ) (see section 3.3.1)
c) in vitro when proliferative phase endometrial explants were treated with
progesterone for 24 hours (see section 3.3.3)
In these circumstances of chronic exposure to progesterone, progesterone receptors will
be down regulated (Critchley et al. 1998b; Perrot-Applanat et al. 1994) and this may be
important in the expression patterns of the antimicrobials observed.
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HBD1 expression is highest in the mid secretory phase of the menstrual cycle suggesting
a positive effect of progesterone. However, when high levels of circulating progesterone
are present in early pregnancy, HBD1 mRNA expression in the decidua is not as high as
levels seen in the mid secretory phase. Data presented in section 3.3.1 similarly show
that when high levels of progesterone are present locally in the form of the LNG-IUS the
expression of HBD1 mRNA is low. It may be that this is a consequence of the prolonged
exposure to progesterone rather than the cyclical changes observed through the
menstrual cycle. HBD2 mRNA was not detected in the decidua. Levels of HBD2 can be
up-regulated by inflammatory mediators such as IL-1 and TNFa and mimics of infection
such as lipopolysaccharide (Diamond et al. 2000; King et al. 2002; Krisanaprakornkit et
al. 2000; Russell et al. 1996). Work is ongoing to determine whether the same is true of
expression of HBD2 in pregnancy derived tissue. Granulysin mRNA is expressed in low
levels in decidua, correlating with similar levels that are observed under the influence of
the LNG-IUS. It is probable that the source of granulysin is the immune cells present at
this time such as uterine NK cells and y6 cytotoxic T cells (Mincheva-Nilsson et al.
2000). The mRNA levels of granulysin observed in early pregnancy were far lower than
those seen in the late secretory phase of the menstrual cycle, when uNK cells are
abundant. It may be that in pregnancy the uNK cells have completed differentiation and
the turn over of mRNA is no longer as high. However, the mRNA expression of
granulysin might increase if the tissue becomes acutely infected. Trophoblastic tissue
did not express any of the natural antimicrobials examined suggesting that at this stage
in pregnancy the fetally derived trophoblast does not have a role in this aspect of innate
immune defence.
There is evidence that the antimicrobials under discussion play a role in control of
genital tract infection. The production of cysteine proteases by Trichomonas vaginalis,
which can degrade recombinant SLPI suggests that the presence of compounds such as
SLPI may be detrimental to this microbe (Draper et al. 1998). Vaginal levels of SLPI
are decreased in women with sexually transmitted infections (STI) (Draper et al. 2000).
Furthermore, high levels of SLPI in the vagina have been associated with lower rates of
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perinatal HIV transmission (Pillay et al. 2001). Draper et al (Draper et al. 1998) suggest
that the lower levels of SLPI in women with STI may predispose those women to HIV
infection. Within the vagina a complex mixture of organisms co-exist, with
Lactobacillus playing a prominent role maintaining a low vaginal pH. If the balance of
microbes is disturbed, bacterial vaginosis can occur with a concommitant increase in
vaginal pH. This increase in pH might reduce the natural antimicrobial secretions,
predisposing to acquisition of infection. In vitro Yasin et al have demonstrated that
neutrophil defensins can protect McCoy cells from C. trachomatis infection (Yasin et al.
1996). An increase in neutrophil defensins in the amniotic fluid of women with
intrauterine infection in labour has been observed (Heine et al. 1998). The levels of
defensins in the amniotic fluid correlated with increasing severity of histologic
chorioamnionitis.
This study examined the effect of infection with C. trachomatis (detected prior to first
trimester termination of pregnancy) on the mRNA expression of SLPI, HBD, HBD2 and
granulysin and no significant differences were observed. The natural antimicrobials are
part of the innate immune response and the women we obtained samples from will most
likely have had the infection for a prolonged period of time. Any initial response to the
organism will no longer be detectable. It was known that all these women had chlamydia
infection detected by an endocervical swab, but whether there was infection in the
sample of decidua analysed is debatable. No obvious histological evidence of infection
was present. A further study looking at women acutely infected with C. trachomatis may
provide further information.
There are limitations to carrying out a study of uterine tissue in women with acute
sexually transmitted infections, hence this study was limited to asymptomatic infection.
During an acute infection women may find examination very uncomfortable and not
tolerate an endometrial sample being taken. Often these women are nulliparous and even
if the procedure can be attempted, obtaining the sample can be technically difficult. A
preliminary study was therefore undertaken to examine the feasibility of using a saliva
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sample as a non-invasive surrogate marker of natural antimicrobial secretion in the
genital tract. Associations between oral and genital tract infections and possible adverse
outcomes in pregnancy have been postulated. Hill et al suggest an association between
maternal periodontal disease with Fusobacterium nucleatum, a common oral species,
and preterm labour. Fusobacterium nucleatum is a frequently isolated species from
amniotic fluid cultures among women with preterm labour and intact membranes (Hill
1998). In the present study SLPI protein levels in paired saliva and vaginal fluid samples
were examined. As yet commercial ELISAs for [3 defensins and granulysin are
unavailable. Median levels of SLPI in saliva samples were comparable to levels
described in other studies (Wahl et al. 1997). SLPI levels in vaginal fluids were slightly
higher than those described in other studies. Two groups describe levels of SLPI in
vaginal fluids of approximately 60ng/ml, decreasing in women with STIs (Draper et al.
2000) and increasing to levels of approximately 550ng/ml in women with HIV (Pillay et
al. 2001). The present study excluded chlamydial infection, but did not look for the
presence of other infections that might affect SLPI levels. A paired analysis was carried
out and each woman was therefore acting as her own control, with the role of infection
not being assessed. This study showed no clear correlation between levels of SLPI in the
saliva and in vaginal fluids. Thus these data show that saliva is not a good surrogate
marker of SLPI secretion in the vagina. It may be that in the presence of infection
greater variablility of results would be observed and a correlation between salivary and
vaginal fluid levels might become apparent. It would be of interest to determine whether
either saliva or vaginal measurements of SLPI were a good marker for adverse events in
pregnancy, such as premature rupture of membranes or preterm labour.
This study has determined the presence of natural antimicrobial peptides in early
pregnancy and further work will need to be undertaken to define in more detail the role
of these molecules. Measurements of natural antimicrobials may still be shown to be
useful in tracking the risk of adverse outcomes in pregnancy.
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Chapter 5
Mediators of natural antimicrobial and




Infection of the female genital tract can have both short and long term sequelae. Rapid
detection of pathogens and induction of an effective immune response are crucial to
limiting these sequelae. Infection in the non-pregnant state can result in pain and
discomfort leading to, in some cases if untreated, infertility and chronic pain (Cates and
Wasserheit 1991). Implantation may be compromised in the presence of infection and if
pregnancy is established preterm rupture of fetal membranes, premature labour and
infection of the fetus can occur (Gravett et al. 1986; Martin et al. 1982). The innate
immune system of the genital mucosal surface is likely to play a role in early elimination
of pathogens and activation of the subsequent adaptive immune responses (Kagnoff and
Eckmann 1997). Two components of this early response are the receptors involved in
pathogen recognition, the Toll-like receptors (TLR) and the natural antimicrobials.
This study investigates the role of bacterial (lipopolysaccharide (LPS) and lipopteichoic
(LTA)) and viral (polyinosinic-polycytidylic acid (poly I:C)) mimics of infection and
some local inflammatory mediators, including prostaglandins and IL-1 (3, in the
regulation of natural antimicrobials in human endometrial epithelial cells (Part A). The
work is then expanded upon in Part B where the regulation of receptors involved in








Several natural antimicrobials have been detected in the endometrium, including HBD1,
human defensin 5, and SLPI: SLPI having maximal expression in the secretory phase of
the menstrual cycle (King et al. 2000; Quayle et al. 1998; Valore et al. 1998). HBD1, 2,
3 and 4 have been detected in the uterus (Garcia et al. 2001; Jameson 1999; Valore et al.
1998). This thesis demonstrates the presence of HBD1 and HBD2 within the
endometrium, showing that both vary in expression through the menstrual cycle (see
chapter 3). The presence of these molecules, which have antimicrobial functions, in the
endometrium suggests that they play a role in protection from infection.
Within the endometrium, as in other systems, inflammatory mediators - IFNy, IL-1 (3 and
IL-ip + TNFa - have been shown to up-regulate mRNA expression of HBD2 (King et
al. 2002). In other systems such as the lung, gut and gingiva, LPS - mimicking Gram-
negative infection- has been shown to up-regulate the expression of the defensins and
SLPI (Diamond et al. 1996; Jin et al. 1998; Krisanaprakornkit et al. 2000). LTA, a
mimic of Gram positive bacterial infection, has been shown to up-regulate SLPI
expression (Jin et al. 1998). It has been demonstrated that intracellular double-stranded
RNA (dsRNA) from a virally infected cell induces gene expression that can be
mimicked by exogenous dsRNA (Field et al. 1967). Polyinosinic-polycytidylic acid
(poly I:C) is a synthetic dsRNA that has been used to simulate a viral-infected state in
cells. The effect of this molecule on natural antimicrobial regulation has not been
examined previously.
This part of the study investigates the role of bacterial (LPS and LTA) and viral (poly
T.C) mimics of infection and some local inflammatory mediators, including




5.3.1 Primary epithelial cell tissue collection and endometrial epithelial cell lines
Endometrial biopsies (n=42) were collected as detailed in section 2.1. Tissue was
separated into glandular and stromal compartments for cell culture. Biopsies used in this
chapter are detailed in Table 12. MFE-296 (Hackenberg et al. 1994) and Hes (Desai et
al. 1994) endometrial epithelial cell lines were used in these studies.
Table 12: Endometrial epithelial samples analysed in this
chapter
Cycle Stage Day of Cycle Number of Biopsies
Proliferative 1-13 28
Secretory 14-28 14
5.3.2 Cell culture and treatments
Epithelial cells were grown to near confluence (7-10 days) in 12 well plates in epithelial
growth medium. Cell lines were seeded at lxlO6 cells per 25cm2 flask and allowed to
adhere over night. Both primary endometrial epithelial cells and endometrial epithelial
cell lines were then treated with mimics of infection (LPS, LTA and poly I:C),
inflammatory mediators (PGE2 PGF2a and IL-1(3) or combinations of these. See Tables
13-15 for details of treatments. These molecules were chosen as they have been reported
to influence antimicrobial expression in the human endometrium (IL-1(3, TNFa and
IFNy) (King et al. 2002) and in other systems (Alexopoulou et al. 2001; Diamond et al.
1996; Hao et al. 2001; Harder et al. 2000a; Jin et al. 1998; Krisanaprakornkit et al. 2000;
Sallenave et al. 1994). Rolipram is a phosphodiesterase inhibiter, maintaining cAMP
levels and therefore potentiating the effect of prostaglandins acting through the EP2/EP4
receptor.
Experiments were done in the presence of fetal calf serum or human serum as
recognition of LPS requires co-factors such as LPS binding protein and CD 14 which
may be more abundant and specific in human serum (Meszaros et al. 1995).
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Combinations of the treatments were used to mimic multiple infections with Gram
negative, Gram positive and/or viral infection and also in combination with the resultant
expression of inflammatory mediators as might be occurring in vivo. All treatments were
carried out in the presence of oestradiol (10"8mol/l) to maintain cell growth. Controls
(cells grown in medium with serum and oestradiol only) were included throughout.
Table 13: Treatments for primary endometrial epithelial cells (in the presence of fetal
calf serum). Results detailed in section 5.4.1.
Treatment Treatment a mimic of: Concentration Incubation
E.coli Seroype 026:B6
lipopolysaccharide (LPS)



















Viral infection 50|ig/ml 8 hours
24 hours
LPS + LTA Combination of Gram negative




LPS + Poly I:C Combination of Gram negative




LTA + Poly I:C Combination of Gram positive











Table 14: Treatments for primary endometrial epithelial cells (in the presence of
human serum). Results detailed in section 5.4.2
Treatment Treatment a mimic of: Concentration Incubation




pge2 Local inflammatory mediator 10"6 M 4 hours
pge2+lps Combination of Gram negative 10"6 M +ljxg/ml 4 hours
bacterial infection and
inflammatory mediator
PGF2a Local inflammatory mediator 1.5x10"6 M 4 hours
PGF2a + IL-1 (3 Combination local inflammatory 1.5xlO"6M + 4 hours
mediator and cytokine lng/ml
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Table 15: Treatments for endometrial epithelial cell lines. Results detailed in section
5.4.3







Infection with a Gram
negative bacteria
Infection with a Gram
positive bacteria
Poly I:C Viral infection
Local inflammatory
mediator



















































PGF2a Local inflammatory Hes
mediator MFE






$ Experiments done in the presence of human serum
* Experiments done in the presence of fetal calf serum
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5.3.3.RNA extraction and Q-RT-PCR
After treatment, cells were harvested in Tri reagent and cDNA prepared. Amounts of
HBD1, HBD2 and SLPI were determined using quantitative real time PCR. (See section
2.4 for details of method)
5.3.4 Immunohistochemistry
To localise the expression of SLPI protein from the primary epithelial cell cultures,
immunohistochemistry was performed as described in section 2.5.
5.2.5 SLPI ELISA
SLPI protein concentrations in culture supernatants were determined by ELISA as
detailed in section 2.6.
5.3.6 Statistical analysis
Significant differences of PCR and ELISA results were determined by analysis of
variance (ANOVA; Statview 3.0). Fisher's protected least significant difference (PLSD)
was used to assign individual differences. P<0.05 was considered significant.
No attempt was made to analyse experiments involving epithelial cells from
proliferative and secretory endometrium separately. However, SLPI mRNA expression
in control epithelial cells originating from the proliferative and secretory phases, grown
in the presence of epithelial growth medium, fetal calf serum and oestradiol until near
confluent were compared. There was no significant difference (as determined by
unpaired t-test) between SLPI levels derived from the two different phases of the
menstrual cycle (Figure 22). Fahey et al (Fahey and Wira 2002) similarly find no
differences between SLPI secretion from different phases of the menstrual cycle. In vivo
SLPI is expressed only in secretory endometrium (see section 3.3.1). This suggests that
after 7-10 days in culture the cells do not exhibit characteristics specific to their original





Figure 22: SLPI mRNA expression in primary endometrial epithelial cells. Cells were
grown in matrigel in 12-well plates for 7-10 days in the presence of epithelial growth
medium, containing fetal calf serum and oestradiol, prior to quantification of SLPI
mRNA expression. Samples from the proliferative (n=14) and secretory phases (n=ll)
of the menstrual cycle were compared. Data is represented as the mean and s.e.m. No




Results are presented in 3 sections with details of the treatments shown in Tables 13-15:
• 5.4.1 Treatment of primary epithelial cells in the presence of fetal calf serum with:
a) mimics of infection: LPS - Gram negative mimic, LTA- Gram postitive mimic
and poly I:C - viral mimic
b) combinations of mimics of infection
c) combinations of mimics of infection and local inflammatory mediators
• 5.4.2 Treatment of primary epithelial cells in the presence of human calf serum with:
a) LPS - Gram negative mimic
b) local inflammatory mediators
c) combinations of mimics of infection and local inflammatory mediators
• 5.4.3 Treatment of endometrial epithelial cell lines
a) mimics of infection: LPS - Gram negative mimic, LTA- Gram postitive mimic
and poly I:C - viral mimic
b) local inflammatory mediators
c) combinations of mimics of infection and local inflammatory mediators
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5.4.1 Results (1)
See Table 13 for details of treatment.
5.4.1.1 LPS and Poly I:C but not LTA affect expression of the natural
antimicrobials HBD1, HBD2 and SLPI
Treatment with LPS resulted in significant changes in the mRNA expression of all three
natural antimicrobials under investigation (Figure 23a, 23b, 23c). HBD1 mRNA
expression was increased 11 fold after 8 hours of treatment and was higher than levels
observed after 4 hours and 24 hours of treatment (Figure 23a). HBD2 mRNA expression
was not significantly different to the control, but levels after 24 hours of treatment were
significantly higher than those observed at 4 and 8 hours post treatment (Figure 23b).
SLPI mRNA expression was increased at 8 hours over levels seen at 4 and 24 hours, and
was significantly decreased when compared to the control after 24 hours of treatment.
Treatment with lng/ml of LPS (data not shown) or lOOng/ml of LPS resulted in no
significant changes compared to the control. The mRNA expression of SLPI at 24 hours
was significantly higher after treatment withlOOng/ml LPS compared to treatment
withlOOOng/ml LPS (Figure 23c).
Primary epithelial cells treated with poly I:C 50pg/ml for 8 and 24 hours resulted in a
significant 7-fold increase in HBD1 mRNA expression at 24 hours (Figure 24a). SLPI
mRNA expression was down-regulated after both 8 hours and 24 hours of treatment with
poly I:C (Figure 24a).
No significant differences were seen in the mRNA expression of HBD1, HBD2 or SLPI
after treatment with LTA 5jig/ml for 4, 8 or 24 hours (Figure 24b).
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Figure 23: Effect of LPS on HBD1, HBD2 and SLPI expression in primary epithelial
cells. Cells were treated with LPS lOOng/ml for 24 hours (n=4) and LPS lOOOng/ml for
4 hours (n=5), 8 hours (n=3) and 24 hours (n=5) in the presence of fetal calf serum
(FCS). mRNA expression of (a) HBD1, (b) HBD2 and (c) SLPI were determined. Data
are presented as the fold changes in mRNA expression relative to the control, mean ±
s.e.m. Paired letters indicate statistical significance.
(a) a: P=0.01, b: P=0.01, c: P=0.01 (b) a: P=0.03, b: P=0.03 (c) a: P=0.003, b: P=0.04, c:
P=0.03, d: P=0.0008
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Figure 24: Effect of the mimics of infection, poly I:C and LTA, on HBD1, HBD2 and
SLPI expression in primary epithelial cells. Data are presented as the fold changes in
mRNA expression relative to the control, mean + s.e.m. Paired letters indicate statistical
significance.
Cells were treated as below and expression of SLPI, HBD1 and HBD2 mRNA were
determined.
(a) Poly I:C 50|ig/ml for 8 hours (n=3) and 24 hours (n=5)
a:P=0.01, b: P=0.005, c: P=0.04
(b) LTA 5|lg/ml for 4 hours (n=5), 8 hours (n=3) and 24 hours (n=6)
■ SLPI
0 ■ HBD1 t
1 3 " ■ HBD2
■dti
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5.4.1.2 SLPI protein expression is localised within the primary epithelial cells, but is
unchanged by treatments with mimics of infection.
SLPI protein was localised to the cytoplasm of the primary epithelial cells using
immunohistochemistry (Figure 25)
SLPI protein concentration in cell culture supernatants as determined by ELISA was not
significantly changed following treatment with LPS, LTA or poly I:C (Figure 26a, 26b,
26c).
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Figure 25: Primary endometrial epithelial cells, immunostained for SLPI. Cells were
grown in matrigel in 12 well plates until subconfluent (7-10 days) prior to
immunostaining. (a) Immunolocalisation of SLPI in primary endometrial epithelial cells.
SLPI is present in the cell cytoplasm and in the secretions from the cells (diffuse
staining), (b) Negative control. The primary antibody was replaced with equimolar
concentrations of an isotype control (IgGl). Note absence of immunostaining.
Scale bar = 50p,m.
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Figure 26: SLPI protein expression was determined in the media from the same
experiments carried out to determine mRNA expression. Data are presented as ng/ml,
mean + s.e.m. No significant differences in SLPI protein secretion were observed.
Cells were treated with:
(a) LPS lOOng/ml for 24 hours (n=3) and LPS lOOOng/ml for 4 hours (n=5), 8 hours
(n=3) and 24 hours (n=5)
(b) LTA 5pg/ml for 4 hours (n=5), 8 hours (n=3) and 24 hours (n=4)

















5.4.1.3 Combinations of treatments result in increases in mRNA expression of HBD2
and HBD1
Mimics of infection cause small changes in natural antimicrobial expression. The
hypothesis proposed was that combinations of infection, or infection in the presence of
inflammatory mediators, as is observed in vivo, might increase levels further. Primary
epithelial cells were treated with combinations of LPS lOOOng + LTA 5|ig/ml, LPS
lOOOng + poly I:C 50pg/ml, LTA 5pg/ml + poly I:C 50pg/ml or LPS lOOOng + IL-1 (3
lng/ml for 24 hours (Figure 27).
Poly I:C had increased HBD1 mRNA expression 7 fold at 24 hours, and this effect was
maintained with the addition of LPS, where a 14 fold increase in HBD1 was observed.
This was significantly higher than the levels seen after treatment with LPS alone (Figure
27a).
HBD2 expression was increased 3.5 fold when treated in combination with LPS and IL-
1 (3 (Figure 27b).
SLPI mRNA expression was significantly deceased after 24 hours of treatment with LPS
lOOOng/ml and this decrease was observed when treatment with LPS was combined with
IL-1 (3, LTA or poly I:C (Figure 27c). No significant changes were observed with SLPI
protein expression (Figure 27d).
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Figure 27: Effect of combinations of treatments on HBD1, HBD2 and SLPI expression
in primary epithelial cells. Cells were treated for 24 hours with LPS lOOOng/ml (n=5),
LTA 5pg/ml (n=6) or poly I:C 50pg/ml (n=5), or at the same doses but in combination,
LPS+IL-13 lng/ml (n=3), LPS+LTA (n=3), LPS+poly I:C (n=3) or LTA+poly I:C
(HBD2 and SLPI n=3). mRNA expression of (a) HBD1, (b) HBD2 and (c) SLPI were
determined. Data are presented as the fold changes in mRNA expression relative to the
control, mean + s.e.m. Paired letters indicate statistical significance.
(a) a: P=0.05, b: P=0.002, c: P=0.01 (b) a: P =0.01
(c) a: P=0.003, b: P=0.008, c: P=0.005, d: P=0.03, e: P=0.001
SLPI protein expression was determined in the media from the same experiments carried
out to determine mRNA expression. Data are presented as ng/ml, mean ± s.e.m. Cells
were treated for 24 hours with LPS lOOOng/ml (n=5), LTA 5pg/ml (n=4) or poly I:C
50pg/ml (n=5), or at the same doses but in combination, LPS+IL-ip lng/ml (n=3),
















5.4.1.4 Summary of results for section 5.4.1
Table 16: Summary of significant effects of mimics of infection on natural
antimicrobial mRNA expression in primary endometrial epithelial cells in the
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lOOOng/ml increases 50ug/ml No effect LPS and Poly
mRNA expression at 8 increases I:C increase
hours mRNA mRNA
expression at expression at
24 hours 24 hours
lOOOng/ml increases No effect No effect LPS and IL-1
mRNA expression at 24 increase
hours when compared mRNA
to 4 and 8 hours expression at
treatment 24 hours
lOOOng/ml decreases 50ug/ml No effect LPS in
mRNA expression at 24 decreases combination
hour. mRNA with: IL-1,
mRNA levels at 8 hours expression at LTA or poly
are higher than those 8 and 24 I:C decreases
observed at 4 and 24 hours mRNA
hours. expression of
mRNA levels are SLPI.






Treatment of primary epithelial cells in the presence of human calf serum with:
a) LPS - Gram negative mimic
b) local inflammatory mediators
c) combinations of mimics of infection and local inflammatory mediators
See Table 14 for details of treatments.
5.4.2.1 Presence of human serum increases the levels of natural antimicrobial mRNA
expression after treatment with LPS
LPS detection and resultant effects require the presence of LPS binding protein and co-
factors, including CD 14. Fetal calf serum may not have sufficient or appropriate soluble
CD 14 to allow maximal effects after treatment with LPS. Experiments were therefore
repeated in the presence of human serum, treating primary epithelial cells with
lOOOng/ml LPS for 30 minutes, 2 and 4 hours.
The mRNA expression of HBD1, HBD2 and SLPI were significantly higher at 4 hours
when treated in the presence of human serum (Figure 28a, 28b, 28c).
SLPI mRNA expression increased approximately 2 fold at 4 hours compared to the
control and expression was significantly increased at 2 hours and 4 hours when
compared to levels at 30 minutes (Figure 28a). This difference was not observed in the
SLPI protein secretion, although there were significantly higher levels of SLPI in the
media collected from cells treated in the presence of human serum as opposed to fetal
calf serum (Figure 28b).
Neither HBD1 nor HBD2 mRNA expression was significantly different to the control at
any time point. HBD1 mRNA expression was significantly higher at 2 and 4 hours when
compared to the levels at 30 minutes (Figure 28c). Similarly HBD2 mRNA expression
was significantly increased at 4 hours when compared to levels at 30 minutes (Figure
28d).
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5.4.2.2 Prostaglandins do not alter the expression ofnatural antimicrobial mRNA
Some inflammatory cytokines have been shown to up-regulate natural antimicrobial
mRNA expression. The effect of another group of inflammatory modulators, the
prostaglandins was therefore examined.
Primary epithelial cells were treated for 4 hours in the presence of human serum with
PGE2 10"6 M alone or in combination with LPS lOOOng/ml, PGF2a 1.5xl0"6 M alone or in
combination with IL-1 (3 lng/ml. As shown previously (section 5.4.2.1) LPS increased
SLPI mRNA expression significantly over the control after 4 hours of treatment and
over treatments with PGE2 alone. PGE2 inhibits the effect of LPS on SLPI mRNA
expression when the treatments are given in combination (Figure 29a). No significant
changes in SLPI protein expression compared to the control were observed (Figure 29b).
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Figure 29: Effect of mediators of inflammation on HBD1, HBD2 and SLPI expression
in primary epithelial cells.
(a) Primary epithelial cells were treated for 4 hours with: LPS lOOOng/ml (n=10 SLPI
and HBD2, n=9 HBD1), PGE210"6 M (n=7), a combination of the two treatments (n=3),
PGF2a 1.5xl0"6 M (n=7) and PGF2a 1.5xl0"6 M + IL-1 (3 lng/ml (n=3) in the presence
of human serum. mRNA expression of HBD1, HBD2 and SLPI were determined. Data
are presented as the fold changes in mRNA expression relative to the control, mean +
s.e.m. Paired letters indicate statistical significance.
a: P=0.002, b: P=0.01, c: P=0.05
(b) SLPI protein expression was determined in the media of primary epithelial cells
treated for 4 hours with; LPS lOOOng/ml (n=10), PGE210"6 M (n=7), a combination of
the two treatments (n=3) and PGF2a 1.5x106 M (n=7) in the presence of human serum.







5.4.2.3 Summary of results for section 4.4.2
Treatment of primary endometrial epithelial cells with LPS lOOOng/ml in presence of
human serum results in:
• higher levels of SLPI, HBD1 and HBD2 mRNA expression and SLPI protein
expression at 4 hours after treatment when compared to experiments carried out in
presence of fetal calf serum.
• an increase of SLPI mRNA at 4 hours compared to the control.
• an increase of HBD1 and HBD2 mRNA at 2-4 hours when compared to levels at 30
minutes.
• PGE2 and PGF2a do not alter SLPI, HBD1 or HBD2 mRNA expression in primary
endometrial epithelial cells.
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5.4.3 Results (3): Use of endometrial epithelial cell lines as a model for antimicrobial
expression.
As some interesting results had been obtained with primary epithelial cell cultures, two
epithelial cell lines were treated with mimics of infection or prostaglandins to assess
effect on natural antimicrobial expression. Treatments are detailed in Table 15.
SLPI expression was detectable but was not significantly increased by any of the
treatments, LTA , poly I:C, LPS (in presence of fetal calf serum and human serum),
PGE2 or PGF2a (data not shown).
Levels of the defensins were too low to detect, and they were not increased to a
detectable level by any of the treatments (data not shown).
MFE cells release very little SLPI into culture supernatants and it was not possible to
determine the regulation of protein release (data not shown).
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5.4.4 Summary results for section 5.4
In vitro studies of primary endometrial epithelial cells and two endometrial epithelial
cell lines have investigated the expression of the natural antimicrobials, SLPI, HBD1
and HBD2. The role of bacterial (Gram negative - LPS and Gram positive - LTA) and
viral (poly I:C) mimics of infection and some inflammatory mediators, including
prostaglandins and IL-1(3 in the regulation of natural antimicrobials in human
endometrial epithelial cells has been determined. LPS and poly I:C increased the mRNA
expression of HBD1 while decreasing the mRNA expression of SLPI. LTA had no
significant effect on the expression of the natural antimicrobials. The response to
treatment with LPS was augmented in the presence of human serum, which may be
providing required co-factors such as CD 14 or undefined cytokines. The prostaglandins,




This study demonstrates the presence and regulation of the natural antimicrobials HBD1,
HBD2 and SLPI in endometrial epithelial cells. These cells are a first line of defence
against infection and as such play a fundamental role in detection of pathogens and
initiation of an immune response. Three mimics of infection were investigated: LPS as a
mimic of Gram negative infection, LTA as a mimic of Gram positive infection and poly
I:C as a mimic of viral infection. The female reproductive tract is susceptible to
infection with organisms from each of these groups of pathogens. These include Gram
negative Neisseria gonorrhoea and Chlamydia trachomatis, Gram positive streptococcus
Group B infection (normally a commensal organism, potentially causing morbidity in
the neonate post delivery), Gram positive anaerobic Peptococcus and human
immunodeficiency virus and herpes simplex virus.
In vitro treatment with LPS and poly I:C treatment lead to increased expression of
HBD1 mRNA in primary endometrial epithelial cells. A combination of treatment with
LPS and poly I:C resulted in a further increase in HBD1 mRNA expression. Poly I:C did
not alter the expression of HBD2 mRNA while expression of SLPI mRNA was
decreased. HBD1 is generally regarded as being constitutively expressed in gingival
tissues (Krisanaprakornkit et al. 1998) the intestine (O'Neil et al. 1999) and the lung
(Zhao et al. 1996), as expression has not been up-regulated by inflammatory mediators
in these systems. While work has shown that viral infection can be inhibited by HBD1
(Daher et al. 1986; Gropp et al. 1999; Nakashima et al. 1993), the effects of viral
infection on the expression of natural antimicrobials have not been examined. It could be
that HBD1, having particular antiviral properties, is unaffected by other mediators and is
selectively up-regulated by viral infection. It may also be that differences in defensin
regulation exist between epithelial cells from distinct sites. Further work is underway to
look at the effects of viral infection on natural antimicrobial expression in cervical
epithelial cells.
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LTA had no significant effect on the mRNA expression of HBD1, HBD2 or SLPI in
vitro. It may be that Gram positive bacteria are uncommon pathogens of the
endometrium and therefore a response to LTA is limited. It may also be that higher or
lower doses of LTA would have resulted in a response.
HBD2 has been detected in the uterus (Bals et al. 1998), although the site of expression
within the uterus was not investigated. However, HBD2 is present at other epithelial
surfaces (Harder et al. 2000b; Krisanaprakornkit et al. 2002; Krisanaprakornkit et al.
2000). These investigators detail the up-regulation of HBD2 by inflammatory mediators
in respiratory and gingival epithelial cells respectively. King et al have demonstrated up-
regulation of HBD2 by IL-1 (3, TNFa and IFNy in endometrial epithelial cells (King et
al. 2002). The HBD2 promoter is reported to have several consensus sites for the
proinflammatory transcription factors NF-kB and AP-1, accounting for its induction by
these mediators (Harder et al. 2000b). Previous studies have shown HBD2 to be up-
regulated by LPS (Becker et al. 2000; McNamara et al. 1999) while others report little
effect of LPS, but have found an increased HBD2 expression upon infection with
pathogenic bacteria (Harder et al. 2000b; O'Neil et al. 1999). This suggests that
components of the bacteria other than LPS are responsible for stimulating defensin
expression. It also suggests that LPS actions may depend on the cell type investigated.
While this study did not show an increase of HBD2 over the control after treatment with
LPS at different doses and time point, it did show an increase of HBD2 at 24 hours when
compared to the levels at 4 hours and 8 hours. A combination of LPS and IL-1 (3 resulted
in significant up-regulation of HBD2, but whether this is a synergistic or additive effect
can not be determined from these studies. This study used E. coli LPS and it might be
that endometrial epithelial cells would respond to LPS from more common genital tract
pathogens, such as C. trachomatis, more effectively.
SLPI has been reported to be an LPS inducible gene in mouse macrophages (Jin et al.
1998). However, this study found that SLPI mRNA expression decreased after treatment
with LPS for 24 hours. Combinations of treatments with other mimics of infection or IL-
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1(3 did not alter the low levels of SLPI expression. Poly I:C also down-regulated levels
of SLPI 24 hours post treatment. This may indicate that, as expected, innate immune
responses to LPS occur over a shorter time period. Following initiation of the adaptive
immune response high levels of a leukocyte protease inhibitor may be inappropriate,
hence the observed down regulation. Experiments carried out over a shorted time course,
but in the presence of human serum (not fetal calf serum), did result in increased mRNA
expression of SLPI mRNA 4 hours post treatment. These changes in mRNA expression
were not observed in SLPI protein secretion. This may be because there is a lag time
between changes in mRNA expression and protein secretion, and in each case the
experiments were terminated at the time points where significant changes in mRNA
expression were observed. Furthermore, SLPI secretion has been demonstrated to
remained associated with the tissue under investigation in culture and increased recovery
observed with mild acid extraction. This is in agreement with the high isoelectric point
(pi) for SLPI, associated with high solubility at low pH (King et al. 2000). In the present
study there were no significant differences between SLPI secretion from control and
treated samples (figures 26a and 27d), and this may be because SLPI remained
associated with the tissue.
LPS activity requires the presence of co-factors such as LPS binding protein and CD 14.
CD 14 can be either soluble in the serum or membrane bound. It has been suggested that
CD 14 of epithelial cell origin mediates the LPS induction of an antibiotic peptide gene
in tracheal epithelial cells (Diamond et al. 1996). Becker at al (Becker et al. 2000) have
demonstrated that the up-regulation of HBD2 after LPS stimulation is CD 14 dependent
in human tracheobronchial epithelium. CD 14 is expressed on non-professional antigen
presenting cells, such as epithelial cells, but expression is generally low (Funda et al.
2001; Song et al. 2001). There may therefore be greater reliance on sCD14 in the serum
(Frey et al. 1992). The initial experiments in this study were carried out in the presence
of fetal calf serum. It was hypothesised that human serum provides species specific
CD 14, therefore resulting in more effective response to LPS and hence improved
defense strategies. This was indeed the case, with significantly greater mRNA
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expression of HBD1, HBD2 and SLPI at 4 hours after treatment with LPS when treated
in the presence of human serum when compared to those samples treated in the presence
of fetal calf serum. This increase was also observed in the secretion of SLPI protein.
Although HBD1 and HBD2 mRNA expression were not significantly increased when
compared to the control, they were both increased at 4 hours after treatment when
compared to levels at 30 minutes after treatment. SLPI mRNA expression was
significantly increased when compared to the control at 4 hours after treatment. It is
possible that CD 14 in human serum plays a role in the response to LPS, although the
role of other factors that differ in the human serum, such as increased amounts of
cytokines, cannot be excluded.
Use of endometrial cell lines to examine further the regulation of the natural
antimicrobials is limited, as they do not express high levels of mRNA for HBD1 and
HBD2, and the expression of these was not stimulated by any treatments in this study.
Furthermore SLPI, which was expressed, was not modulated by the treatments in this
study. These cell lines are therefore not good models for continued work looking at the
effects of mimics of infection on antimicrobial expression.
The role of all these molecules in the elimination of infection has been concentrated
upon. It should be borne in mind that the natural antimicrobials have several other
actions that may be important. The defensins have been shown to be chemotactic for T
cells and dendritic cells (Chertov et al. 1996; Yang et al. 1999a) and may play a part in
linking and activating the adaptive immune response. SLPI has generalized anti¬
inflammatory actions including inhibition of neutrophil elastase and cathepsin G
(Thompson and Ohlsson 1986) and inhibition of NFkB (Lentsch et al. 1999). It therefore
plays an important part in limiting the damage that can occur as a result of inflammatory
responses. A combination of these functions and the antimicrobial activity of these
molecules probably contribute to the immune responses in vivo.
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In summary, the natural antimicrobials HBD1, HBD2 and SLPI have been detected in
endometrial epithelial cells. Their regulation by mimics of infection (LPS, LTA and poly
I:C) and prostaglandins was examined. LPS was observed to have the widest effect on
natural antimicrobial mRNA expression and up-stream components of the response to
LPS, the Toll-like receptors and CD 14, have therefore been examined further in the
following section, Part 5B.
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Part 5B
Mediators of Toll-like receptor
gene transcription in the endometrium
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5.6 Introduction
The mimics of infection including LPS and LTA, discussed in Part 5A, are described as
pathogen associated molecular patterns (PAMPS). They are conserved elements of
pathogens, which can be recognized by defence systems. The receptors involved in their
recognition (pathogen recognition receptors, PRR) include toll like receptors (TLRs) and
their associated co factors such as CD14. Ten TLRs have been described to date (TLR 1-
10). Ligands have been described for 5 of these TLRs (Table 4); TLR2 (bacterial
lipoproteins and peptidoglycans), TLR3 (double-stranded RNA), TLR4
(lipopolysaccharide (LPS) and HSP60), TLR5 (flagellin), and TLR9 (unmethylated CpG
DNA motifs found in bacterial DNA (vertebrate DNA CpG dinucleotides occur
infrequently and are highly methylated)) (Underhill and Ozinsky 2002). The most
relevant of these to Gram negative bacterial recognition appear to be TLR4 and TLR9.
TLR4 expression has been demonstrated in the endometrium (Young et al. 2002) and the
regulation of TLR4 has been examined in a variety of systems, but not in the
endometrium. LPS and IFNy induce TLR 2 and TLR 4 expression in human endothelial
cells (Faure et al. 2001), in intestinal epithelial cells (Abreu et al. 2002) and in
monocytes and polymorphonuclear leukocytes (Muzio et al. 2000). Monocyte-like THP-
1 cells regulate TLR mRNA levels in response to a variety of stimuli including phorbol
esters, LPS, bacterial lipoproteins, live bacteria, and cytokines (Zarember and Godowski
2002). TLR9 has not been demonstrated in the endometrium and its regulation has not
been examined.
CD 14 acts as a co factor in the recognition of LPS and can either be present in the serum
as soluble CD 14 or as a membrane bound form on leukocytes (paricularly monocytes
and macrophages) and epithelial cells. The expression of mCD14 on epithelial cells is
far lower than that seen on leukocytes, but the regulation of CD 14 on epithelial cells
might influence the effects following recognition of LPS. LPS has been shown to up-
regulate the expression of CD14 on endothelial cells (Jersmann et al. 2001). Another
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group has examined the effect of prostaglandins on CD 14 expression in mouse
macrophages. PGEj and PGE2 among the prostaglandins tested strongly stimulated the
expression of the CD14 gene in the cells (Iwahashi et al. 2000). No published work has
examined the expression of CD 14 within the epithelial cells of the endometrium.
This study investigates the role of a bacterial mimic of infection (LPS) and some local
inflammatory mediators, including prostaglandins, IFNy, and combinations of IL-1(3 and




5.7.1 Primary epithelial cell tissue collection and endometrial epithelial cell lines
Endometrial biopsies were collected as detailed in sections 2.1 and 5.2.1. Tissue was
separated into glandular and stromal compartments for cell culture. MFE-296
(Hackenberg et al. 1994) and Hes (Desai et al. 1994) endometrial epithelial cell lines
were used in these studies.
5.7.2 Cell culture and treatments
Epithelial cells were cultured as described in section 5.2.2. Both primary endometrial
epithelial cells and endometrial epithelial cell lines were then treated with; LPS as a
mimic of infection, inflammatory mediators (PGE2 PGF2a, IL-1 (3, TNFa and IFNy) or
combinations of these as section 5.2.2. See Tables 17 and 18 for details.
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Table 17: Treatments for endometrial epithelial cell lines, Hes and MFE
Treatment Treatment a mimic of: Concentration Incubation
LPS (E.coli
Seroype 026:B6)








10"6 M 4 hours5
pge2+lps Combination of Gram
negative bacterial infection
and inflammatory mediator
10"6M+ l^ig/ml 4 hours5








1.5xl0"6 M 4 hours5












* Experiments carried out in the presence of fetal calf serum
$ Experiments carried out in the presence of human serum
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Table 18: Treatments for primary endometrial epithelial cells
Treatment Treatment a mimic of: Concentration Incubation










10"6 M +lpg/ml 4 hours5
PGF2a Local inflammatory
mediator
1.5xl0"6 M 4 hours5
IL-lp + TNFa Local inflammatory
cytokines




* Experiments carried out in the presence of fetal calf serum
$ Experiments carried out in the presence of human serum
187
5.7.3.RNA extraction and Q-RT-PCR
After treatment, cells were harvested in Tri reagent and cDNA prepared. Amounts of
CD14, TLR4 and TLR9 mRNA were determined using quantitative real time PCR. (See
section 2.4 for details of method)
5.7.4 Statistical analysis
Significant differences were determined by analysis of variance (ANOVA; Statview
3.0). Fisher's protected least significant difference (PLSD) was used to assign individual
differences. P<0.05 was considered significant.
No attempt was made to analyse experiments involving epithelial cells from
proliferative and secretory endometrium separately (see section 5.2.6).
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5.8 Results
5.8.1 LPS affects expression of CD14 in an endometrial epithelial cell line, but has no
affect on primary epithelial cell CD14 mRNA expression.
To further examine the components of the pathways involved up stream of natural
antimicrobial expression, the effects of LPS lOOOng/ml, PGE2IO"6 M, PGF2a 1.5xl0"6 M,
IFNy lOng/ml and IL-1 (3 lng/ml + TNFa 2ng/ml on CD 14 mRNA expression was
determined (Figure 30). See Tables 17 and 18 for details of treatment.
LPS increased the expression of CD 14 mRNA in Hes cells 2.2 fold over the control at 2
hours, which was significantly higher than levels seen after 4 hours of treatment (Figure
30a).
CD 14 mRNA expression in MFE cells was significantly decreased at 2 hours when
compared to levels at 30 minutes after treatment with LPS (Figure 30a).
No other treatments had an effect on CD 14 mRNA expression (Figure 30a).
Treatment of primary endometrial epithelial cells with the same treatments resulted in no
significant changes in CD 14 mRNA expression (Figure 30b)
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Figure 30: CD 14 expression in (a) endometrial epithelial cell lines (MFE and Hes) and
(b) primary endometrial epithelial cells in the presence of human serum. Data are
presented as the fold changes in mRNA expression relative to the control, mean ± s.e.m.
Paired letters indicate statistical significance.
(a) MFE and Hes cells were treated with LPS lOOOng/ml for 30 minutes (n=5), 2 hours
(n=5) and 4 hours (n=5).
4 hour treatment with, PGE2 106 M (n=5), LPS 1000ng/ml+PGE2 10"6 M (n=5),
PGE210"6 M+ rolipram (a phosphodiesterase inhibitor) (MFE n=5, Hes n=4) and PGF2a
1.5xl0"6 M (n=5).
IFNy lOng/ml at 4 hours (n=3) and 24 hours (n=3) and IL-ip lng/ml + TNFa 2ng/ml at
4 hours (n=3) and 24 hours (n=3) was also carried out.
a: P=0.002, b: P=0.04, c: P=0.001, d: P=0.001
(b) Primary endometrial epithelial cells were treated with LPS lOOOng/ml for 30 minutes
(n=4), and 4 hours (n=10). 4 hour treatment with; PGE2 10"6 M (n=7), LPS
1000ng/ml+PGE2 10"6 M (n=3), PGF2a 1.5xl0"6 M (n=6). IFNy lOng/ml at 24 hours











5.8.2 Inflammatory mediators, PGE2, IFNy and IL-J + TNFa increase expression of
TLR4 mRNA in an endometrial epithelial cell line, but have no effect on TLR9 mRNA.
The TLR are pathogen recognition receptors, TLR4 particularly for LPS and TLR9 for
unmethylated CpG DNA motifs. Regulators of their mRNA expression were examined.
Treatments are detailed in Tables 17 and 18.
PGE2 increased the mRNA expression of TLR4 in Hes cells 1.5 fold over the control at
4 hours and levels were significantly higher than after treatment with LPS alone or PGE2
in combination with LPS or rolipram (a phosphodiesterase inhibitor, which will increase
cAMP levels) (Figure 31a). Expression of TLR4 mRNA was increased by PGE2 in
primary epithelial cells but was not significant due to wide variations in the results
(Figure 31b).
IFNy increased TLR4 mRNA expression 6.5 fold at 24 hours in Hes cells and IL-1 (3+
TNFa increased TLR4 mRNA expression 4.8 fold in MFE cells (Figure 31a). The effect
of IFNy and IL-1 (3 + TNFa were not observed in the primary epithelial cells (Figure
31b). LPS lOOOng/ml and PGF2a had no effect on TLR4 mRNA expression.
PGE2, PGF2a, IFNy and IL-1 (3 + TNFa had no effect on TLR9 mRNA expression in the
cell lines examined or in the primary epithelial cells (data not shown).
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Figure 31: TLR4 mRNA expression in endometrial epithelial cell lines (MFE and Hes)
(a) and primary endometrial epithelial cells (b) in the presence of human serum. Data
are presented as the fold changes in mRNA expression relative to the control, mean +
s.e.m. Paired letters indicate statistical significance.
(a) MFE and Hes cells were treated with LPS lOOOng/ml for 30 minutes (n=5), 2 hours
(n=5) and 4 hours (n=5).
4 hour treatments with LPS 1000ng/ml+PGE2 10"° M (n=5), PGE2 10"6 M (n=5),
PGEGO6 M + rolipram (MFE n=5, Hes n=4), PGF2a 1.5xl0"6 M (n=5), IFNy lOng/ml
(n=3), IL-1(3 lng/ml + TNFa 2ng/ml (n=3) were also carried out.
MFE and Hes cells were treated for 24 hours with IFNy lOng/ml (n=3) and IL-ip
lng/ml + TNFa 2ng/ml (n=3).
a: P=0.0003, b: P=0.007, c: P=0.04, d: P=0.004, e: P=0.005, f: P=0.0002, g: P=0.008
(b) Primary endometrial epithelial cells were treated with LPS lOOOng/ml for 30 minutes
(n=4), and 4 hours (n=10). 4 hour treatment with; LPS lOOOng/ml + PGE2 10"6 M (n=3),
PGE2 10"6 M (n=7), PGF2a 1.5xl0"6 M (n=6), IFNy lOng/ml at 24 hours (n=3) and IL-lp
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5.8.3 Summary of results
Table: Summary of significant effects of treatments on CD14 and TLR4 mRNA
expression in endometrial epithelial cell lines MFE and Hes*
Treatment** CD14 TLR4
MFE Hes MFE Hes
LPS -I T no effect no effect
PGE2 no effect no effect no effect T
PGF2a no effect no effect no effect no effect
IFNy no effect no effect no effect T
TNFa + IL-1(3 no effect no effect T no effect
*CD14, TLR4 and TLR9 mRNA expression in primary endometrial epithelial cell was
unaffected by any of these treatments
**TLR9 mRNA expression was unaffected by any of these treatments
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5.9 Discussion
This study demonstrates the presence and regulation of CD 14 and TLR4 and TLR9
mRNA in endometrial epithelial cells. If CD 14 does indeed play a role in detection of
LPS, its regulation is of interest. This has not been examined in the endometrium.
Fichorova et al (Fichorova et al. 2002) have examined immortalized vaginal and cervical
epithelial cells and were unable to demonstrate mRNA expression of TLR4. These cells
were unresponsive to LPS but did respond to whole Gram negative bacteria and bacterial
lysates. They demonstrated the presence of soluble (s)CD14 and propose that sCD14 can
act as a co-receptor for non-TLR4 ligands. Jersmann et al show an up-regulation of
CD 14 on endothelial cells following treatment with LPS (Jersmann et al. 2001). In
contrast Cario et al (Cario et al. 2000) did not detect CD 14 expression in 3 intestinal
epithelial cell lines while Funda et al (Funda et al. 2001) who did detect CD 14
expression, showed no modulation of CD 14 expression in 3 intestinal epithelial cell lines
following treatment with LPS. The results in this study were endometrial cell line
dependent. Hes cells showed an increased CD 14 mRNA expression, while LPS
treatment of MFE cells resulted in decreased CD 14 mRNA expression. No effect was
demonstrated in primary endometrial epithelial cells. It is unclear why such differing
results were obtained. Hes is reported to be an immortalized endometrial cell line,
derived from the endometrial lining of hysterectomy specimen removed due to
leiomyomata (Desai et al. 1994). In contrast, MFE is a glandular derived endometrial
carcinoma epithelial cell line (Hackenberg et al. 1994). It may be that the underlying
different pathological origins of these epithelial cells results in differing responses to
microbial mimics.
In other systems the role of inflammatory mediators in the expression of CD 14 have
been investigated. PGE2 has been shown to stimulate CD 14 expression in mouse
macrophages (Iwahashi et al. 2000). IFNy and TNFa enhance LPS binding to
neutrophils via increased expression of CD 14 (Takeshita et al. 1998), while TNFa
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increases murine CD 14 expression in epithelial cells but not myeloid cells (Fearns and
Loskutoff 1997). This latter group suggest that the changes in CD14 seen after treatment
with LPS may an indirect effect, with inflammatory mediators playing a role in CD 14
expression. The present study found no effect of PGE2, PGF2a, IFNy or IL-1 (3 + TNFa
on the expression of CD 14 in primary endometrial epithelial cells or endometrial
epithelial cell lines. The effects of LPS on CD 14 expression may of course still be
indirect via another mediator not examined, or the effect may be a direct effect of
signaling events following LPS binding. The functional significance of changes in CD 14
mRNA expression needs to be determined. Levels of CD 14 expression on epithelial cells
are low, if present at all. If CD 14 is present on the membrane surface at low levels small
increases in expression could magnify the resultant responses.
LPS is believed to bind to cells via a complex, which includes TLR4 (Chow et al. 1999).
The signaling pathway is homologous to the IL-1 signalling pathway, resulting in NFkB
activation (Gay and Keith 1991; Medzhitov et al. 1997). It has been proposed that TLR9
is a receptor for CpG DNA motifs found within bacterial DNA (Bauer et al. 2001;
Hemmi et al. 2000). Thus far TLR9 expression has not been described in endometrial
epithelial cells and its regulation in endometrial cells has not been addressed. The
regulation of TLR4 has been examined in myloid cells (Muzio et al. 2000), endothelial
cells (Faure et al. 2000) and intestinal epithelial cells (Abreu et al. 2002) where
inflammatory mediators, IFNy, TNFa and LPS have been shown to increase TLR4
expression. This study confirmed these findings in endometrial epithelial cell lines
where mRNA expression was increased by PGE2 and IFNy in Hes cells, and by IL-1 (3 +
TNFa in MFE cells. In contrast primary endometrial epithelial cell TLR4 expression
remained unchanged after treatment with the same mediators. This may represent
differences in the regulation of TLR4 between the primary cells and cell lines such as
differences in the numbers of receptors on the cell surfaces for IFNy, IL-1 (3 or TNFa.
TLR4 expression was unaltered by treatment with LPS. In other systems such as the gut
it has been suggested that TLR4 down regulation may be a protective mechanism where
cells are continually exposed to LPS and a constant inflammatory response would be
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deleterious (Abreu et al. 2001). Within the endometrium, which is normally sterile, this
protective effect is not required. TLR9 mRNA was expressed in both the primary
endometrial epithelial cells and the endometrial epithelial cell lines, but expression was
unaltered by treatments of PGE2 PGF2a, IFNy or IL-1 (3 + TNFa.
In summary CD14, TLR4 and TLR9 mRNA has been detected in endometrial epithelial
cells. CD14, TLR4 and TLR9 were found to be differentially regulated: CD14 by LPS
either directly or indirectly via an unknown mediator, TLR4 by inflammatory molecules
and TLR9 by none of the mediators examined in this study. It is likely that all of these
molecules will play a role in protecting the endometrium from infection.
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5.10 Overall Summary Chapter 5
Toll-like receptors are an important component of the pathway involved in the
recognition of pathogens. Previous work has demonstrated a down-steam activation
pathway resulting from TLR ligation that leads to activation of NFkB (Alexopoulou et
al. 2001; Cario et al. 2000; Chow et al. 1999) and can stimulate the expression of natural
antimicrobials (Becker et al. 2000; Krutzik et al. 2001). This chapter has examined local
mediators that might modulate some of the natural antimicrobials and TLRs. Part A
showed an increase in natural antimicrobial mRNA expression following treatment of
endometrial epithelial cells with LPS. The mechanism of this response may be through
TLR4, the expression of which has been shown to be modulated by some local
inflammatory mediators. One can see how a complex set of interactions evolves in the
presence of infection as the target organ tries to limit pathogenic sequelae. Figure 32 for
summarizes possible events at the endometrial mucosal surface as defined by this
chapter. Future studies will continue to delineate the roles of the natural antmicrobials
and TLRs more clearly.
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Figure 32: Possible role of Toll-like receptors and natural antimicrobials at the mucosal
surface of the female reproductive tract. Toll-like receptors are activated on contact with
a ligand such as LPS, LTA or CpG motifs. This may or may not be in the presence of
co-factors such as CD 14. A cascade of events follows culminating in translocation of
NFkB to the nucleus and up-regulation in gene expression of effector molecules such as
the natural antimicrobials. These effector molecules will go on to have direct or indirect
















Early immune responses to
Chlamydia trachomatis
in a cervical epithelial cell line
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6.1 Introduction
The early recognition of infection by the host is a fundamental component of the
immune response, providing an early line of defence against pathogens (Janeway
1992b). However, activation of innate defence mechanisms by pathogens not only
provides early protection for the host, but can also trigger cytokine and chemokine
cascades that shape the specific acquired immune response (Fearon and Locksley 1996).
It is now recognised that there is more specificity in the activation of the innate immune
system than was initially believed. This has been attributed to the variety of pattern
recognition receptors (PRRs) expressed on host cells that recognise highly conserved
motifs that are defined as pathogen-associated molecular patterns (PAMPs).
To come in contact with a professional antigen presenting cell (APC), pathogens first
have to gain access to the body, often via epithelial surfaces, such as the respiratory
tract, gastrointestinal tract and reproductive tract. Chlamydia trachomatis infection is
one of the most common sexually transmitted infections (Gerbase et al. 1998; Morgan
2002): Serovars D and E being the commonest serovars associated with human genital
infection (Workowski et al. 1994). Within the female reproductive tract C. trachomatis
can colonise epithelial cells without disseminating (Shaw et al. 2001) and initiate an
inflammatory response. It is therefore important for the host to generate an appropriate
response at the site of infection that controls the organism but does not cause damage.
Commensal organisms are abundant at many epithelial sites in the body but do not cause
disease. It has been postulated that pathogens are capable of activating cells via PRRs in
ways that commensal organisms do not (Svanborg et al. 1999). This could provide the
'danger' signals that activate innate immune components and subsequently drive the
acquired immune response (Matzinger 1994). Expression of PRRs by epithelial cells and
the triggering of an inflammatory response are central to this concept.
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The Toll-like receptors (TLR) are a family of PRR. TLRs play a fundamental role in
mediating the innate immune response, recognising PAMPs such as LPS, lipoteichoic
acid and unmethylated CpG DNA motifs. Downstream signalling events are thought to
involve pathways resulting in the activation of nuclear factor k b (NF-kb)(Cario et al.
2000; Kopp and Medzhitov 1999; Medzhitov et al. 1997; Muzio et al. 1998). Activation
of the adaptive immune response then requires MHC class II expression and antigen
presentation.
Following recognition of a pathogen, a cascade of events occurs as the host attempts to
control infection. This includes the secretion of chemokines and cytokines such as IL-8,
GM-CSF and IL-6 following in vitro infection of epithelial cells with C. trachomatis
(Rasmussen et al. 1997). Natural antimicrobials are effectors of the innate immune
system that have been shown to have antimicrobial activity (Bals et al. 1998; Hiemstra et
al. 1996; Lehrer et al. 1993; McNeely et al. 1995; Tomee et al. 1997). The role of natural
antimicrobials in the response to genital tract chlamydial infection has not been
characterised.
This study uses a cervical epithelial cell line (HeLa) to characterise the mediators of
early events in the innate and adaptive immune responses following infection with C.
trachomatis serovar E. The expression of components of the TLR pathway, MHC class
II activation, natural antimicrobials, chemokines and cytokines involved in cell
recruitment and inflammation are described. By building up a pathway of events that





The human cervical cell line HeLa, was grown or maintained in Iscove's modified
Dulbecco's (IMDM) medium supplemented with the appropriate concentration of fetal
bovine serum. No antibiotics or other supplements were used unless stated otherwise.
6.2.2 Chlamydiae
C. trachomatis serovar E was used throughout, propagated in HeLa cell monolayers (see
section 2.3 for details).
6.2.3 Infection protocol
HeLa cells were treated with C. trachomatis serovar E (MOI 0.1 and 0.01), heat killed
C. trachomatis (MOI 0.1), and LPS (Salmonella minnesota R595) (lOOOng/ml and
lOOng/ml). As a further control, cells were treated with a cell lysate; control uninfected
HeLa cells were processed in the same way as infected HeLa cells when harvesting C.
trachomatis. The subsequent cell lysate from the uninfected HeLa cells acted as a
control for cellular components, which may have been stimulating the innate immune
response. Cultures were incubated at 37°C for 2 hours, 4 hours, 8 hours, 24 hours or 48
hours. At each time point supernatant was collected and stored at -70°C for subsequent
sandwich ELISA; cells were lysed in Tri reagent and stored at -70°C for subsequent
mRNA extraction. Experiments were performed three times.
To confirm the infectivity of C. trachomatis, HeLa cells were grown in 8 well chamber
slides and treated as above. 72 hours after treatment slides were fixed in acetone and
stained for chlamydial LPS as described in section 2.5.4. (see Figure 33)
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Figure 33: Detection of chlamydial LPS in HeLa cells. HeLa cells were treated as
follows:
a) untreated control, medium alone
b) cell lysate
c) heat killed C. trachomatis (MOI 0.1)
d) LPS (Salmonella minnesota R595), lOOOng/ml
e) and (f) C. trachomatis (MOI 0.1)
Scale bar = 50 |xm.
Scale is the same for a - e, with a higher magnification of e shown in f.
72 hours post inoculation, cells were stained with fluorescent (FITC - green) antibody to
chlamydial LPS. No staining is seen in untreated cells (a) and cells treated with cell
lysate (b). Cells treated with S. minnesota LPS show minimal staining (c), probably due
to cross reactivity with the antibody. Cells treated with heat killed C. trachomatis also
show a small amount of staining (d), as chlamydial LPS will survive the heating process.
Clear staining is seen in those cells treated with live C. trachomatis (e and f). C.
trachomatis has a biphasic growth cycle. Infectious elementary bodies (EBs) enter the
host cells and differentiate into larger reticulate bodies (RBs). The RBs divide within an
expanding endosome resulting in an intracellular chlamydial inclusion. After a period of
growth RBs reorganise into new infectious EBs that are released by cell lysis or
exocytosis. A higher magnification of e is shown in f. Cell nuclei have been stained with




6.2.4.RNA extraction and Q-RT-PCR
After treatment cells were harvested in Tri reagent and cDNA prepared. Fold changes in
amounts of mRNA for IL-8, CD14, TLR4, TLR9, HBD1, HBD2, HBD3, SLPI, MCP1,
IL-la, TGF(3, COX 2, PGDH, PGES, PGFS, MAL, MyD88, IkBa, HLA and CIITA
were determined using quantitative real time PCR. (See section 2.4 for details of
method). There were no significant differences between the 18S levels in the control or
chlamydia infected samples (Figure 34a). When the mRNA expression of a ubiquitous
nuclear gene, (3 actin, was compared to the mRNA expression for 18S there were no






















Figure 34: (a) No significant differences between 18S mRNA Ct values of control and
chlamydia (MOI 0.1) infected cells as determined by Q-RT-PCR. Data represents the
mean and s.e.m of 33 experiments (11 different primer/probe sets analysed), (b) No
significant differences between expression of P actin and 18S mRNA were observed.
Data represents the mean and s.e.m of three experiments.
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6.2.5 SLPI ELISA
SLPI protein concentrations in cell culture supernatants were determined by ELISA as
detailed in section 2.6.1.
6.2.6 PGE2 ELISA
PGE2 was measured in cell culture supernatants by ELISA as detailed in section 2.6.2.
6.2.7 IL-8 ELISA
IL-8 was measured in cell culture supernatants by ELISA as detailed in section 2.6.3.
6.2.8 Flow cytometric analysis
HeLa cells infected with C. trachomatis and uninfected control cells were harvested and
labelled with a PC5-conjugated anti-CD14 antibody as described in section 2.7.
Activated U937 cells, a monocyte cell line, were used as a positive control. Activation of
U937 cells was achived following treatment with TPA lOOng/ml for 72 hours. CD 14
expression was analysed by flow cytometry using a Becton Dickenson FACScan
(Mountain View, CA). Data is presented as forward scatter versus FL-3.
6.2.9 Statistical analysis
Significant differences of PCR and ELISA results were determined by analysis of
variance (ANOVA; Statview 3.0). Fisher's protected least significant difference (PLSD)
was used to assign individual differences. P<0.05 was considered significant.
Mean and s.e.m are presented.
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6.3 Results
6.3.1 Up-regulation ofIL-8 expression and components initiating the response following
stimulation ofHeLa cells
Treatment with C.trachomatis increased IL-8 mRNA expression and secretion of mature
protein in a time - and dose - dependent manner (Figure 35a). Following infection at
MOI of 0.1 the mRNA expression was maximal at 8 hours post infection, increased 200
fold (P<0.0001) and then decreased over the following 40 hours. MOI of 0.01 resulted in
a lower and delayed response at 24 hours, with an 80-fold increase (P=0.0002). A
parallel increase of IL-8 was seen in the supernatant with levels of 1590pg/ml at 48
hours after infection at MOI 0.1 (P<0.0001) and 831pg/ml after infection at MOI 0.01
(P<0.0001) (Figure 35b). Heat killed C.trachomatis and cell lysate also induced IL-8
mRNA expression and secretion of mature protein, but the response was of a smaller
magnitude (Figure 36a and 36b). LPS had a non significant effect on IL-8 mRNA
expression and protein secretion (Figure 36a and 36b).
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Figure 35: Kinetics of IL-8 expression after infection with C. trachomatis serovar E
(MOI 0.1 and 0.01), heat killed chlamydia (MOI 0.1), uninfected cell lysate and LPS
(lOOOng/ml and lOOng/ml). Cells were exposed to treatments for the indicated periods of
time. Thereafter, the culture supernatant was stored, cells lysed and mRNA extracted.
Data represents the mean and s.e.m of three experiments, (a) shows IL-8 mRNA
expression. Each time point represents the fold change compared to the uninfected
control sample (medium alone) at that time point, (b) shows IL-8 protein secretion into
the culture supernatant of C. trachomatis infected cells as measured by ELISA.
Letters indicate significant increases over control samples.
(a) a: P<0.0001, b: P<0.0001, c: PcO.OOOl, d: P=0.019, e: P=0.002
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Figure 36: Kinetics of IL-8 expression after treatment with heat killed chlamydia (MOI
0.1), uninfected cell lysate and LPS (lOOOng/ml). Cells were exposed to treatments for
the indicated periods of time. Thereafter, the culture supernatant was stored, cells lysed
and mRNA extracted. Note different scale of x-axis compared to Figure 35. Data
represents the mean and s.e.m of three experiments.
(a) shows IL-8 mRNA expression. Each time point represents the fold change compared
to the uninfected control sample (medium alone) at that time point, (b) shows IL-8
protein secretion into the culture supernatant as measured by ELISA.
Letters indicate significant increases over control samples.
(a) a: P=0.0032, b: P=0.0092
(b) a: P=0.0440
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6.3.2 Chemokine and cytokine mRNA up-regulated following infection with C.
trachomatis
Pooled cDNA from the three experiments indicated that mRNA for MCP-1, IL-la,
TGF(3 and COX-2 showed a trend to increased over 8 hours and then returned towards
pre treatment levels (Figure 37 and 38). COX-2 mRNA expression was 11.4 fold above
the control at 24 hours post infection (P=0.0002) (Figure 38a). In keeping with increased
COX-2 mRNA expression, the trend of PGDH mRNA expression was observed to
decrease and the PGES and PGFS to increase (Figure 38b). ELISAs were carried out for
PGE2 to determine the functional significance of the raised COX-2 mRNA expression,
but levels had not increased significantly by 48 hours (data not shown).
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Figure 37: mRNA expression of MCP-1, IL-la and TGF(3 shows a trend to increase up
to 8 hours post infection with C. trachomatis serovar E (MOI 0.1). At the time points
indicated cells were harvested and mRNA extracted. cDNA from three experiments was
pooled and mRNA expression quantified. Data is presented as the fold change compared
to the uninfected control sample (medium alone) at that time point using quantitative
real time PCR.
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Figure 38: Up-regulation of COX2 mRNA over 24 hours (a), with later increases in
PGES mRNA and PGFS mRNA observed. The trend of PGDH mRNA expression is
decreased over a similar time course (b). Cells were treated with C. trachomatis serovar
E (MOI 0.1 or MOI 0.01) and then mRNA extracted at the time points indicated. Data
for COX2 represents the mean and s.e.m (n=3). For PGDH, PGES and PGFS cDNA
from three experiments was pooled and mRNA expression quantified. Data is presented
as the fold change compared to the uninfected control sample (medium alone) at that
time point using quantitative real time PCR.
Letters indicate significant increases over control samples.






















6.3.3 Recognition of Chlamydial infection, possible roles ofTLR
For an innate response to be initiated TLRs are likely to play an important role. It was
therefore decided to look at the expression of two of these, TLR9 and TLR4, and CD 14
which complexes with TLR4. TLR9 mRNA expression was increased by 3.25 fold at 24
hours post infection with C. trachomatis (P=0.0275) (Figure 39). TLR4 expression did
not change significantly over the 48 hours (Figure 39). In contrast the associated mRNA
for CD 14 clearly increased to a maximum 4 fold above the control at 4 hours (PcO.OOOl)
(Figure 39). Flow cytometry was performed to assess CD 14 expression on the HeLa cell
surface. An activated monocyte cell line U937 showed 12% of cells being positive for
CD 14. Very low, if any, CD 14 expression was observed on the HeLa cells and
expression was not significantly changed 4 hours, 8 hours or 24 hours following
chlamydial infection, with less than 1% of cells being CD14 positive in both the control
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Figure 39: Kinetics of TLR4, CD 14 and TLR9 mRNA expression after infection with
C. trachomatis serovar E (MOI 0.1). Each time point represents the fold change mRNA
compared to the uninfected control sample (medium alone) at that time point. Data
represents the mean and s.e.m (n=3), with the exception of data for TLR9 and TLR4 at 2
hours where n=2 and therefore no s.e.m shown.
Letters indicate significant increases over control samples,
a: PcO.OOOl, b: P=0.0275
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Figure 40: CD 14 expression as assessed by flow cytometry. Activated U937 monocytes
express CD 14 while HeLa cells have very low/absent expression, which is not increased
after infection with C. trachomatis.
(a) Unstained activated U937 cells (b) Activated U937 cells stained with an antibody for
CD 14, 12% of cells positive for CD14.
(c and d) HeLa cells were stained with an antibody for CD 14 4 hours, 8 hours and 24
hours post infection with C. trachomatis. This shows the results at 8 hours post infection
which were representative of samples at the other time points, (c) Uninfected HeLa cells
(d) HeLa cells infected with C. trachomatis.
Data is presented as forward scatter versus FL3, FL3 being used as the fluorochrome is
PC5.
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6.3.4 Downstream events following TLR ligation: up-regulation of Myd88, MAL and
iKBa.
TLRs have a Toll/IL-1 receptor (TIR) domain and require an adaptor of signal
transduction. Myd88 and Myd88-adaptor-like (MAL) are proteins with a TIR domain,
which act as signal transducers. The mRNA for both Myd88 and MAL were up-
regulated 1.75 fold 8 hours after infection with C. trachomatis (Figure 41a). This was
not a significant rise over the control for MyD88, but was significantly higher than the
control for MAL (P=0.05). Levels at 8 hours were significantly higher than levels at 2, 4
and 48 hours post infection for both MyD88 and MAL (P<0.03).
NF-kB has been implicated as a transcription factor following TLR ligation. IkBoc
expression was examined as a marker of NF-kB activation. By 8 hours this had
increased 2 fold (P=0.002) and was increased by 3.8 fold at 24 hours (PcO.OOOl),
suggesting NF-kB is activated following chlamydial infection. This increase in mRNA
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Figure 41: (a) Up-regulation of Myd88 and MAL mRNA following treatment treated
with C. trachomatis serovar E (MOI 0.1). Data represents the mean and s.e.m (n=3).
(b) Up-regulation of IkBoc mRNA following treatment treated with C. trachomatis
serovar E (MOI 0.1), but not after treatment with LPS (lOOOng/ml). Data represents the
mean and s.e.m (n=3), with the exception of samples at 2hours where no s.e.m is shown
as n=2. Letters indicate significant increases over control samples.
(a) a: P=0.05 (b) a: P=0.002, b: P<0.0001, c: P<0.0001
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6.3.5 Activation of the adaptive immune response
mRNA expression of MHC class II (HLA-DR) and its transcriptional activator, CUTA,
were examined to define whether the infected HeLa cells could be potential targets for
recognition by activated CD4 T cells. The mRNA expression of CIITA increased 3.3




























Figure 42: CIITA mRNA expression is up regulated after infection with C. trachomatis
serovar E (MOI 0.1). However HLA-DR mRNA expression does not change
substantially over the time course observed. Each time point represents the fold change
mRNA compared to the uninfected control sample (medium alone) at that time point.
Data represents the mean and s.e.m (n=3), with the exception of data at 2 hours where
n=2 and therefore no s.e.m is shown.
Letters indicate significant increases over control samples,
a: P=0.0002, b: PcO.OOOl
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6.3.6 Antimicrobial expression following C. trachomatis infection; up-regulation ofSLPI
As expression of receptors involved in initiation of innate immune responses were
modified by chlamydial infection, the expression of the natural antimicrobials HBD1,
HBD2, HBD3 and SLPI were examined.
SLPI expression was initially down regulated, but at 24 hours was 2.6 fold above the
control (P=0.0002) (Figure 43a). Stimulation with LPS induced a similar but non
significant change in expression although the magnitude of the response was lower
(Figure 43a). This increase in mRNA expression following chlamydial infection was
associated with an increase in SLPI protein, as determined by ELISA (Figure 43b).
While all supernatant samples had less than 0.05ng/ml of SLPI initially, after 48 hours
uninfected control supernatant samples had a mean of 0.88ng/ml and chlamydia (MOI
0.1) treated samples had mean levels of 1.57ng/ml of SLPI in the cell supernatant.
Levels of HBD1 and 2 in Hela cells were almost undetectable and could not be induced
by chlamydial infection (data not shown). HeLa cells expressed HBD3, but expression
was not modified by chlamydial infection (data not shown).
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Figure 43: Up-regulation of SLPI mRNA and protein expression after infection with C.
trachomatis. Cells were exposed to treatments, C. trachomatis serovar E (MOI 0.1) or
LPS (lOOOng/ml), for the indicated periods of time, (a) SLPI mRNA expression. Each
time point represents the fold change compared to the uninfected control sample
(medium alone) at that time point. Data represents the mean and s.e.m (n=3), with the
exception of samples at 2 hours where no s.e.m is shown as n=2.
(b) SLPI protein secretion into the culture supernatant. Data represents the mean and
s.e.m (n=3). Letters indicate significant increases over control samples.
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Epithelial cells at mucosal surfaces are common targets for many intracellular
pathogens, acting either as the principal host cell for replication or as a route of entry for
dissemination to other sites of the body. C. trachomatis infects the epithelium of the
genital tract and is responsible for over 90 million new cases of human sexually
transmitted infections (STIs) worldwide each year (Beagley and Timms 2000). The
design of a safe, effective vaccine has been hampered by the fact that C. trachomatis can
cause a persistent infection with resulting pathology, mediated by the host inflammatory
immune response (Beatty et al. 1994; Darville et al. 1997). It is therefore important to
define the innate response following primary infection of epithelial cells, with a view to
understanding how this could limit bacterial growth directly and also how it could shape
the acquired immune response.
Secretion of IL-8 as a consequence of infection of HeLa cells with C. trachomatis has
been shown previously (Rasmussen et al. 1997). This study was designed to
demonstrate whether infection was required for IL-8 induction, or if exposure to dead
organisms or the products of dead cells would induce the same effects. Figures 35 and
36 show that although infection induces the greatest increase in IL-8 production, it is not
an absolute requirement. Heat killed organism and cell lysate both elicited a response,
albeit reduced, when compared to the effect of the live organism. Techniques commonly
used to evaluate C. trachomatis measure multiplicity of infection and therefore live
organisms, the contribution of dead organisms and their components therefore remain
unknown. We show that these components do contribute to responses observed to a
small extent. Heat killed chlamydia will have intact heat stable components such as LPS
which may be initiating effects. S. minnesota R595 is representative of and has been
shown to be more potent than C. trachomatis LPS (Ingalls et al. 1995). LPS alone had
the least effect on IL-8 expression suggesting any role that it does play in initiating the
response to C. trachomatis is minimal. Other components of C. trachomatis, such as
CpG motifs or heat shock proteins that may mediate this response were not examined
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and could be the subject of further studies. Interestingly the cell lysate, which was
devoid of chlamydia - acting as a control for cellular components which would be
produced in the natural course of the lytic life cycle of C. trachomatis, also caused an
increase in IL-8 expression. Cell damage and resulting debris may act as "danger"
signals (Gallucci and Matzinger 2001; Matzinger 1994), alerting the body to potential
pathology and may play a part in propagating the inflammatory response in the genito¬
urinary tract. Sauter et al (Sauter et al. 2000) present data showing selective activation of
dendritic cells when exposed to necrotic cells, but not when exposed to apoptotic cells,
with the differentiation between processes putatively carried out via PRR. This data
suggests that exposure of epithelial cells to cell products can also provide an activating
signal, although the nature of recognition remains to be defined.
Toll-like receptors are a family of PRRs, to date ten TLRs have been described. Ligands
have been described for 5 of these TLRs; TLR2 (bacterial lipoproteins and
peptidoglycans), TLR3 (double-stranded RNA), TLR4 (lipopolysaccharide (LPS) and
HSP60), TLR5 (flagellin), and TLR9 (unmethylated CpG DNA motifs) (Underhill and
Ozinsky 2002). The most relevant of these to chlamydial detection appear to be TLR4
and TLR9. The exact mechanisms of recognition have not been elucidated for all the
TLRs and may be via direct binding or via co-ligands such as CD 14 and MD2, as in the
case of TLR4 (da Silva Correia et al. 2001; Shimazu et al. 1999; Wright et al. 1990). In
the present study mRNA expression of TLR4 was not greatly increased, while its co-
receptor CD 14 mRNA was up-regulated within 4 hours of infection. This supports data
from Heinemann et al 1996 (Heinemann et al. 1996) who showed that monocytes
infected with C. pneumonia up-regulated CD 14 surface expression 8 hours post
infection. The fact that TLR4 mRNA expression was not induced, correlates with the
data presented here showing that LPS does not stimulate the maximal response in terms
of IL-8 secretion (see Figure 36). Previous work has been unable to detect TLR2 or
TLR4 mRNA in HeLa cells infected for 12 to 48 hours with C. trachomatis serovar E
(Dessus-Babus et al. 2002). Fichorova et al (Fichorova et al. 2002) report a lack of
TLR4 mRNA expression in immortalised human endocervical epithelial cells. They
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suggest that CD 14 can act as a co-receptor for non-TLR4 ligands, enhancing the
sensitivity of genital tract epithelial cells to bacteria. Alternatively it has been suggested
that TLR4 and CD 14 are not solely responsible for LPS recognition and a number of
other molecules (depending on the cell type), such as CDllb/CD18, CD66, HSP70 and
HSP90 might be involved (Triantafilou and Triantafilou 2002). In other systems such as
the gut it has been suggested that TLR4 down regulation may be a protective mechanism
where cells are continually exposed to LPS and a constant inflammatory response would
be deleterious (Abreu et al. 2001). Chlamydial DNA unmethylated CpG motifs, which
are recognised by TLR9, are possible candidate PAMPs. This study demonstrated that
mRNA expression of TLR9 increased 4 hours following inoculation with C.
trachomatis, and was maximal at 24 hours. Prior to this study, TLR9 expression had not
been described in cervical epithelial cells.
Downstream signalling events after ligand binding to the TLR follow those seen after
activation of the IL-1R, culminating in the nuclear translocation of NF-kB (Cario et al.
2000; Kopp and Medzhitov 1999; Muzio et al. 1998). The data presented here shows
small increases in the signal transduction proteins MyD88 and MAL, which are known
to activate NF-kB (Fitzgerald et al. 2001). NF-kB is a transcription factor involved in
inflammatory and immune responses (Baldwin 1996). IkBcc is an endogenous inhibitor
of NF-kB, whose expression is increased by activation of NF-kB, resulting in a negative
feedback loop (Sun et al. 1993). These experiments show an increase in the expression
of IkBcc suggesting activation of the NF-kB pathway. Many of the cytokines,
chemokines and antimicrobials examined in these experiments have NF-kB binding sites
in their gene sequences including IL-8 (Mukaida et al. 1991), COX-2 (Schmedtje et al.
1997) and HBD2 (Diamond et al. 2000). NF-kB may therefore play a crucial part in the
initiation of the cascade of results observed.
Infection of epithelial cells initiates a cascade response, which activates the innate
immune response. The MHC class II transactivator (CIITA) is the major regulator of
expression of MHC class II genes and therefore plays a fundamental role in the
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regulation of the adaptive immune response. It is interesting to observe that the adaptive
immune response appears to be up-regulated, with an increase in CIITA mRNA
expression, but without MHC II mRNA up-regulation. This may be because it is too
early in the cycle of events to observe these effects. This model system is limited in that
there are no other complementary cells present. In vivo, natural killer cells, which
infiltrate the area following infection, would be a source of IFN-y. IFN-y is known to
play two roles in chlamydial infection, firstly it can regulate chlamydial growth (Beatty
et al. 1993), arresting growth at the EB stage and secondly IFN-y is an inducer of MHC
class II. Alternatively C. trachomatis may be affecting host genes and down regulating
MHC class II expression. Zhong et al (Zhong et al. 2001; Zhong et al. 1999) have
demonstrated that C. trachomatis can down regulated MHC II through the degradation
of upstream factor-1 (USF-1, a transcription factor required for IFN-y induction of
CIITA). This may be a mechanism whereby C. trachomatis attempts to evade
recognition by activated T cells, leading to low grade persistent infection.
Infection with C. trachomatis induced mRNA expression of both intracellular (IL-la,
COX 2) and soluble (IL-8, MCP-1, TGF(3) mediators of the innate immune response. IL-
8 and MCP-1 have chemotactic properties for both monocytes and NK cells, and may
therefore provide a link between the innate and adaptive immune responses.
Intracellular gene products such as PGE2, following the increased expression of COX-2,
may act in an autocrine or paracrine fashion to further modify the immune response (Yu
and Chadee 1998). PGE2 has been demonstrated to up-regulate CD 14 expression in
mouse macrophages and may thus maintain or amplify the immune response (Iwahashi
et al. 2000). It is interesting to note that the mRNA expression of all of these mediators
shows a trend to decrease by 48 hours post infection, after an initial trend of up-
regulation. It was thought that this might be due to secretion of anti-inflammatory
cytokines such as TGF(3 but mRNA expression of this cytokine also decreased after 24
hours. Dessus-Babus et al (Dessus-Babus et al. 2002) suggest that IL-11 may exert anti¬
inflammatory activity, showing that HeLa cells secrete increased levels of IL-11
following infection with the disseminating serovar L2 strain of C. trachomatis compared
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to levels seen with the non disseminating serovar E strain. Other markers such as those
involved in the adaptive immune response detailed above did not decrease suggesting
that the cells continue to be capable of mRNA synthesis. The housekeeping genes 18S
and (3 actin were also observed to remain constant over time (see Figure 34). Whether
this observed down regulation of mRNA expression is due to the inherent instability of
mRNA or whether there is some as yet undefined anti-inflammatory mechanism C.
trachomatis has evolved to dampen down the acute inflammatory response, thereby
improve the chances of establishing a persistent infection, is uncertain.
SLPI, a protease inhibitor that has antimicrobial activity, was up-regulated in this study
and may play a role in limiting chlamydial invasion of epithelial cells. In addition to
antimicrobial effects, SLPI also inhibits the NF-kB signal transduction pathway (Jin et
al. 1997; Lentsch et al. 1999) and may be limiting the inflammatory response to C.
trachomatis in an attempt to protect the host while at the same time potentiating the
pathology caused by infection. Due to their low ionic strength a and (3 defensins are
likely to exert their effects intracellularly in phagocytic vacuoles, or extracellularly at the
skin surface and at mucosal surfaces (Yang et al. 2002). Natural antimicrobials are
thought to exert their effects through the disruption of microbial membrane integrity
(Risso 2000). In vitro (3 defensin 2 has been up-regulated following stimulation with
LPS and bacterial lipoprotein. This has been dependent on CD 14 and TLR2 expression
respectively (Becker et al. 2000; Birchler et al. 2001). Furthermore, human defensin and
porcine protegrin have been shown to protect McCoy cells from infection by C.
trachomatis, by damaging the membrane and allowing leakage of cellular contents
(Yasin et al. 1996). The antimicrobials may therefore play an important part in resisting
infection. The expression of the (3 defensins in HeLa cells was low, and was not up-
regulated by infection. Islam et al (Islam et al. 2001) have demonstrated that mRNA
expression of some antibacterial peptides, including HBD1 can be down regulated in
enteric Shigella infections. It may be that chlamydia is employing a similar strategy of
down regulation and hence self-preservation.
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Recognition of pathogens and resultant sequelae at mucosal surfaces can occur through a
variety of processes. This data suggests that LPS is not a predominant ligand in the
activation of epithelial cells as a primary defence mechanism to C. trachomatis. Other
components such as bacterial DNA or cellular debris released as a consequence of the
lytic cycle of C. trachomatis may play a role. Figure 44 summarises the effects observed
in this study following in vitro infection of a cervical epithelial cell line with C.
trachomatis. A better understanding of the early immune responses to C. trachomatis
provides insight into the pathogenesis of infection and allows consideration and
development of rational control strategies.
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This chapter summarises the results obtained in this thesis. Detailed discussion
accompanied each chapter and therefore the wider context of this work is discussed.
Finally, suggestions for future study are presented.
7.1 Synopsis of Results
The aim of this thesis has been to characterise and investigate the control of natural
antimicrobial peptides in the female reproductive tract. Work has concentrated on
uterine tissue: endometrium, first trimester decidua, a cervical cell line; and briefly
vaginal and salivary secretions. In the course of study the role of the pattern recognition
receptor family, the Toll-like receptors (TLRs) as an integral part in the recognition of
and initiation of a response to pathogens was realised and this role was investigated
further. A schematic diagram of possible interactions between these components of the
innate immune system is shown in Figure 45.
The presence of mRNA for the natural antimicrobial peptides, HBD1, HBD2, SLPI and
granulysin in the endometrium has been described and immunohistochemical studies
carried out to localise SLPI protein expression. Expression of all the natural
antimicrobials displayed cyclical variation. HBD1 was maximal in the mid secretory
phase, granulysin in the late secretory phase, F1BD2 in the menstrual phase and SLPI in
the late secretory and menstrual phases. Similarly the presence of mRNA for HBD1,
SLPI and granulysin but not HBD2 within first trimester decidua was described. None of
the antimicrobials under investigation were expressed in trophoblast tissue. Exogenous
sex steroid hormones in the form of the combined oral contraceptive pill and the
levonorgestrel intrauterine system significantly decreased mRNA expression of HBD1
and 2 and granulysin within endometrial tissue. mRNA levels of SLPI were not
significantly altered by the combined oral contraceptive pill or the levonorgestrel
intrauterine system. There was no significant effect of chlamydial infection on natural
antimicrobial mRNA expression in first trimester decidual samples. Preliminary work
was undertaken to investigate the possibility of using salivary measurements of natural
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antimicrobials as non-invasive surrogate markers of natural antimicrobial secretion in
the genital tract, but no correlations between levels of SLPI in saliva and vaginal
secretions were found.
In vitro studies investigated the expression of the natural antimicrobials, SLPI, HBD1
and HBD2, the Toll-like receptors, TLR4 and TLR9 and the co-receptor CD14 in
primary endometrial epithelial cells and two endometrial epithelial cell lines (MFE and
Hes). The role of bacterial (Gram negative - lipopolysaccharide and Gram positive -
lipoteichoic acid) and viral (polyinosinic-polycytidylic acid) mimics of infection and
some inflammatory mediators, including prostaglandins, IFNy, and combinations of IL-
1(3 and TNFa in the regulation of natural antimicrobials and TLRs in human
endometrial epithelial cells was determined. LPS and poly I:C increased the mRNA
expression of HBD1 while decreasing the mRNA expression of SLPI. LTA had no
significant effect on the expression of the natural antimicrobials. The response to
treatment with LPS was augmented in the presence of human serum, which may be
providing required co-factors such as CD 14 or undefined cytokines. The prostaglandins,
PGE2 and PGF2a, did not alter natural antimicrobial, TLR4, TLR9 or CD 14 expression
in primary endometrial epithelial cells. However PGE2 and IFNy increased TLR4 mRNA
expression in the endometrial epithelial cell line Hes and TNFa and IL-1(3 increased
TLR4 mRNA expression in the endometrial epithelial cell line MFE. LPS increased
CD14 expression in Hes cells, while decreasing CD 14 expression in MFE cells. TLR9
expression was not altered by any of these treatments.
Having examined the effects of mimics of infection, work was undertaken to
characterise early events following infection of a cervical epithelial cell line (HeLa) with
C. trachomatis in vitro. Both live organisms and heat-killed organisms initiated IL-8
and COX-2 production suggesting that invasion of host cells and subsequent
multiplication of the organism are not essential to induce an inflammatory response. LPS
appeared to play a minor role. Interestingly, products of lysed cells, which would be
produced during the natural lytic cycle of the organism also induced IL-8 production.
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HeLa cells expressed mRNA encoding TLR4 and TLR9, and CD 14. TLR9 and CD 14
mRNA expression were up-regulated by C. trachomatis infection, no effect was seen on
TLR4 mRNA expression. mRNA for the Class II transactivator was increased, while
MHC class II expression was unchanged up to 48 hours post infection. The natural
antimicrobial SLPI was up-regulated while HBD1 and HBD2 were not expressed by
HeLa cells. HBD3 mRNA expression was unaffected by C. trachomatis infection.
Expression profiles of the natural antimicrobials and Toll-like receptors suggest that they
contribute to the innate immune armoury of the female reproductive tract. Further
studies are required to take these concepts and convert them into clinically applicable
treatments within reproductive health care.
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7.2 Discussion: The wider context
Research work is undertaken to further knowledge and understanding of the
environment. Questions are answered and further questions arise. Ultimately within
medical research it is hoped that the understanding gained may lead to benefits for
others, through the design of medical interventions. The studies in this thesis increase
our understanding of a component of the innate immune events within the female
reproductive tract. As the use of synthetic antibiotics are more widely and commonly
used the resistance of organisms to the antibiotics that we have is becoming of greater
concern (Nollette 2000). The discovery of natural antimicrobial substances has opened
up new areas of possibility for the treatment of infections. These treatments could be
utilised both in the non-pregnant and pregnant state to prevent or treat sexually
transmitted infections. The potential maternal and fetal sequelae of these infections
might therefore be attenuated.
Within the female reproductive tract it has been envisaged that the natural antimicrobials
may make up an important component of topical microbicides. An ideal microbicide
should be broad spectrum, inexpensive, easy to use, safe to use and easy to store. Initial
interest focused on existing spermicides, which reportedly have microbicidal activity,
such as nonoxynol-9 (N-9) and benzalkonium chloride (Belec et al. 2000), both
detergent like substances. The safety of these compounds, particularly N-9, has been
called into question. N-9 can inactivate many sexually transmitted pathogens including
C. trachomatis and N. gonorrhoea (Cook and Rosenberg 1998; Patton et al. 1992),
however, it has been demonstrated to cause vaginal irritation, inflammation, immune
cell infiltration and changes in the natural vaginal flora. N-9 may therefore enhance the
infectivity of some microbes, particularly HIV (Fichorova et al. 2001). Investigators are
therefore exploring new potential microbicides such as sulphated polysaccharides
(Pauwels and De Clercq 1996; Pearce-Pratt and Phillips 1996) and natural
antimicrobials.
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Natural antimicrobials under investigation include the insect derived cecropins and the
vertebrate derived magainins and protegrins. The cecropins have been shown to have
anti-chlamydial activity in vitro (Ballweber et al. 2002). A synthetic 22 amino acid
analogue of the magainin peptide from the African clawed frog has undergone testing as
an antifungal, but has not got FDA approval. Dr R. Lehrer (California, USA) is
undertaking work developing protegrins for clinical treatment, and a pharmaceutical
company, Intrabiotics, is developing a protegrin derived antimicrobial. The limitation of
the defensins as antimicrobials is that they are pH and salt sensitive (Bals et al. 1998;
Goldman et al. 1997; Singh et al. 1998). Defensins are also inactivated by serum (Yasin
et al. 1996). Yu et al (Yu et al. 2000) have therefore been designed salt insensitive a
defensins, and these compounds still have wide antimicrobial activity. Theta defensins
have been described in rhesus monkeys. The theta defensins are cyclical peptides formed
by the ligation of two a defensins, which results in a peptide with greater antimicrobial
activity (Tang et al. 1999). The natural antimicrobials, although small peptides, are
larger than other agents used therapeutically. This and their positive overall charge
makes the penetration of these substances into tissues slow. Smaller ring peptides, which
penetrate tissues more effectively have therefore been developed (Fernandez-Lopez et
al. 2001). These limitations will need to be further addressed before these compounds
could be used within the female reproductive tract. The expense of large-scale
production of these peptides has also been a limitation, although synthesis of neutrophil
defensins has been achieved (Raj et al. 2000).
Another approach to use of natural antimicrobials would be to develop compounds that
induce local production of natural antimicrobials. A synthetic salicylic acid-like
compound has been described to induce antimicrobial peptides in plants (Schroder and
Harder 1999). Isoleucine, an essential amino acid, induces HBD2 expression and is a
candidate for further investigation (Fehlbaum et al. 2000). It has been suggested that the
amino acid may work by binding to a Toll-like receptor. A number of inflammatory
cytokines, such as IFNy, IL-1(3 and IL-ip + TNFa, induce antimicrobial expression
within human endometrial epithelial cells (King et al. 2002). The limitation of these
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molecules is the cascade of other inflammatory events that they initiate which may cause
detrimental effects if not controlled. The studies presented in this thesis examine the role
of mimics of infection such as LPS as potential inducers of natural antimicrobial
activity. Once again the limitation of these compounds is the other inflammatory events
that are potentially stimulated.
Mimics of infection, LPS and LTA, are examples of pathogen associated molecular
patterns (PAMPs) that act as ligands for pattern recognition receptors (PRR),
particularly the TLRs. Signalling events after ligation of the receptors initiate gene
expression. The TLR pathway could therefore be a target for manipulation and
modulation. Shock due to Gram-negative bacterial sepsis is a consequence of an acute
inflammatory response to LPS. A stabilised endotoxin antagonist has been developed
which can block the symptoms of experimentally induced septic shock (Bunnell et al.
2000; Christ et al. 1995). This antagonist blocks TLR4-mediated transgene activation in
a dose-dependent manner (Chow et al. 1999). Others have also examined the potential of
agonists and antagonist to TLR4 as a mechanism to influence the inflammatory
processes. C. trachomatis LPS is a weak inducer of an inflammatory response (Ingalls et
al. 1995). Sweet et al (Sweet et al. 2001) therefore re-engineered the LPS containing
Lipid A of C. trachomatis, expressed it in an E. coli mutant and determined the residues
responsible for the poor induction of inflammatory response. They suggest a possible
future strategy would be to delete and replace this area with the complimentary region
from E. coli, which may result in a more effective immune response to C. trachomatis.
Epithelial cells release antimicrobial peptides in response to PAMPs such as LPS and
LTA (Becker et al. 2000; Birchler et al. 2001; Diamond et al. 1996) and these responses
are putatively TLR dependent. TLRs can also induce differential gene expression,
resulting in the release of distinct cytokine patterns which may then direct the adaptive
immune response (O'Neill 2002). Further research into this area is required, but it could
be envisaged that once microbial stimulators of specific cytokine responses are known,
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with resultant beneficial or detrimental immune responses, these responses could be
modified to the hosts benefit.
The application of studies defining components of the innate immune system are not
limited to the site at which they have been defined, such as within the female
reproductive tract, but can be used to help understand immune responses at other
mucosal surfaces. Treatments developed for use at one site might well be applicable for
use at other sites or in other situations. It is hoped that the research described in this
thesis adds to our understanding and will provide the basis for further studies and
possibly, with development, future clinical interventions.
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7.3 Suggestions for future studies
1) The contraceptives studied, COCP and LNG-IUS, significantly decreased mRNA
expression of natural antimicrobials. There are wide ranges of effective
contraceptives available at present. Future contraceptives need to either provide
improved side effect profiles, or additional benefits to the user. A contraceptive
designed with an optimal antimicrobial profile would have such additional benefits.
There are two ways in which to address this problem; firstly when a new
contraceptive is designed, trials should assess the effects of the method on
components of the immune system including the natural antimicrobials. Studies
developing new contraceptives are ongoing and are incorporating this approach into
the assessment of new contraceptives. The other approach would be to take existing
available contraceptives and modify them to enhance their antimicrobial activity.
2) Preliminary results looking for correlations between antimicrobial secretions at
different mucosal surfaces were inconclusive. Techniques to determine the levels of
antimicrobials other than SLPI, particularly the (3 defensins, need to be optimised.
Studies could then be extended to examine expression of the natural antimicrobials
in situations of acute infection. The role of the natural antimicrobials through
pregnancy could also be assessed in longitudinal studies. Antimicrobial levels at
different mucosal sites could be determined at different stages through pregnancy
and the pregnancy outcomes evaluated, possible markers for adverse pregnancy
outcomes may be defined.
3) The research on Toll-like receptors is in its infancy and future studies need to
continue to define the roles of these receptors in the female reproductive tract more
clearly. Down stream events following receptor ligation need to be assessed and the
therapeutic potential of these receptors investigated.
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Appendix I: Source General Materials









Neutral Buffered Formalin (NBF)
Phosphate Buffered Saline (PBS)
Ethanol











Culture flasks and culture plates
DEAE-dextran
Chlamdia transport medium (high glucose)
Source
Pipelle, Laboratoire CCD, Paris, France
Monovette, Sarsted, Amsterdam, Holland
Becton Dickenson, Madrid, Spain
Sarsted
Sigma, Poole, Dorset, UK.


















Costar, High Wycombe, UK
Pharmacia, Sweden
Moredun Research Institute scientific
services, See Appendix II
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Cell Line Source
MFE-296 European collection of cell cultures
(ECACC), CAMR, Salisbury, UK





Epidermal growth factor (EGF) Preprotech Ltd., London, UK.
Vascular endothelial growth factor (VEGF) Preprotech
Basic fibroblast growth factor (bFGF) Preprotech
Progesterone Sigma
RU 486 Gift from Dr. D. Philibert, Roussel-
UCLAF, Romainville, France
Lipopolysaccharide (LPS) E. coli Serotype Sigma
026:B6
LPS Salmonella minnesota RE-595 Calbiochem, Darmstadt, Germany
Lipoteichoic acid (LTA) Staphylococcus Sigma
aureus
Polyinosinic Polycytidylic acid (Poly I:C) Sigma
Chlamydia trachomatis serovar E Gift from Dr I Clarke, University of
Southampton and Dr M Holland, London
School of Hygiene and Tropical Medicine,
London, UK
Prostaglandin E2 (PGE2) Gift from Control Therapeutics, East
Kilbride, UK




























Eppendorf AG, Hamberg, Germany
BDH Laboratories Supplies, Poole,UK
Sigma-Aldrich Co.Ltd











Acetone BDH Laboratory Supplies
Histoclear National Diagnostics, Atlanta, Georgia,
USA
PBS See Appendix II
PBS+Tween See Appendix II
TritonXlOO Sigma
Hydrogen peroxide BDH Laboratory Supplies
Horse/Goat serum Vector Laboratories, Peterborough, UK
Rabbit serum Diagnostics, Scotland, UK
0.01M Sodium Citrate See Appendix II
Mouse immunoglobulin (SLPI, cytokeratin Vector Laboratories
and chlamydial LPS)
Goat immunoglobulin (HBD2) R&D Systems, Oxford, UK
Rabbit immunoglobulin (HBD2) Vector Laboratories
Anti-SLPI Hycult Biotechnology, Uden, Netherlands
Anti-HBD2 (goat polyclonal) Santa Cruz Biotechnology,
Autogenbioclear
Anti-HBD2 (rabbit polyclonal) Alpha Diagnostics, Autogenbioclear
Anti-cytokeratin Dako Ltd., Cambridge, UK
Anti-chlamydial LPS Moredun Research Institute scientific
services, Edinburgh, UK
Biotinylated horse anti-mouse/anti-goat Vector Laboratories
Biotinylated goat anti-rabbit Vector Laboratories
Biotinylated rabbit anti-mouse Dako Ltd
FITC conjugate rabbit anti-mouse Dako Ltd
Avidin-biotin-peroxidase complex (ABC Vector Laboratories
Elite)
Diaminobenzidine (DAB) Vector Laboratories
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Harris' hematoxylin Pioneer Research Chemicals Ltd.,
Colchester, UK
Xylene BDH
Pertex Cellpath pic, Hemel Hempsted, UK
Glycerol/PBS (Citifluor) Citifluor Ltd, Fanshaw Street, London, UK
ELISA Source































Antibodies produced in house, Medical
Research Council, Edinburgh
Scottish Antibody Production Unit, Law
Hospital,UK
Sigma
Antibodies produced in house, Medical
Research Council, Edinburgh
Gift from Control Therapeutics, East
Kilbride, UK
281
Anti-IL-8 coating antibody R&D Systems
Anti-IL-8 detection antibody R&D Systems
IL-8 recombinant standard R&D Systems
Flow cytometric analysis Source
Acutase Sigma
Isotype control antibody (VPM 20) Moredun Research Institute scientific services
PC5-conjugated anti-CD 14 antibody Immunotech, Marseille, France
Paraformaldehyde BDH
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Appendix II: Recipes for solutions
All chemicals listed were from Sigma and all dilutions were in distilled water unless
otherwise stated
1. Blocking/protecting solution
In 1 litre: 20g 2% polyvinylpyrrolidone
5g bovine serum albumin
lml preservatives Boehringer Mannheim
1.9g EDTA (5 mmol/L)
6.1g Tris (50 mmol/L)
2. Complete medium (cRPMI)











made up to 5L in deionised water, supplemented with:




25ml 10 OOOU/ml Nystatin suspension
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4. Epithelial growth medium
500ml cRPMI supplemented with
25ng/ml epidermal growth factor
lng/ml vascular endothelial growth factor
5ng/ml basic fibroblast growth factor
10"8 mol/1 oestradiol
5. ELISA buffer
In 1 litre: 9g NaCl (150mmol/L)
12.lg Tris (lOOmmol/L)










lml tetramethyl benzidine : 1ml urea-hydrogen peroxidase : 10ml sodium acetate
5g/l urea-hydrogen peroxidase (0.5% in 50mM sodium acetate, pH6)
3g/l tetramethyl benzidine in dimethylformamide
in 100mmol/l sodium acetate, pH6
lOOmM sodium acetate




8. ELISA wash buffer









10. Neutral buffered formalin (NBF)




11. Phosphate buffered saline (PBS)
In 1 litre: 5 PBS tablets
pH 7.4 - 7.6
12. PBS + Tween







in dimethylformamide (DMF) / dimethylsulphoxide (DMSO) 1:1
diluted 1:1000 to use
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14. 0.1M Sodium citrate buffer
In 1 litre: 29.4g Tri-sodium citrate BDH
O.lg sodium azide
pH 6
Diluted 1:10 to use
15. TE Buffer
10mmol/l Tris pH8.0
lmmol/1 EDTA in DEPC water
16. Tris buffer





5pm paraffin sections were dewaxed in histoclear and rehydrated in descending grades
of alcohol. After washing, an antigen retrieval step was performed. Sections were
pressure cooked for 5 minutes in 0.01M sodium citrate (pH6), left to cool for 20 minutes
and then washed in PBS for 10 minutes. Frozen sections were fixed in NBF for 10
minutes and then washed in PBS for 10 minutes. All sections where then treated with
3% hydrogen peroxide in distilled water for 10 minutes to block non-specific
endogenous peroxidase activity. Sections were then washed for 10 minutes in PBS.
Additionally in one run, to reduce non-specific staining due to endogenous biotin, an
avidin-biotin blocking step was carried out. Sections were incubated in avidin for 15
minutes at room temperature, then washed in PBS, followed by an incubation with biotin
for 15 minutes at room temperature. Depending on the primary anti-HBD2 antibody
subsequently used, a non-immune block of diluted horse or goat serum was then applied
for 20 minutes in a humidified chamber at room temperature. In an attempt to further
reduce non-specific staining, on one occasion a rabbit serum non-immune block with 5%
bovine serum albumin (BSA) was used in place of the horse serum. The non-immune
block was then carefully removed and the primary anti-HBD2 antibody applied. The two
antibodies tested were:
i) HBD2 goat polyclonal diluted 1:50, 1:100, 1:150 and 1:200 in horse serum
incubated for 1 hour at 37°C
ii) HBD2 rabbit polyclonal diluted 1:100 in goat serum incubated overnight at 4°C
The primary antibody was substituted with an equimolar concentration of goat or rabbit
immunoglobulin (IgG) respectively in negative control sections.
After the primary incubation, sections were washed for 10 minutes between each stage
with PBS + Tween. Antibody binding was detected by the application of biotinylated
horse anti-goat IgG or goat anti-rabbit IgG as appropriate, followed by an avidin-biotin-
peroxidase complex (Elite ABC), both for 60 minutes at room temperature. The protocol
was then completed as for SLPI (section 2.5.1).
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Appendix IV: Conference Proceedings
D.C. Fleming. G. Entrican and R.W. Kelly: Mediators of the Response to Chlamydia
trachomatis in Epithelial cells. Poster: Society for Gynecologic Investigation, Los
Angeles, USA, 2002
D.C. Fleming. G. Entrican and R.W. Kelly: Innate immunity and cytokine response to
Chlamydia trachomatis. Poster: British Society of Immunology, UK, 2001
D.C. Fleming. A.King, H.O.D. Critchley, R.W. Kelly and A.A. Calder: Hormonal
Contraception modulates Natural Antimicrobial Expression in Human Endometrium.
Oral presentation: Blair Bell Research Society Competition Meeting, December 2001
D.C. Fleming. A.King, H.O.D. Critchley and R.W. Kelly: Effect of Hormonal
Contraception on Natural Antimicrobial Expression in Human Endometrium. Oral
presentation: Munro Kerr Society, June 2001
D.C. Fleming. G. Entrican and R.W. Kelly: Acute Chlamydia trachomatis infection
alters Toll-like receptor gene transcription in cervical epithelial cells. Oral presentation:
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Regulation of natural antibiotic expression by inflammatory
mediators and mimics of infection in human endometrial
epithelial cells
Anne E.King1'3, Diana C.Fleming1, Hilary O.D.Critchley2 and Rodney W.Kelly1
'MRC Human Reproductive Sciences Unit and department of Reproductive and Developmental Sciences, University of Edinburgh,
Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3 9ET, UK
3To whom correspondence should be addressed. E-mail: a.king@hrsu.mrc.ac.uk
The natural antibiotic molecules, (3-defensins 1 and 2 (HBD1/2) and secretory leukocyte protease inhibitor (SLPI),
have an important role in mucosal defence and are present in the uterus. This study details their regulation in
primary endometrial epithelial cells and in two endometrial cell lines (MFE/HES). Cells were treated with
proinflammatory molecules and mimics of infection [lipopolysaccharide (LPS) and lipoteichoic acid (LTA)]. mRNA
for HBD1, HBD2 and SLPI was detected in primary endometrial epithelial cells using real-time quantitative PCR.
HBDI mRNA was present at very low levels preventing conclusive study of its regulation. However, HBD2 mRNA
expression was increased by interferon-y, interleukin (IL)-ip alone and IL-lp+tumour necrosis factor (TNF)-a.
SLPI mRNA was not affected by proinflammatory mediators, although protein levels fell in the presence of
IL-ip + TNFa. LPS had little effect on antimicrobial expression. However, there was a trend towards increased
expression with LTA treatment for 4-8 h. Antimicrobial expression in endometrial cell lines was similar to that in
primary cells, although SLPI was increased by IL-ip + TNFa treatment. These results suggest that in endometrium
some natural antibiotics (e.g. SLPI) may be constitutively expressed providing a basal level of protection, while
others (e.g. HBD2) are inducible .allo.wing, maximal antimicrobial activity during infection. Natural antimicrobials
will have an important role in endometrium in protecting against infection.
Key words: defensins/endometrium/infection/iriflammatory mediators/SLPl
Introduction
Successful human implantation and pregnancy are reliant on
the prevention of genital tract infections that can compromise
both fertility and the fetus itself. The molecules of the innate
immune system, present at mucosal surfaces, are likely to be
crucial in the limitation of such infections.
Natural antimicrobial molecules are small, cationic peptides
often present at epithelial surfaces (Huttner and Bevins, 1999;
Hancock and Diamond, 2000). These molecules are a crucial
component of the innate immune system offering a broad
range of antibacterial, antiviral and antifungal protection. In
the human there are two major groups: the a and p defensins.
The a-defensins 1-4 [human neutrophil peptide (HNP) 1-4]
are present in neutrophils while a-defensins 5 and 6 [human
defensin (HD) 5/6] are located in the Paneth cells of the gut
and at other epithelial surfaces. The p-defensins [human beta
defensin (HBD) 1—4] are located at epithelial surfaces and are
likely to play a major role in mucosal defence. Similarly,
secretory leukocyte protease inhibitor (SLPI), a neutrophil
elastase inhibitor with antimicrobial activity, is present at
© European Society of Human Reproduction and Embryology
mucosal sites and may have an anti-infective role (Franken
et al., 1989; Tomee et ai, 1998).
Several natural antimicrobials have been detected in the
human endometrium. HBDI, HD5 and SLPI have been detected
in endometrial epithelium, with both HD5 and SLPI showing
maximal expression in the secretory phase of the menstrual
cycle (Quayle et al., 1998; Valore et al., 1998; King et al.,
2000). SLPI is also present in first trimester and term decidua
(Denison et al., 1999; King et al., 2000). HBD2 and 4 have
been detected in the uterus (Bals et al., 1998; Garcia et al.,
2001), while HBDI and 3 have been located in placenta and
placental membranes respectively (Zhao et al., 1996; Jia et al.,
2001). The presence of these molecules in endometrium at the
time of implantation and during pregnancy suggests a role in
the protection of the fetus from infection.
Several of the natural antibiotics are regulated by inflam¬
matory molecules such as interleukin (IL)-l, tumour necrosis
factor (TNF)-a and lipopolysaccharide (LPS) in systems such
as lung, gut and gingiva (Sallenave et al., 1994; Diamond
et al., 1996; Jin et al., 1998; O'Neil et al., 1999; Harder et al.,
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2000; Krisanaprakornkit et al., 2000). Conserved motifs on
pathogens, pathogen-associated molecular patterns (PAMPS),
such as LPS can be used to mimic infection. The control of
natural antimicrobial expression in endometrium is unclear,
although the IL-1 system is thought to be active in the glandular
epithelium (Simon et al., 1993). This study investigates the
role of inflammatory molecules and bacterial products associ¬
ated with infection in the regulation of natural antibiotics in
human endometrial epithelial cells.
Materials and methods
Tissue collection
Endometrial biopsies were collected from women undergoing gynae¬
cological procedures for benign conditions. All women reported
regular menstrual cycles (25-35 days) and had not received any form
of hormonal treatment in the 3 months preceding biopsy. Biopsies
were dated from the patient's last menstrual period (LMP). Histo¬
logical dating according to published criteria (Noyes et al., 1950)
and circulating sex steroid concentrations were consistent with the
date of LMP. Written informed consent was obtained from all patients
prior to biopsy collection and ethical approval was received from the
Lothian Research Ethics Committee.
Tissue samples were collected in RPM1 1640 medium (Sigma,
Poole, Dorset, UK) and were subsequently divided into two portions.
Endometrium was: (i) fixed in 10% neutral buffered formalin overnight
at 4°C, stored in 70% ethanol and then wax embedded; and (ii)
separated into glandular and stromal compartments for cell culture.
Separation of endometrial biopsies into glandular and stromal
compartments
This method for separation of glandular and stromal compartments
of endometrium was adapted from that of O'steertVr al. \Osteen et al.,
1989). Several modifications were made and the details of the
method used in this study are described below. Endometrial biopsies
were washed twice in phosphate-buffered saline (PBS; Sigma),
sliced into small fragments, immersed in collagenase/DNAase (1 and
0.1 mg/ml; both Sigma) and incubated for 80 min at 37°C. After
incubation, RPMI 1640 medium was added and tissue was broken
up using a syringe. This yielded single cells and larger, glandular
fragments. This suspension was centrifuged (450 g, 3 min) and then
cells/fragments were resuspended in fresh medium and allowed to
separate by density sedimentation. After 5 min the supernatant
(stromal compartment) was removed leaving 2 ml of medium. Fresh
medium was added and the density sedimentation was repeated. The
remaining 2 ml of medium contained glandular fragments that were
centrifuged as above. Medium was discarded and the epithelial
fragments were incubated with collagenase/DNAase for 2 h at 37°C.
After incubation, medium was added and the cell suspension was
centrifuged (see above). Medium was removed and the epithelial cell
pellet was resuspended in 50% Matrigel (BD Biosciences, Bedford,
MA, USA).
Cell culture
Primary endometrial epithelial cells
Primary endometrial epithelial cells were grown in Matrigel (see
Figure 1 showing cells immunostained for SLPI) in RPMI 1640
medium supplemented with 10% fetal calf serum (Mycoplex; PAA
Laboratories, Teddington, UK), penicillin (50 pg/ml; Sigma), strepto¬
mycin (50 pg/ml; Sigma), gentamycin (5 (ig/ml; Sigma), epidermal
growth factor (25 ng/ml; Peprotech Ltd, London, UK), vascular
endothelial growth factor (1 ng/ml; Peprotech), basic fibroblast growth
Figure 1. Primary endometrial epithelial cells. Cells were grown in
Matrigel in 12-well culture plates for 7-10 days prior to immuno-
staining. (a) Immunolocalization of SLPI in primary endometrial
epithelial cells. SLPI was present in the cell cytoplasm and in
secretions from the cells (diffuse staining), (b) Negative control.
The primary antibody was replaced with equimolar concentrations
of an isotype control. Note absence of immunostaining. Scale
bar = 50 |im.
factor (5 ng/ml; Peprotech) and estradiol (10 7 mol/1). These growth
factors were included in the culture medium as there is evidence that
endometrial epithelial cells express their receptors and hence they
are likely to be involved in modulation of cell growth (Li et al.,
1994; Zhang et al., 1995; Sangha et al., 1997; Meduri et al., 2000).
Cells were grown to near confluence (7-10 days) in 12-well plates
(Nunc, Gibco, Paisley, UK) and then treated with inflammatory
mediators or mimics of infection. Tfie inflammatory mediators investi¬
gated were as follows: IL-1P (1 ng/ml; Peprotech), TNFa (2 ng/ml;
Peprotech), IL-1 (3 + TNFa, interferon (IFN)-y(IO ng/ml; Peprotech),
IL-6 (5 ng/ml; Peprotech) and phorbol,l-myristate, 13-acetate (PMA,
10"7 mol/1; Calbiochem, Nottingham, UK). These molecules were
investigated because they have been reported to influence natural
antibiotic expression in other systems (Sallenave et al., 1994; Harder
et al., 2000; Krisanaprakornkit et al., 2000). Dose dependence and
kinetics of the response of endometrial epithelial cells to IL-1P and
TNFa were determined in the HES endometrial epithelial cell line
by measuring SLPI mRNA expression. The response observed at 24
h was greater than at 4 h and concentrations 5-fold higher than those
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detailed above did not enhance the response. Hence, all subsequent
experiments were carried out for 24 h using 1 ng/ml of IL-1 (3 and
2 ng/ml of TNFa. The bacterial products LPS (1-1000 ng/ml; E.coli,
Serotype 026:B6; Sigma) and lipoteichoic acid (LTA; 5 pg/ml;
Staphylococcus aureus; Sigma) were used as mimics of Gram-
negative and Gram-positive bacteria respectively. Time-course
experiments were performed with LPS (1 pg/ml) and LTA (5 pg/ml).
Both treatments were tested at 4, 8 and 24 h. LPS (1 |ig/ml) was
also studied in combination with LTA and IL-1. This mimics dual
infection with Gram-negative and positive micro-organisms and also
infection in combination with the resultant expression of inflammatory
mediators.
All treatments contained estradiol (10-8 mol/1) to maintain cell
growth. Controls (estradiol only) were included throughout. Immuno-
histochemical staining (using mouse anti-human cytokeratin antibody,
clone MNF116; Dako Ltd, Cambridge, UK) of representative primary
cell cultures for the epithelial marker, cytokeratin, determined that at
the time of treatment the purity of epithelial cells was >90%. The
majority of contaminating cells were likely to be of stromal origin
and morphologically resembled fibroblasts.
Cell lines
MFE-296 [(Hackenberg et al., 1994); ECACC, CAMR, Salisbury,
UK] and HES [(Desai et al., 1994); a gift from Dr D.Knissj
endometrial epithelial cell lines were seeded at 1X106 cells/flask
(25 cm2; Corning Costar, High Wycombe, UK) and allowed to adhere.
Cells were then treated with IL-1 (3 (1 ng/ml), TNFa (2 ng/ml),
IL-1 (3 + TNFa, IFNy (10 ng/ml) and PMA (10-7 mol/1) for 24 h.
RT and real-time quantitative PCR
After treatment, cells were harvested in Tri.reagent (Sigma) and RNA
was extracted as detailed in the manufacturer's protocol.
Amounts of HBD1, HBD2 and SLPI mRNA were determined
using real-time quantitative PCR. This method detects fluorescence
release from a specific probe allowing measurement of PCR progress.
The amount of specific amplicon was related to ribosoinal 18S
(constant relative to the amount of cDNA present) and subsequently
to an internal control.
Details of RT and quantitative PCR are described elsewhere (King
et al., 2000). Briefly, RNA samples were reverse transcribed using
random primers. PCR reaction mixtures were made containing Sure
Start Taq DNA polymerase (0.025 IU/p.1; Stratagene, Amsterdam,
The Netherlands), dNTPs (all at 200 p.mol/1) and specific forward
and reverse primers (300 nmol/1; Biosource, Nivelles, Belgium) and
probe (200 nmol/1; Biosource) for the natural antibiotic. Primers and
probe (all at 50 nmol/1; PE Biosystems, Warrington, UK) forribosomal
I8S were also added. Samples were measured in triplicate and no
template controls were included in all runs. PCR reactions were ran
on ABI Prism 7700. Contamination of cDNA samples with genomic
DNA was measured by detection of (3-actin signal in control RNA
samples (without reverse transcriptase). All samples had a (3-actin
signal that was only detectable above a previously defined, arbitrary
level of 27 cycles (King et al., 2001), indicating that there was no
major genomic DNA contamination.
Primers and probes were designed using PRIMER express software
(PE Biosystems; Table I). Primers and probes were validated at the
above concentrations and linearity of response was confirmed using
serial dilution of a standard pool of cDNA. Within assay variations
of the PCR measurement of specific amplicons in cDNA were
calculated from six replicates (Table I).
Immunohistochemistry
Matrigel was removed from primary epithelial cells and they were
fixed in neutral buffered formalin for 10 min at room temperature
Endometrial antimicrobials
and subsequently permeabilized with Triton X100 (0.05%; Sigma).
Non-specific endogenous peroxidase activity was blocked by treatment
with 3% hydrogen peroxidase (BDH Laboratory Supplies, Poole,
UK) in distilled water for 10 min at room temperature. Cells then
underwent a non-immune block using diluted normal horse serum
(Vectastain 4002; Vector Laboratories, Peterborough. UK) for 20 min
at room temperature. Cells were incubated overnight at 4°C with
200 |il mouse anti-SLPI antibody (1:200 in diluted horse serum;
HyCult Biotechnology, Uden, The Netherlands). In negative control
wells, cells were incubated with equintolar concentrations of mouse
immunoglobulin (Ig; Sigma). Cells were then incubated with biotiny 1-
ated horse anti-mouse IgG (Vector Laboratories), followed by an
avidin-biotin peroxidase detection system (both for 60 min at room
temperature; Elite ABC 6101; Vector Laboratories). Diaminobenzidine
(DAB; Vector Laboratories) was used to identify positive staining
(Figure 1). Cells were counterstained with Harris's haemotoxylin
(Pioneer Research Chemicals Ltd, Colchester, UK) and stored in
ethanol.
SLPI ELISA
SLPI concentrations in culture supernatants were determined by
ELISA. Throughout the ELISA all dilutions were made in ELISA
buffer (150 mmol/1 NaCl, 100 mmol/1 Tris, 0.00015% phenol red
solution, 2 mmol/l EDTA, 150 mg/1 2-methylisothiazolone, 150 mg/1
bromonitrodioxane, 2 mg/ml bovine serum albumin, 0.05% Tween-
20, 0.01% hexadecyltrimethylammonium bromide, pH 7.2). Assay
plates (96-well; Nunc Maxi-Sorp) were coated overnight at 4°C with
200 |il/well of goat anti-SLPI (2 pg/ml; R&D Systems, Oxford, UK)
and then blocked for 30 min with 200 pl/well of blocking/protecting
solution (2% polyvinylpyrrolidone, 5 mg/ml bovine serum albumin,
preservatives, 5 mmol/1 EDTA, 50 mmol/1 Tris). Plates were washed
with wash buffer (150 mmol/1 NaCl, 5 mmol/1 Tris, 0.025% Tween-
20, pH 7-7.5) and subsequently 200 |il of standard/sample were
added to each well and incubated for 2 h at room temperature on a
plate shaker. Two non-specific binding wells (200 pi buffer only)
were included on each plate. Standards were added in duplicate and
their concentration range was 0.024-25 ng/ml (recombinant SLPI;
R&D Systems). Plates were washed and then incubated for 1 h with
200 pl/well of biotinylated mouse anti-SLPI (1:10000; Hycult) as
above. After further washing, 200 pl/well of streptavidin peroxidase
(1:4000; Roche, Lewes, UK) was added and incubation was for
20 min, as above. Plates were washed again and then 200 pl/well of
substrate (0.4 g/1 urea-hydrogen peroxidase, 0.16 g/1 tetramethyl
benzidine in 100 mmol/1 sodium acetate; pH 6) was added. After
10 min, wells were quenched with 50 pl/well of IM sulphuric acid.
Plates were read in a plate reader at 450 nm. Intra- and inter-assay
coefficients of variation were 12.80 and 14.76% respectively.
Statistical analysis
Significant difference was determined by analysis of variance
(ANOVA; Statview 3.0). Fisher's protected least squares differences
test was used to assign individuakdifferences. P < 0.05 was considered
significant.
No attempt was made to analyse experiments involving epithelial
cells derived from proliferative and secretory endometrium separately.
However, SLPI mRNA expression in epithelial cells originating from
the proliferative and secretory phases was compared using the control
samples. There was no significant difference between SLPI levels in
cells derived from the proliferative phase and from those in the
secretory phase. In vivo, SLPI is expressed only in secretory endomet¬
rium. This suggests that after 7-10 days in culture, the cells do not
exhibit characteristics specific to their original menstrual cycle phase
and so it is appropriate to treat them as one group for statistical analysis.
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Table I. Sequences of quantitative PCR primers and probes for natural antibiotics. Within-assay variation of PCR measurements for each set of primers and
probe is shown
Forward primer Reverse primer Probe Within-assay
1 variation
HBD1 TCAGCAGTGGAGGGCAATG CCTCTGTAACAGGTGCCTTGAAT CTCTATTCTGCCTGCCCGATCTTTACCAA 2.6%
HBD2 CTGATGCCTCTTCCAGGTGTTT CTGGATGACATATGGCTCCACTCT AAGGCAGGTAACAGGATCGCCTATACCACCA 0.4%
SLPI GCATCAAATGCCTGGATCCT GCATCAAACATTGGCCATAAGTC TGACACCCCAAACCCAACAAGGAGG 9.7%
Results
Regulation of natural antibiotic expression in primary cul¬
tures of endometrial epithelial cells
The role of inflammatory mediators and mimics of infection
in the regulation of HBD1, HBD2 and SLPI in primary
endometrial epithelial cells was investigated.
HBD1
Primary cultures of endometrial epithelial cells expressed very
low levels of HBD1 (data not shown). This low level of
expression made investigation of HBD1 regulation inappro¬
priate. Successful detection of HBD1 mRNA in whole
endometrial biopsies served as a positive control.
HBD2
HBD2 mRNA expression was up-regulated by treatment with
several inflammatory mediators. IL-ip alone, TNFa alone and
IL-lp+TNFa increased HBD2 levels by 9-, 4- and 8-fold
respectively (Figure 2a; P < 0.03). Treatment with IFNy
caused mRNA expression to increase by 9.5-fold (P < 0.01).
IL-6 and PMA treatment had no effect on HBD2 expression.
LPS at several doses had no effect '&n HBD2 mRNA
expression (data not shown). However, treatment with LPS
(1000 ng/ml) for 8 h showed a decrease in HBD2 mRNA
levels followed by an increase at 24 h (Figure 2b; P = 0.055).
LTA treatment caused a trend towards increased expression of
HBD2 at 4 h, with a subsequent significant decrease in
expression at 24 h (Figure 2b; P < 0.02). No significant
synergistic effect of treatment with LPS in combination with
LTA or IL-ip was detected, although increased HBD2 expres¬
sion was apparent in the presence of both LPS and IL-ip
(Figure 2b; P < 0.04). However, this can be accounted for by
the up-regulation of HBD2 mRNA in the presence of IL-lp
alone (see above).
SLPI
SLPI mRNA expression was not affected by treatment with
any of the inflammatory mediators tested (Figure 3a; not
significant).
SLPI mRNA expression was down-regulated by treatment
with LPS (1000 ng/ml) for 4 and 24 h (Figure 3b; P < 0.05).
All other doses and incubation times had no effect on SLPI
levels. LTA treatment resulted in a trend towards increased
expression of SLPI at 4 h (Figure 3b; not significant). LPS, in
combination with LTA or IL-ip, caused a down-regulation of
SLPI mRNA expression after 24 h of treatment (Figure 3b;
P < 0.01). This is consistent with the results for treatment
with LPS alone and does not reflect an effect of LTA or IL-1J3.
In addition, SLPI protein was localized to the cytoplasm of
the primary epithelial cells using immunohistochemistry
(Figure 1) and changes to SLPI protein concentrations in
cell culture supernatants were determined by ELISA. In the
presence of IL-l[3+TNFa, SLPI concentrations were reduced
(Figure 3c; P < 0.04), although treatment with the other
inflammatory molecules did not affect SLPI levels. SLPI
concentrations were reduced by treatment with LTA for 24 h
(Figure 3d; P < 0.03). There was also a trend towards
increased SLPI release in the presence of LPS + IL-ip.
Regulation of natural antibiotic expression in endometrial
epithelial cell lines
Expression of HBD1, HBD2 and SLPI was investigated in
the MFE and HES endometrial epithelial cell lines. Natural
antibiotic expression in these cell lines was similar to that
found in primary endometrial epithelial cells. HBD1 mRNA
was expressed at very low levels in MFE cells and was
undetectable in HES cells (data not shown). Similarly, HBD2
was undetectable in both cell lines under control conditions,
although mRNA expression became detectable at very low
levels in MFE cells treated with IL-ip+TNFa for 24 h (in
two of three experiments; data not shown). SLPI mRNA was
detected in both cell lines and was up-regulated by treatment
with IL-lp+TNFa (Figure 4a: MFE, P < 0.01; Figure 4b:
HES, P = 0.05). SLPI protein release by HES cells into
culture supernatants was increased by treatment with TNFa
both alone and in combination with IL-lp (Figure 4c;
P < 0.01). MFE cells released very little SLPI into culture
supematants and so it was not possible to determine the
regulation of protein release.
Discussion
This study details the presence and regulation of natural
antibiotic molecules in endometrial epithelial cells. Human
p-defensins 1 and 2 and SLPI were detected in primary cultures
of endometrial epithelial cells. This is consistent with previous
reports detailing the expression of HBD1 and SLPI in the
endometrial epithelium and at other mucosal sites (Zhao et al.,
1996; Valore et al., 1998; King et al., 2000). HBD2 has also
been detected in the uterus (Bals et al., 1998), although this
report did not investigate the site of expression within the
organ. However, HBD2 is present at other epithelial surfaces
(Harder et al., 2000; Krisanaprakornkit et al., 2000).
The regulation of natural antibiotic molecules has not been
previously described in endometrial epithelial cells. Our in-
vitro study, the first detailing natural antimicrobial regulation
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Figure 2. Regulation of HBD2 mRNA expression in primary
endometrial epithelial cells. Sample numbers are shown
below the x-axis. Note that the total number of treatment samples
exceeds the number of controls. In most experiments, there were
several different treatments relating to one control. Due to the
distribution of results from primary cell cultures, data were
logarithmically transformed prior to statistical analysis by ANOVA.
(a) Proinflammatory mediators. Cells were treated with IL-ip
(1 ng/ml), TNFa (2 ng/ml), IL-ip+TNFa, IFNy (10 ng/ml),
PMA (10~7 mol/1) or IL-6 (5 ng/ml) for 24 h. a,b,c,d: P < 0.03.
(b) Mimics of Gram-negative, Gram-positive and dual infection.
Cells were treated with LPS (1 pg/ml) or LTA (5 pg/ml) for 4, 8
or 24 h or with LPS in combination with LTA or EL-lp for 24 h.
a: P = 0.055; b,c: P < 0.04.
in genital tract cells, shows that HBD2 expression is induced
by the presence of inflammatory mediators such as IL-lp,
TNFa and IFNy. This is consistent with previous reports
stating that HBD2 is up-regulated by inflammatory molecules
in gingival and respiratory epithelial cells and at sites of
inflammation (Liu et al., 1998; Harder et al., 2000; Krisanap-
rakornkit et al., 2000). It should be noted that the actions of
IL-1 are affected by IL-1 receptor antagonist and IL-1 receptor
levels which vary throughout the menstrual cycle (Simon et al.,
1993, 1995) and hence, levels of these molecules may influence
natural antibiotic expression in vivo. The HBD2 promoter is
reported to have several consensus sites for the proinflammat¬
ory transcription factors NFkB and AP-1, accounting for its
induction by the above mediators (Harder et al., 2000).
Additionally, several sites for the transcription factor NF-IL6
have been detected in the HBD2 promoter, although the
cytokine IL-6 (which stimulates transcription via NF-IL6) was
reported to have no effect on HBD2 expression in lung
epithelial cells (Harder et al., 2000). Similarly, IL-6 did not
alter HBD2 levels in endometrial epithelial cells. The protein
kinase C stimulator, PMA, up-regulates HBD2 in gingival
epithelial cells (Krisanaprakornkit et al., 2000), although it
had no effect in our system, suggesting that differences
in defensin regulation exist between epithelial cells from
distinct sites.
HBD1 mRNA was found to be expressed at very low levels
in both primary endometrial epithelial cells and in endometrial
cell lines. As HBD1 has previously been detected in endomet¬
rial epithelium in vivo (Valore et al., 1998), our results suggest
that a stromal mediator is needed to maintain expression of
this defensin in the epithelium. Previous studies have detailed
constitutive HBD1 expression in several epithelial cell types
and have reported resistance to treatment with proinflammatory
cytokines. Our investigation into the regulation of HBD1
expression in endometrium was limited by the low expression
of the molecule.
SLPI is also reported to be up-regulated by inflammatory
cytokines and LPS (Sallenave et al., 1994; Jin et al., 1998).
However, in primary endometrial epithelial cells, SLPI mRNA
expression was unaltered by treatment with proinflammatory
molecules, while protein concentrations in culture medium fell
after treatment with IL-lp+TNFa. In a previous study, we
reported that SLPI expression in endometrium is increased
during the secretory phase of the menstrual cycle, suggesting
regulation by progesterone (King et al., 2000). This, along
with our current findings, suggests that in endometrium SLPI
may be controlled primarily by the local steroid environment,
resulting in peak expression around the time of implantation.
However, inflammatory pathways such as the IL-1 system are
also involved at this time (Simon et al., 1994) and may be
involved in the regulation of SLPI expression under certain
circumstances. It should be noted that treatment of both the
HES and MFE cell lines with a combination of IL-1 p and TNFa
resulted in increased SLPI expression. This may represent
differences in regulation of SLPI between the primary cells
and cell lines, e.g. there maybe differences in IL-1 and TNF
receptor numbers on the cell surfaces. Also, in the MFE cell
line a synergistic action of IL-ip and TNFa was observed.
This may be due to the presence of several sites on the SLPI
promoter that can respond to these two cytokines, as has
previously been reported for the rat /zoxll gene (Kuemmerle,
1998). For example, the SLPI promoter contains several
AP-1 sites and is thought to be responsive to NFkB (Abe
et al., 1991; Nguyen et al., 1999).
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Figure 3. Regulation of SLPI mRNA and protein expression in primary endometrial epithelial cells. Sample numbers are shown below the
.v-axis. Note that the total number of treatment samples exceeds the number of controls. In most experiments, there were several different
treatments relating to one control. Treatment of cells was as described in Figure 2. Due to the distribution of results from primary cell
cultures, data were logarithmically transformed prior to statistical analysis by ANOVA. (a) SLPI mRNA—proinflammatory mediators,
(b) SLPI mRNA—mimics of Gram-negative, Gram-positive and dual infection. a,b.c,d,e: P < 0.05. (c) SLPI protein—proinflammatory
mediators, a: P < 0.04. (d) SLPI protein—mimics of Gram-negative, Gram-positive and dual infection, a: P < 0.03.
1 5JjiiiLi lit
control IL-1 TNFa IL-1 + IFNy PMA
TNFa
control IL-1 TNFa IL-1 + IFNy PMA
TNFa
control IL-1 TNFa IL-1 + IFNy PMA
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Figure 4. Regulation of SLPI mRNA and protein expression in endometrial cell lines. Cells were treated with IL-lp (1 ng/ml), TNFa
(2 ng/ml), IL-lp+TNFa, IFNy (10 ng/ml) or PMA (10~7 mol/1) for 24 h. The results shown represent the mean of three experiments,
(a) SLPI mRNA—MFE cell line. a,b,c: P < 0.01. (b) SLPI mRNA—HES cell line, a: P = 0.05. (c) SLPI protein—HES cell line.
♦Mean of two samples. a,b: P < 0.01.
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time of treatment were varied. Synergistic actions between
LPS and other mediators were not observed. Previous studies
in other systems have reported contradictory results. Some
have shown HBD2 to be up-regulated by LPS (McNamara
et al., 1999; Becker et al., 2000). However, others have
reported little effect of LPS, but have found increased HBD2
expression upon infection with pathogenic bacteria, suggesting
that other components of the bacterial cell wall are involved
in stimulating defensin expression (O'Neil et al., 1999; Harder
et al., 2000). This also suggests that LPS actions may depend
on the cell type investigated. Also, our study used E.coli LPS
and it may be that endometrial epithelial cells would respond
to LPS from genital tract pathogens (e.g. Chlamydia). SLPI
has been reported to be an LPS inducible gene in macrophages
(Jin et al., 1997). However, we found SLPI expression to be
decreased after treatment for 24 h with 1 pg/ml of LPS. This
may indicate that, as expected, innate immune responses to
LPS occur over a short time period. Following initiation of
the adaptive response, high levels of a leukocyte protease
inhibitor may be inappropriate, hence the observed down-
regulation. Similarly, at shorter time points LTA caused a trend
towards increased expression of HBD2 and SLPI that was not
observed after 24 h. Indeed, protein concentrations of SLPI
fell after exposure to LTA for 24 h. Responses to PAMPs such
as LPS and LTA are thought to be mediated by interactions
with cellular or soluble CD 14 and subsequent signalling via
Toll-like receptors (Chow et al., 1999; Becker et al., 2000). It
may be that the poor response to PAMPs by the endometrial
epithelial cells was due to low levels of CD14 expression and
inadequate soluble CD14 in bovine serum.
The main role for HBD1, HBD^ and , SLPI in human
endometrium is likely to be in the prevention of uterine
infection. Each of these molecules has been shown to have
antimicrobial activity, and hence they are likely to be important
in the control of sexually transmitted infections. They may
serve to limit the spread of disease from the lower to upper
genital tract, where infection is associated with infertility
(Cates and Wasserheit, 1991; Paavonen, 1993). Also, local
defences are crucial to successful pregnancy. A total of 20%
of preterm births are associated with uterine infection (Romero
et al., 1989c) and increased amounts of HNP1-3 and another
antimicrobial compound, lactoferrin, have been detected in
these circumstances (Heine et al., 1998; Pacora et al., 2000).
This suggests that these natural antimicrobials have a protective
effect and HBDs and SLPI are likely to have a similar role.
Constitutively expressed natural antibiotics such as SLPI
will provide a basal level of antimicrobial protection in the
uterus. This will ensure antimicrobial protection at times
when infection may jeopardise endometrial receptivity (e.g.
implantation). IL-1 (3, TNFa and IFNy are produced by
the endometrium under physiological conditions, with TNFa
produced by epithelial cells (Tabibzadeh et al., 1995), IL-1P
by epithelial and isolated stromal cells (Tabibzadeh and Sun,
1992; Simon et al., 1993) and IFNy by T cells and polymor¬
phonuclear cells (Tabibzadeh, 1994; Yeaman et al., 1998).
These molecules may contribute to regulation of the natural
antibiotics during the normal menstrual cycle. In addition, up-
regulation of these cytokines occurs during infection and the
presence of both IL-1 (3 and TNFa has been reported in, amniotic
fluid from patients undergoing preterm labour associated with
infection (Romero et al., 1989a,b).
Although an antimicrobial role is likely to be the main
function of HBDs and SLPI in the endometrium, it should be
noted that these molecules have several other actions that may
be important. HBD2 chemoattracts immature dendritic cells
and memory T cells to sites of inflammation via the CCR6
chemokine receptor (Yang et al., 1999). This will result in
activation of the adaptive immune system during infection.
HBD2 has also been shown to activate rat mast cells resulting
in histamine and prostaglandin D2 release (Niyonsaba et al.,
2001). SLPI has generalized anti-inflammatory actions
including inhibition of neutrophil elastase and cathepsin G
(Thompson and Ohlsson, 1986), down-regulation of matrix
metalloproteinase production by monocytes (Zhang et al.,
1997) and inhibition of NFkB (Lentsch etal., 1999). Activation
of DNA synthesis in porcine endometrial epithelial cells has
also been reported (Badinga et al., 1999).
In summary, the natural antimicrobials HBD1, HBD2 and
SLPI have been studied in a primary endometrial epithelial
cell culture model and in two endometrial epithelial cell lines.
Each of these molecules is expressed in the endometrial
epithelium and, as in other systems, they are differentially
regulated, suggesting that they provide both constitutive and
inducible antimicrobial protection.
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